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ABSTRACT 
Liver receptor homolog-1 (LRH-1; NR5A2) is an orphan member of the Ftz-F1 
family of nuclear receptors, which comprises four members (NR5A1-NR5A4). LRH-
1 has been linked to a number of key developmental, metabolic and proliferative 
processes and is known to play an important role in the regulation of cholesterol 
biosynthesis, lipid homeostasis and the control of steroid aromatisation.  In this 
respect, LRH-1 is recognised to play an important role in breast cancer, where it acts 
to regulate aromatase activity, leading to the paracrine production of estrogen. 
Recent findings have also suggested a direct role for LRH-1 in cancer, where LRH-1 
is found to be involved in the induction of intestinal tumours and LRH-1 has been 
found by immunohistochemistry in tumour cells of human mammary ductal 
carcinomas. 
Recently, a gene expression microarray analysis of estrogen responses in an 
engineered breast cancer cell line, where Estrogen Receptor-α (ERα) activity can be 
conditionally repressed, provisionally identified LRH-1 as an estrogen responsive 
gene that may be important in the estrogen-regulated growth of breast cancer cells. 
Based on this initial observation, I have gone on to study the role of LRH-1 in the 
estrogen response in breast cancer cells.  Using ERα-positive breast cancer cell lines, 
I have confirmed that LRH-1 levels increase in response to estrogen and are 
inhibited by anti-estrogens (tamoxifen and ICI 182,780). Using 5`RNA Ligase 
Mediated Rapid Amplification of cDNA Ends (5`RLM-RACE) to characterise the 5’ 
end of the LRH-1 mRNA, I have found that the estrogen regulation of LRH-1 is 
mediated through a previously undescribed gene promoter, which results in the 
production of a variant LRH-1 mRNA species that initiates transcription just 
upstream of exon 2 of the LRH-1 gene. Further, reverse transcriptase polymerase 
chain reaction (RT-PCR) showed that the newly identified variant LRH-1 transcript 
is expressed in tissues in which LRH-1 expression has previously been described. 
Moreover, this variant was seen to be the major form of LRH-1 expressed in breast 
cancer cell lines.  
Having established the estrogen regulation of LRH-1, studies were carried out to 
investigate the role of LRH-1 in growth and gene expression in breast cancer cells. 
siRNA-mediated inhibition of LRH-1 expression inhibited proliferation of MCF-7, 
ZR-75-1 and T47-D breast cancer cell lines but did not inhibit BT474 and MDA-
MB-231 breast cancer cells, in which LRH-1 is not expressed. Further, a group of 
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recently described synthetic agonists for LRH-1 stimulated the growth of breast 
cancer cell lines expressing LRH-1 in a dose dependent manner, but did not 
stimulate growth in those breast cancer cell lines which do not express LRH-1. 
Finally, RNA interference experiments directed against LRH-1 identified ERα as an 
important LRH-1 regulated gene.  
These results show that LRH-1 potentially plays a key role in regulating estrogen 
responses in ERα–positive breast cancer cells, primarily through the direct regulation 
of ERα gene expression. These new findings, taken together with the previously 
described role for LRH-1 in regulating aromatase gene expression identify LRH-1 as 
a potentially important target for the development of new therapies for the treatment 
of breast cancer.  
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SERM   Selective Estrogen Receptor Modulator 
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SF-1   Steroidogenic Factor-1 
SF-1-LUC SF1 promoter-Luc 
SHC SHC (Src homology 2 domain containing)  
transforming protein 
SHP   Small Heterodimer Partner 
SIN-3   SIN3 homolog A, transcription regulator 
siRNA   Small interfering RNA 
SNP   Single Nucleotide Polymorphism 
SOFT   Suppression of Ovarian Function Trial 
SPH   Sphingosine 
SRB   Sulphordiamine B 
SRC   Steroid Receptor Coactivator  
SMRT Silencing Mediator of Retinoic acid and Thyroid  
Hormone Receptor (NCoR2/TRAC2) 
SNRIs   Selective Nor-adrenaline Re-uptake Inhibitor 
SPHK   Spingosine Kinase 
SP-1   Sp1 transcription factor 
SSRIs   Selective Serotonin Re-uptake Inhibitors 
STAR   Study of Tamoxifen and Raloxifene 
STAT   Signal Transducer and Activator of Transcription  
SUMO   Sumoylation 
T3   Triiodothyronine 
TAILORx  Trial Assigning IndividuaLized Options for  
Treatment (Rx) 
TAP   Tobacco Acid Pyrophosphate 
TBE   Tris-Borate-EDTA 
TBP   TATA Binding Protein 
TCA   Trichloroacetic Acid 
TEMED  Tetramethylethylenediamine 
TetO   Tetracycline Operator sequence 
TEXT   Tamoxifen and Exemestane Trial 
TGF-β   Transforming Growth Factor-β 
TIF-2   Transcriptional Intermediary Protein 2 (SRC-2/GRIP1) 
TNF-α   Tumour Necrosis Factor-α 
TR   Thyroid Receptor 
TRAM1  Translocation Associated Membrane Protein 1 
TRAP220 Thyroid hormone Receptor-Associated Protein  
complex 220 kDa component 
tRNA   transfer Ribonucleic Acid 
tTa   Trancriptional activator 
TTR   Time To Recurrence 
UM   Ultrarapid Metaboliser 
VDR   Vitamin D3 Receptor 
VEGF   Vascular-Endothelial Growth Factor 
WHEL   Women’s Healthy Eating and Living 
XBP-1   X-box Binding Protein 1 
ZEBRA  Zoladex Early Breast Cancer Association 
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1 INTRODUCTION 
1.1 Breast cancer- an overview 
Breast cancer is the most common malignancy afflicting women and the leading 
cause of cancer-related mortality in the western world (Hortobagyi et al., 2005). 
Worldwide, more than 1.2 million women are diagnosed with breast cancer each 
year, affecting 10-12% of the female population and resulting in 500,000 deaths per 
year. In the United Kingdom, breast cancer comprises 18% of all female cancers. In 
2005 there were 45,947 new cases (>99%) in women and approximately 14,000 
deaths (National Statistics, 2008, Online, 2008, Registry, 2008). The lifetime risk of a 
woman being diagnosed with breast cancer is 1 in 9. Whilst it is not possible to 
predict who will develop the disease, there is considerable epidemiological data to 
help identify those women who are at increased risk for breast cancer and provide 
options for reducing risk.  
More than 80% of cases of breast cancer occur in women over 50 years of age, with 
the highest incidence in the 50-69 year age group. The incidence of breast cancer has 
been increasing for many years in economically developed countries. The age-
standardised incidence of breast cancer per 100,000 women increased from 74 in 
1975 to 123 in 2005 (Coleman, 2000). The introduction of a national screening 
programme in the UK in 1988 led to a transient increase in breast cancer incidence in 
women aged 50-64 years as early, undiagnosed cancers were detected (Forrest, 1986). 
This increase lasted for the first 4-7 years of the programme. However, an underlying 
increase in the incidence predating screening continues today and is particularly 
evident in the older age groups (Coleman, 2000). 
Mortality rates for breast cancer have fallen in many developed countries since 1990, 
having been previously stable or increasing for several decades (Beral et al., 1995, 
Peto et al., 2000, Jatoi and Miller, 2003). This reduction has been attributed to earlier 
detection following the implementation of breast screening, decreased 
pharmacological use of steroid hormones (oral contraceptive pill (OCP), hormone 
replacement therapy (HRT)) and the use of adjuvant therapies such as tamoxifen 
(Berry et al., 2005). As the incidence of breast cancer is high and the 5-year survival 
rate is approximately 80%, many women are alive who have been diagnosed with 
breast cancer. Hence, an estimated 550,000 women are alive in the United Kingdom 
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having received the diagnosis of breast cancer (Maddams J, 2008).  
There are many risk factors associated with an increased risk of developing breast 
cancer, however only 25% of women with a sporadic case of breast cancer will have 
an identifiable risk factor. Risk factors for breast cancer include age, ethnicity, 
geographical location, length of lifetime exposure to endogenous estrogens 
(ovulatory cycles), serum estrogen levels, age at first pregnancy, previous benign 
breast disease, exposure to ionising radiation, exposure to exogenous hormones 
(HRT/OCP), body weight, diet, alcohol intake, height, socio-economic status, 
mammographic density of breasts, previous history of breast cancer and a family 
history of breast cancer (particularly 1st degree relatives) (Colditz and Rosner, 2000, 
Anderson et al., 2005, Vogel, 1998, Jatoi et al., 2005, Ferlay J, 2004, Ziegler et al., 
1993, Tominaga, 1985, Shimizu et al., 1991, Hankinson et al., 2004, Hartmann et al., 
2005, Dupont et al., 1993, London et al., 1992, Radiation, 2000, Ronckers et al., 
2005, Cancer, 2002, 1996, Marchbanks PA, 2002, 1997a, Beral et al., 2002, Holmberg 
and Anderson, 2004, Key et al., 2002, Calle et al., 2003, Bingham et al., 2003, 
Hamajima et al., 2002, Baan et al., 2007, Allen et al., 2009, Hunter and Willett, 1993, 
van den Brandt et al., 2000, Monninkhof et al., 2007, Boyd et al., 1995, Boyd et al., 
2002, Stone et al., 2006, Chen and Thompson, 1999, Lalloo et al., 2003, Vogel VG, 
2003, Evers and Jonkers, 2006, Deng, 2006, Claus et al., 1994, Metcalfe et al., 2004, 
Antoniou et al., 2003, Newman et al., 1988, Evans et al., 2003).  
The link between hormones and breast cancer growth and development has been 
recognized for more than a century. In 1896, George Beatson reported that removal 
of the ovaries from premenopausal women with advanced breast cancer produced a 
dramatic decrease in tumour size and improved the patient’s prognosis (Beatson, 
1896). However, in 1900, Stanley Boyd presented national case reports for 
oophorectomy and noted that only one-third of the patients responded to ovarian 
ablation and that the response lasted, on average, for 1-2 years (Boyd, 1900). The 
discovery of estrogenic hormones produced in the ovary by Allen and Doisy 
prompted the search for therapeutic estrogen antagonists to reduce the incidence of 
breast cancer in individuals predisposed to the disease by their sensitivity to 
estrogenic hormones (Allen and Doisy, 1923, Lacassagne, 1936). Subsequent 
laboratory, epidemiological and clinical studies have established that estrogens 
stimulate the growth of breast cancers, and have led to the development of 
endocrine approaches for the treatment of breast cancer (Clemons and Goss, 2001). 
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Estrogen actions are mediated by two estrogen receptors, ERα and ERβ. Whilst the 
importance of ERβ in breast cancer is at present unresolved (Giguere et al., 1998, 
Fuqua et al., 2003), ERα is expressed in the majority of breast cancers and its 
presence correlates with response to endocrine therapies. Thus, current clinical 
practice involves determination of the ERα status of the malignant cells, followed by 
adjuvant treatment of ERα-positive cases with endocrine agents that inhibit ERα 
activity (Ali and Coombes, 2002).  
Inhibition of ERα activity is achieved with two main strategies; using anti-estrogens, 
primarily tamoxifen, that bind to ERα to inhibit its activity, or by blocking estrogen 
synthesis, such that ERα is not activated. Peripheral estrogen synthesis is the main 
source of estrogens in post-menopausal women and drugs that reduce peripheral 
estrogen biosynthesis, by blocking the activity of the aromatase enzyme, are used as 
second- and third-line agents in hormone-sensitive disease, once resistance to 
tamoxifen has developed. Whilst tamoxifen has become the principal form of 
adjuvant treatment in pre- and post-menopausal women, recent studies with third-
generation aromatase inhibitors such as letrozole and arimidex, indicate that these 
agents may be superior to tamoxifen in causing regression of breast cancers, in terms 
both of response rates and duration of response (Johnston and Dowsett, 2003, 
Bonneterre et al., 2001, Mouridsen et al., 2001).  
A significant proportion of patients who present with primary breast cancer, and all 
patients with ERα-positive metastatic disease, eventually develop resistance to all 
strategies that are designed to limit ERα activation by estrogens. Resistant tumours 
often remain ERα-positive and respond to change of endocrine agent. In particular, 
it has been shown that a proportion of patients who relapse following tamoxifen 
treatment respond to aromatase inhibitors (Buzdar and Howell, 2001) or to more 
potent anti-estrogens (Morris and Wakeling, 2002), demonstrating ERα-dependence 
for the continued growth of tamoxifen-resistant tumours. These clinical findings, as 
well as data from in vitro studies implicating ERα in endocrine resistance, 
demonstrate a need for identifying new diagnostic and therapeutic agents for breast 
cancer treatment. 
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1.2 Estrogens and the mammary gland 
1.2.1 The human breast 
The mammary gland, or breast, is a modified sweat gland, which produces milk in 
women. Each breast has one nipple surrounded by an areola, which has several 
sebaceous glands (Gray et al., 2005). The mammary gland is divided into 15-25 lobes 
and comprises a branching glandular ductal system, which lies in a stromal fat pad 
(Figure 1) (Ali and Coombes, 2002). Each duct has a layer of epithelial cells 
responsible for milk production; these are surrounded by an outer layer of 
myoepithelial cells, which being contractile, aid milk ejection into the ductal space 
squeezing the underlying epithelial cells (Ali and Coombes, 2002).  
1.3 Role of estrogen in the normal breast 
Estrogens regulate a number of physiological processes in various tissues including 
the uterus, bone, prostate, colon, lung, heart, brain and mammary gland. Whilst 
estrogens are not required for the prenatal development of the mammary gland, they 
are required to initiate further development during puberty (Fisher et al., 1998). In 
the adult breast, estrogen is required for maintaining the ducts and regulating the 
minor dynamic changes seen in side branching that occur during the menstrual cycle 
(Hennighausen and Robinson, 2005). Estrogen stimulates a number of physiological 
processes in the mammary gland, including proliferation in epithelial and stromal 
cells (Shyamala and Ferenczy, 1984). Estrogens also increase mammary gland glucose 
metabolism, progesterone levels, lipid synthesis, histamine release and immune cell 
recruitment (Shyamala and Ferenczy, 1982, Toft and O'Malley, 1972, Zucchi et al., 
2004, Xu et al., 2005, Shelesnyak, 1959, Zeppa and Womack, 1962, Gouon-Evans et 
al., 2002, Kayisli et al., 2004). 
Treatment with estrogen has been shown to rescue impaired mammary development 
in rats following oophorectomy but not in those following hypophysectomy, 
indicating a role for both pituitary hormones and estrogen in the development of the 
mammary gland (Kleinberg et al., 2009). Insulin-like growth factor-1 (IGF-1) has 
been shown to have a minor independent effect on mammary development, but 
estrogen is required for full ductal elongation (Ruan et al., 1995, Sternlicht, 2006). In 
mouse models both estrogen and progesterone contribute to mammary gland 
development, although estrogen is responsible for ductal outgrowth and minor 
Figure 1.1 Structure of normal and malignant breast tissue. a | Anatomy 
of the human mammary gland. Each mammary gland contains 15–20 lobes, 
each lobe containing a series of branched ducts that drain into the nipple. b | 
Each duct is lined with a layer of epithelial cells, responsible for milk 
production. These are surrounded by an outer layer of myoepithelial cells 
with contractile properties. The glandular ducts are embedded in fibroblast 
stroma. c | This structure breaks down in breast cancer, resulting in an 
epithelial cell mass. b and c are immunostained using antibodies to the 
estrogen receptor (ER; brown stained nuclei), showing that only a small 
proportion of epithelial cells are ER positive in the normal breast. Taken from 
Ali and Coombes. Endocrine-responsive breast cancer and strategies for 
combating resistance. Nat Rev Cancer. 2002; 2(2), 101-112. 
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branching, whilst progesterone promotes tertiary branching and alveolar 
development that completes the ductal tree (Sternlicht, 2006). Estrogen’s action is 
mediated by estrogen receptors ERα and ERβ. Approximately 15-25% of epithelial 
cells in the normal resting breast express ERα, although this number changes 
through the menstrual cycle. It has been proposed that ERα-positive cells promote 
the proliferation of ERα-negative cells, by the secretion of paracrine factors 
(Mastroianni et al., 2009). By contrast, in breast cancers ERα-positive cells do 
proliferate. However, the mechanisms by which ERα-positive epithelial cells are 
converted from being quiescent in the normal context to being proliferative in breast 
cancer still remain unclear.  
1.3.1 Estrogen synthesis and the breast 
The theca and granulosa cells of the ovary are the principal source of estradiol in 
women. It is suggested that the theca cells secrete androgens, which are aromatized 
to estrogens in the granulosa cells (Hillier et al., 1994). Estriol and estrone are 
subsequently produced from estradiol in the liver.  Aromatase activity is found in a 
number of tissue including fat, muscle, nervous tissue and the testis (Matsumine et 
al., 1986, Miller, 1991, Naftolin et al., 1975, Brodie and Inkster, 1993). The 
synchytotrophoblast produces estriol in pregnancy (Siiteri and MacDonald, 1966). 
Levels of estradiol vary according to the menstrual cycle, with highest concentrations 
seen prior to ovulation (Flood et al., 1976, Baird and Fraser, 1974).  
Estrogens are produced through several hydroxylation reactions that principally form 
2-hydroxyestrone, 4-hydroxyestrone, 4-hydroxyestradiol, 16α-hydroxyestrone and 
16α-hydroxyestradiol (Figure 1.2) (Clemons and Goss, 2001). Women producing 
estrogen through 16α-hydroxylation, are more susceptible to developing breast 
cancer than those who produce estrogen through the 2-hydroxylation pathway 
(Meilahn et al., 1998, Kabat et al., 1997, Ursin et al., 1999). 
In premenopausal women, the ovaries under the cyclical control by the pituitary 
gland are the major source of circulating estrogen, with only a small percentage of 
serum estrogen being due to synthesis in peripheral organs (Travis and Key, 2003). 
However, following cessation of ovarian function in postmenopausal women 
estrogen production from the aromatization of adrenal and ovarian androgens in 
extragonadal tissues such as the muscle, liver and fat tissues becomes the main 
source of estrogen (Santen et al., 1986). In postmenopausal women the mechanisms  
Pregnenolone 	  	  	  	  	  	  	  	  	  	  	  	  Progesterone 	   	  	  	  	  	  	  Deoxycor1costerone 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cor1costerone	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  17-­‐Hydroxypregnenlone 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  17-­‐Hydroxyprogesterone 	   	  	  	  	  	  	  	  	  Deoxycor1sol 	   	  Cor1sol	  	  
Cholesterol	  
	  	  	  	  	  	  DHEA 	   	  	  	  	  	  	  	  	  	  	  Andrstenedione	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  E1	  
	  	  	  	  	  	  	  	  Testosterone	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  E2	  	  
Catabolism	  of	  estrogen	  
2-­‐OH-­‐E1	  
2-­‐OH-­‐E2	  
4-­‐OH-­‐E1	  
4OH-­‐E2	  
	  	  	  16α-­‐OH-­‐E1	  
	  	  	  16α-­‐OH-­‐E2	  
4-­‐MeO-­‐E1	  
4-­‐MeO-­‐E2	  
4-­‐OH-­‐3-­‐MeO-­‐E1	  
4-­‐OH-­‐3-­‐MeO-­‐E-­‐2	  
2-­‐MeO-­‐E1	  
2-­‐MeO-­‐E2	  
2-­‐OH-­‐3-­‐MeO-­‐E1	  
2-­‐OH-­‐3-­‐MeO-­‐E2	  
16α-­‐OH-­‐E1	  
17β-­‐HSD	  
Estriol	  
P-­‐450scc	  
	  3β-­‐HSD 	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CYP21 	   	   	  	  	  	  	  CYP11	  
	  3β-­‐HSD 	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CYP21	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CYP11	  
	  3β-­‐HSD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  P-­‐450	  aromatase 	   	   	   	  	  
	  17β-­‐HSD 	   	  	  	  	  	  	  	  	  	  	  17β-­‐HSD
	  17-­‐KSR 	   	  	  	  	  	  	  	  	  	  	  17-­‐KSR	  	  
	  P450	  aromatase
Estrogen	  Receptor	  
Synthesis	  of	  estrogen	  
CYP17 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CYP17	  
CYP17
Estrogen-­‐response	  element	   Gene	  expression	  
Growth	  
s1mula1on	  
COMT	  
COMT	  
COMT	  
Figure 1.2 Pathways of Estrogen Synthesis and Catabolism and the Sensitivity of Tissue to 
Estrogens. 3β-HSD denotes 3β-hydroxysteroid dehydrogenase, 17β-HSD 17-hydroxysteroid 
dehydrogenase, 17-KSR 17-ketosteroid reductase,  DHEA dehydroepiandrosterone, P-450 
cytochrome P-450, SCC side-chain–cleavage enzyme, CYP17 17β-hydroxylase, CYP21 21-
hydroxylase, CYP11 11β-hydroxylase, E1 estrone, E2 estradiol, 2-OH-E1 2-hydroxyestrone, 2-OH 
E2 2 hydroxyestradiol,  2-MeO-E1 2-methoxyestrone,  2-MeO-E2 2-methoxyestradiol,  2-OH-3-
MeO-E1 2-hydroxyestrone 3-methyl ether, 2-OH-3-MeO-E2 2-hydroxyestradiol 3-methyl ether, 4-
OH1-hydroxyestrone,  4-OH-2-hydroxyestradiol,  H-3-MeO-E1 4-hydroxyestrone ether,  3-methyl 
4-OH-3-MeO-E2 4-hydroxyestradiol 3 methyl ether, 16αΟΗ-E1 16α-hydroxyestrone, 16α-OH-E2 
16α-hydroxyestradiol, and COMT catechol O methyltransferase. Taken from Estrogen and the risk 
of breast cancer: Clemons M, Goss P. NEJM 344(4) 276-385 
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controlling estrogen production are not clear. Cytochrome CYP17 (P-450 17α-
hydroxylase) and cytochrome CYP19 (P-450 aromatase) are involved in estrogen 
biosynthesis, and polymorphisms associated with varying activity for both genes have 
been identified (Miyoshi and Noguchi, 2003). Elevated serum concentrations of 
estrone and estradiol have been demonstrated in women with a CYP17 A2/A2 
genotype compared with the A1/A1 genotype among 469 postmenopausal  
women not taking hormone therapy (Haiman et al., 1999, Tworoger et al., 2004). A 
number of studies have shown that these polymorphisms are not associated with an 
increased risk of breast cancer (Helzlsouer et al., 1998, Weston et al., 1998). A recent 
study has shown that premenopausal women carrying the G allele of the CYP19 
Single Nucleotide Polymorphism (SNP) rs1008805 have an increased risk of 
developing breast cancer, thereby supporting a role for variation in estrogen 
biosynthesis in premenopausal breast cancer risk (Talbott et al., 2008). The CYP19 
gene has a complex promoter structure, with at least 6 promoters demonstrating 
tissue-specificity (Clyne et al., 2004). Promoter II (PII) is associated with CYP19 
expression in the ovary. Estrogen synthesis in normal breast tissue is stimulated by 
the promoter I.4 (PI.4), however a change in promoter usage occurs in breast cancer 
tissue from PI.4 to PII and PI.3, which are more active and result in increased 
aromatase expression (Zhou et al., 1996, Clemons and Goss, 2001) (see section 1.18). 
Estrogens diffuse through cell and nuclear membranes, before binding to estrogen 
receptors (ER) in target cells and tissues. The ligand-receptor complex activates 
specific sequences in the regulatory region of target genes, known as estrogen-
response elements (EREs) (Figure 1.3) (Clemons and Goss, 2001). These target 
genes are involved in many aspects of cell function, including cell growth and 
differentiation. ERα levels are low in normal breast tissue and vary in different 
women, with high levels associated with an increased risk of developing breast cancer 
(Khan et al., 1994). ERα levels in the breast increase with age, and are higher in 
Caucasians than in Afro-Caribbean and Japanese women (Shoker et al., 1999, 
Lawson et al., 1999). A mechanism for carcinogenesis may involve loss of a tumour-
suppressor gene(s) resulting in a failure to down-regulate the ERα (Shoker et al., 
1999). The degree of variability in the expression of ERα and ERβ is also higher in 
invasive tumours than in normal breast tissue (Leygue et al., 1998). 
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Figure 1.3 Estrogen action at the molecular level. Three distinct pathways of regulation 
of gene expression are shown. First, in classic estrogen signalling, ligand-bound estrogen 
receptor (ER) activates gene expression — either through direct binding of dimeric ER to 
specific DNA response elements, EREs, in complexes including co-activators (CoAs) and 
histone acetyl transferases (HATs), or through protein–protein interactions with other 
transcription factors, particularly members of the activation protein 1 (Ap1) and specificity 
protein 1 (Sp1) families — to facilitate binding to serum response elements (SREs) and 
activation of transcription (a). Second, ER can also be activated as a consequence of 
signalling events downstream of receptor tyrosine kinases (RTKs) such as the epidermal 
growth factor receptor (EGFR), ERBB2 (also known as HER2) and the insulin-like growth 
factor receptor (IGFR) (b).Phosphorylation (P) by the Erk or Akt serine/threonine kinases 
leads to ligand- independent activation of the ER. Third, signalling can be mediated through 
non-genomic mechanisms localized at the cell membrane or in the cytoplasm (c). Ligand 
binding induces the assembly of functional protein complexes that involve other signalling 
molecules and that activate intracellular signalling cascades, resulting in transcription factor 
(TF) activation. Two recently characterized mechanisms that ultimately activate 
transcription independently of ER binding to DNA are illustrated: ligand-induced 
methylation (M) of ER and formation of an ER–PI3K–Src–focal adhesion kinase (FAK) 
complex that activates Akt (d), and activation of Erk by ER–Src–PELP1 complexes (e). 
Taken from Musgrove, EA and Sutherland RL. Biological determinants of endocrine 
resistances in breast cancer. Nat Rev Cancer 2009; 631-643. 
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1.3.2 Estrogen receptors in breast cancer development 
The two forms of ER are encoded by two different genes, with ERα located on 
chromosome 6q25.1 and ERβ on chromosome 14q22-24 (Menasce et al., 1993, 
Enmark et al., 1997). In the mammary gland, ERα expression is only observed in 
luminal epithelial cells of ducts and lobules, which contrasts with ERβ, where 
expression is more widespread being found in luminal epithelial cells,  
myoepithelial cells and in fibroblasts (Speirs et al., 2002). Significantly, in the normal 
breast ERα-positive cells are non-proliferating, although these lie in close proximity 
to dividing cells (Clarke et al., 1997), suggesting a paracrine mode of action for 
estrogen stimulated proliferation in the luminal cell population. In post-menopausal 
women there is an increase in ERα-positive/Ki67-positive cells; whilst the 
percentage of ERα cells increases, proliferation decreases. 
1.4 Histopathology of breast cancer 
The World Health Organization classifies both benign and malignant breast lesions 
by histological pattern (Rosen, 2001). Epithelial tumours comprise the largest group, 
including intraductal papilloma, adenomas, intraductal and lobular carcinoma in situ, 
invasive (ductal and lobular) carcinoma (Figure 1.4). Invasive ductal carcinoma is by 
far the most common type. 
1.4.1 In-situ carcinoma 
These are pre-invasive carcinomas, the proliferation of whose epithelial cells remains 
confined by an intact basement membrane, with no invasion into the surrounding 
stroma (Rosen, 2001).  
Ductal Carcinoma In-Situ (DCIS) 
The advent of breast screening resulted in a marked increase in the detection of 
DCIS, which accounts for 25-30% of all screen-detected tumours (Schwartz et al., 
2000). Almost all DCIS (>90%) is impalpable, asymptomatic and detected by 
screening (often as microcalcifications). The remaining 10% are symptomatic, often 
with nipple discharge, a palpable mass or seen as Paget’s disease of the breast. There 
are a number of risk factors for DCIS including age at first pregnancy, nulliparity and 
a family history of breast cancer (Raktovich, 2000). The spread of DCIS locally is 
along the branching ducts that form the glandular breast, and explains why the 
a             b 
Figure 1.4 Hematoxylin-eosin (H&E) staining of 
different breast cancers (a) invasive ductal carcinoma (b) 
invasive lobular carcinoma, classic appearance with tumor 
cells arranged in a single layer traveling between collagen 
fibers. The nuclei are small and relatively uniform in size 
and shape, (c) Ductal carcinoma in-situ and (d) lobular 
carcinoma in-situ – arrow points to focus of carcinoma. 
Slides from Charing Cross Hospital Pathology Department 
archive. 
c             d 
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majority of DCIS recurs near the site of the initial tumour (Holland et al., 1998).  
Lobular In Situ Neoplasia (LISN) 
LISN (known as lobular carcinoma in situ or LCIS) is not a pre-malignant lesion, but 
is a high-risk marker of invasive cancer. It is often an incidental finding during breast 
biopsy, and accounts for 0.5% of symptomatic and 1% of screen-detected tumours. 
Patients with LISN are often younger, pre-menopausal with bilateral and multi-
centric disease of lower grade and almost all-express ER (Akashi-Tanaka et al., 2000).  
1.4.2 Invasive carcinoma 
Invasive ductal carcinoma (IDC) 
About 80% of breast cancers are invasive (infiltrating) ductal carcinoma, not 
otherwise specified (NOS), a generic term used to distinguish between these tumours 
and other specific forms of ductal carcinoma, such as tubular, medullary, metaplastic 
and adenoid cystic carcinomas (Rosen, 2001). Invasive ductal carcinomas include a 
subset of tumours that express in part characteristics of one of the specific types of 
breast carcinoma but do not constitute pure examples of the individual tumours.  
Invasive lobular carcinoma (ILC) 
ILC is the second most common type of invasive breast cancer accounting for 8-
14% of all invasive breast cancers (Arpino et al., 2004). ILC clinically presents as an 
ill-defined thickening of the breast rather than a mass. MRI is more accurate than 
either mammography or ultrasonography in defining the extent of the disease 
(Weinstein et al., 2001). ILC has a higher incidence of being bilateral, multifocal and 
multicentric than IDC (Cornford et al., 1995, Sastre-Garau et al., 1996).  
1.5 Prognostic factors in breast cancer 
Adjuvant systemic therapy is an important component of breast cancer treatment, 
and aims to extend disease free survival and overall survival. When assessing which 
patients are suitable for treatment, an assessment of systemic risk is made, based on a 
number of prognostic factors: 
1. Axillary lymph node status – Involvement of local and regional lymph nodes 
is one of the most important prognostic factors in breast cancer (Carter et al., 
1989, Galea et al., 1992). The 10 years survival reduces from 75% to 25-30% in 
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those women with nodal involvement compared to those with no nodal 
involvement, and the greater the number of nodes, the worse the prognosis 
(Neville et al., 1992). Metastatic involvement to a higher axillary level, 
particularly those in the apex, carries a worse prognosis (Rosen and Groshen, 
1990, Bedwani et al., 1981). 
2. Tumour size – Smaller tumours (<15mm) have been shown to have a ‘better 
prognosis’ than those >15mm, with a risk of axillary lymph nodal involvement 
of 40% vs. 12-20% respectively (Henson et al., 1991, O'Dwyer, 1991, Neville et 
al., 1992, Carter et al., 1989, Galea et al., 1992). 
3. Differentiation – Juan Hassiman first suggested a correlation between the 
microscopic appearance of tumours and their degree of malignancy in the 19th 
Century (Carstens et al., 1985). Certain types of invasive breast cancer carry a 
more favourable prognosis – which include tubular, mucinous, cribriform, 
medullary and lobular, than invasive cancer of no special type (ductal NST) 
(Contreras and Sattar, 2009, Eichhorn, 2004, Gatti et al., 2006, Tan et al., 2008, 
Sullivan et al., 2005, Carstens et al., 1985). Bloom and Richardson developed a 
numerical grading system assigned by pathologists to invasive breast cancers 
(Bloom and Richardson, 1957). It is the most common type of cancer grade 
system currently used, based on three morphologic features of invasive breast 
cancers: 1) The degree of tumour tubule formation (percentage cancer 
composed of tubular structures), 2) The mitotic activity of the tumour (rate of 
cell division), 3) The nuclear pleomorphism of tumour cells (nuclear grade, 
change in cell size and uniformity) Each of these features is assigned a score 
ranging from 1 to 3. The scores are then added together for a final score ranging 
from 3 to 9. This value is then used to grade the tumour as follows: 3-5, Grade 1 
tumour (well-differentiated), 6-7, Grade 2 tumour (moderately-differentiated), 8-
9, Grade 3 tumour (poorly-differentiated). 
4. Lymphovascular invasion – The presence of lymphovascular invasion closely 
correlates with local and regional lymph node involvement (Ejlertsen et al., 
2009). 
5. Estrogen receptor/progesterone receptor status – A response is seen in 50-
60% of patients to endocrine therapy with ERα-positive tumours, compared to 
a minimal response seen in ERα-negative patients (Horwitz and McGuire, 1975, 
Hunt, 2001). In patients with ER/PR-positive tumours the response rate 
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increases to 78%. 
6. Histopathology of BRCA1 mutations – Cancers associated with BRCA1 
mutations have a significantly higher mitotic rate, are less likely to be ER/PR-
positive, more aneuploid and have greater lymphocytic infiltration than sporadic 
cancers (Armes et al., 1998, Karp et al., 1997, Robson et al., 1998, 1997b, 
Marcus et al., 1996). 
7. Expression of growth factor receptors – Expression of EGFR is inversely 
correlated with ER positivity, and therefore may be associated with endocrine 
resistance (Nicholson et al., 1994). Slamon et al showed that HER-2 gene 
amplification independently predicted poorer overall survival and disease free 
survival in a multivariate analysis in node positive patients (Slamon et al., 1987). 
Larger tumour size and higher grade (poor prognostic factors) have been also 
correlated with HER-2 over expression (Pietras et al., 1995, Rilke et al., 1991). 
The Nottingham Prognostic Index (NPI) was developed in 1982 as an aid to the 
management of breast cancer (Galea et al., 1992). By using multivariate analysis 3 
factors were found to be significant: Tumour grade, number of lymph nodes 
involved and size of the tumour and calculated using the following formula: 
NPI = pathological tumour size (cm) x 0.2 + lymph node stage (1,2,3) + 
histological Grade (1,2,3).  
The lymph node stage: 1 (no nodes affected), 2 (if up to 3 glands are affected) or 3 (if 
more than 3 glands are affected). Similarly the tumour grade is scored as either 1 (for 
a grade I), 2 (for a grade II) or 3 (for a grade III). Cut off points of 2.4, 3.4, 4.4, 5.4 
and 6.4 are used to divide the patients into six prognostic groups: excellent (EPG), 
good (GPG), moderate (MPG) I and II, poor (PPG) and very poor (VPG) giving 10 
year survival rates of 96%, 93%, 82%, 75%, 53% and 39% respectively. 
1.6 Endocrine therapy for breast cancer 
More than a third of women who initially present with localised breast cancer will go 
on to develop metastatic disease during their life, with an average overall survival 
time from 18-30 months (Perez, 1990). In women with metastatic disease receiving 
no treatment, the overall average survival is 12 months (Cold et al., 1993). 
Approximately 75% of women with breast cancer express ERα with estrogen 
believed to be the main stimulant for the growth of these tumours (Fisher et al., 
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1988, Grann et al., 2005). Inhibition of estrogen signalling has been the main form of 
hormonal therapy for patients with ER-positive breast cancer. This was achieved 
initially by oophorectomy in premenopausal women and adrenalectomy or 
hypophysectomy for post-menopausal women, but more recently with medical 
therapy. For the past 30 years tamoxifen, an anti-estrogen that blocks the binding of 
estrogen to its receptor has been the main stay of treatment. Recently developed 
compounds that inhibit aromatase, the enzyme that converts androgens to estrogens 
has led to a shift away from tamoxifen blocking the synthesis of estrogens (Figure 
1.5) (Simpson et al., 1999). Nevertheless, the demonstration that tamoxifen prevents 
breast cancer development in women at high risk, together with its estrogenic actions 
in several key tissues means that it remains an important drug. Each of these 
strategies is discussed below in relation to the drugs currently in clinical use. 
1.6.1 Tamoxifen 
The first non-steriodal antiestrogen MER25 was discovered in 1958 but it proved to 
be too toxic for long-term use (Lerner et al., 1958, Kistner, 1959, Holtkamp et al., 
1960, Herbst et al., 1964). A successor compound, clomiphene 
(chloamiphene/MRL41), a mixture of two isomers was originally investigated as an 
experimental, post-coital contraceptive but was subsequently developed as a fertility 
drug (Clark and Markaverich, 1981). By the 1960s the direct role of estrogen in 
breast cancer growth was substantiated with the description of estrogen receptors in 
breast cancers and a clinical correlation with hormonal dependency (Sander, 1968, 
Johansson et al., 1970, Korenman and Dukes, 1970, Jensen et al., 1971).  
Tamoxifen, (ICI 46,474;Nolvadex) was discovered in 1962 by Dr Arthur L Walpole. 
It had been identified as an effective postcoital contraceptive and was then 
developed as a morning after pill (Harper and Walpole, 1966, Harper and Walpole, 
1967a, Harper and Walpole, 1967b). Tamoxifen was found to induce ovulation rather 
than reduce fertility, and therefore was subsequently used as a fertility treatment 
(Klopper and Hall, 1971, Williamson and Ellis, 1973). It was not until the mid 1970s 
that the anti-tumour activity of the anti-estrogen was described in vivo (Jordan, 1975, 
Jordan and Koerner, 1976, Jordan and Jaspan, 1976, Nicholson et al., 1976). 
In 1973, tamoxifen was approved for the treatment of breast cancer in the UK and 
in the USA by 1977. Fromson et. al. described the metabolism of tamoxifen, with 
the major metabolic route being hydroxylation to form 4-hydroxytamoxifen (see  
Figure1.5 Mechanism of action of aromatase inhibitors and tamoxifen. 
Estradiol binds to the estrogen receptor (ER), leading to dimerization, 
conformational change and binding to the estrogen response elements (EREs) 
upstream of estrogen-responsive genes including those responsible for 
proliferation. Tamoxifen competes with estradiol for ER binding  whereas 
aromatase inhibitors reduce the syntheis of estrogens from their androgen 
precursors. Taken from Johnston SRD, Dowsett, M. Aromatase Inhibitors for 
breast cancer: lessons from the laboratory. Nat Rev 3. 2003. 821-831 
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below), which was found to have a high binding affinity for the ERα with anti-
tumour properties in the carcinogen dimethyl-benzanthracene (DMBA) induced 
mouse model of mammary tumourogenesis (Fromson et al., 1973a, Fromson et al., 
1973b, Jordan et al., 1977b, Jordan et al., 1977a, Jordan et al., 1980). Lippman et. al. 
showed that tamoxifen inhibited the growth of MCF-7 cells (Lippman and Bolan, 
1975, Brooks et al., 1973). The molecules involved included cell cycle proteins 
having key roles in G1 phase progression (Figure 1.6a) (Wang et al., 2008b, Varma et 
al., 2007, Bosco et al., 2007, Hui et al., 2002, Venditti et al., 2002, Prall et al., 1998). 
Cells treated with anti-estrogens, or withdrawn from estrogen, were also found to 
induce apoptotic pathways (Mandlekar and Kong, 2001, Riggins et al., 2005). The 
mechanism is thought to involve the Bcl-2 family and an increase in the apoptotic 
messenger ceramide (Figure 1.6b).  
Tamoxifen is a lipophilic pro-drug, readily absorbed by the gastro-intestinal (GI) 
tract without modification and is 98% bound to albumin after entering the 
circulation (Buckley and Goa, 1989). It undergoes extensive metabolism in the GI 
tract and the liver into the less active form N-desmethyltamoxifen, and two most 
active forms 4-hydoxytamoxifen and 4-hydroxy-N-desmethyl tamoxifen (endoxifen) 
(Figure 1.7a) (Jordan et al., 1977a, Allen et al., 1980, Borgna and Rochefort, 1981, 
Lien et al., 1991). The hydroxylated metabolites result from first pass metabolism in 
the liver and enter the bloodstream via the enterohepatic circulation (Borgna and 
Rochefort, 1981, Lien et al., 1988, Lien et al., 1989). Animal studies using 14C 
radiolabelled tamoxifen have shown that the metabolites of tamoxifen are excreted 
in the faeces (Boocock et al., 1999). 4-hydroxytamoxifen and endoxifen have similar 
binding affinities for ER, and inhibition of 17β-estradiol induced cell proliferation 
but other metabolites do not bind ER well as they lack the 4-hydoxy-group (Borgna 
and Rochefort, 1981). Endoxifen is found at a more than six-fold increased 
concentration than 4-hydroxytamoxifen in the plasma of patients treated with 
tamoxifen (Johnson et al., 2004). 
Treatment with tamoxifen for 5 years in women expressing ERα results in a 41% 
relative risk reduction of recurrence and a 34% relative risk reduction of death 
(Figure 1.7b) (2005). The National Surgical Adjuvant Breast and Bowel Project 
(NSABP) B-14 trial and the Scottish adjuvant tamoxifen trial demonstrated no 
benefit of taking tamoxifen for more than 5 years. The Eastern Cooperative 
Oncology Group (ECOG) trial however, studying indefinite tamoxifen therapy in 
Figure 1.6 Anti-estrogen action on the cell cycle and apoptotic pathways. (a) Anti-estrogen (AE) 
treatment of cultured breast cancer cells leads to estrogen receptor (ER) binding and subsequent rapid 
decreases in the expression of MYC, followed by decreased expression of cyclin D1. Downregulation of 
MYC leads to de-repression of CDKN1A(which encodes p21) transcription. In addition, because cyclin 
D1–cyclin- dependent kinase 4 (CDK4) complexes function as a cellular ‘sink’ for the CDK inhibitors p21 
and p27, the reduction in cyclin D1–CDK4 abundance makes p21 and p27 available for cyclin E1–CDK2 
binding, and so indirectly contributes to the inhibition of cyclin E1–CDK2 activity. The decrease in activity 
of both CDK2 and CDK4 prevents RB phosphorylation (P) and therefore impedes transition into S phase. 
Treatment with the pure anti-estrogen ICI 182780, but not tamoxifen, leads to an increase in the expression 
of p27 and molecular markers that are characteristic of quiescence (G0), that is, the formation of p130–
E2F4 complexes and the accumulation of hyperphosphorylated E2F4. (b) Proteins and processes that are 
upregulated during anti-estrogen-induced apoptosis are indicated in green; red crosses indicate proteins that 
are downregulated. Apoptotic concentrations of tamoxifen elicit caspase activation downstream of 
responses such as activation of the stress kinases Jun N-terminal kinase (JNK) and p38 MAPK, activation 
of the intracellular second messenger ceramide, transcriptional downregulation of anti-apoptotic molecules 
including BCL-2, and upregulation of pro-apoptotic molecules such as IRF1, BIK and possibly BAK. In 
addition, anti-estrogens have effects on the interferon (IFN) and nuclear factor-κB (NF-κB) pathways, and 
on survival signaling through Akt downstream of receptor tyrosine kinases (RTKs), as well as synergistic 
effects on tumour necrosis factor (TNF)-mediated apoptosis. These pro-apoptotic effects of tamoxifen are 
opposed by autophagy. JAK, janus kinase; Stat, signal transducer and transcription activator. Taken from 
Musgrove, EA and Sutherland RL. Biological determinants of endocrine resistances in breast cancer. Nat 
Rev Cancer 2009; 631-643. 
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node positive patients showed a statistically significant improvement in disease free 
survival (85%-73%) with extended tamoxifen use (Stewart et al., 2001, Tormey et al., 
1996, Fisher et al., 2001). The Adjuvant Tamoxifen Treatment – Offer More? 
(ATTOM) and Adjuvant Tamoxifen –Longer against Shorter (ATLAS) trials 
examining the efficacy of long term tamoxifen, reported an increased disease free 
(not significant p=0.4) but not overall survival advantage to longer tamoxifen 
(Verma et al., 2009). In this study the risk of endometrial cancer doubled with 
extended tamoxifen treatment. 
The most common side effects of tamoxifen include hot flushes (50% women), 
vaginal discharge and irregular menses (Fisher et al., 1989, Fisher et al., 1996, Love et 
al., 1991). These side effects occur more in pre/peri-menopausal women. The most 
important side effect of tamoxifen is an increased risk of endometrial cancer, which 
results in 80 extra cases per 10,000 in tamoxifen treated women at 10 years. The 
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) analyzing data from 
37,000 women demonstrated an increase in endometrial cancer by twofold in women 
taking tamoxifen for 1-2 years and fourfold in those taking it for 5 years (1998). 
Tamoxifen is also associated with an increase in endometrial polyps, ovarian cysts 
and endometrial hyperplasia (Uziely et al., 1993, Kedar et al., 1994). The overall 
reduction of risk in developing breast cancer outweighs the increased risk of 
developing endometrial cancer. In post-menopausal women, tamoxifen increases 
bone mineral density of the axial skeleton, however in premenopausal women there 
may be a decrease in bone density (Kristensen et al., 1994, Love et al., 1992, Powles 
et al., 1996). Tamoxifen has been shown to reduce total cholesterol and low-density 
lipoproteins, an effect that explains the reduction in cardiovascular deaths seen as a 
result of treatment (Rutqvist and Mattsson, 1993, Costantino et al., 1997). 
1.6.2 Raloxifene 
Raloxifene, initially studied as an osteoporotic drug, is a second generation selective 
estrogen receptor modulator (SERM) that has estrogen antagonist properties in the 
breast and endometrium and estrogenic activity on lipid metabolism, bone and blood 
clotting (Figure 1.8a) (Jordan, 2003). The term SERM has been coined to describe 
anti-estrogens such as tamoxifen and raloxifene, which have anti-estrogenic, or 
antagonist activities in some tissues, but show estrogen-like, or agonist activities in 
other tissues. The ideal SERM would be a drug that acts as an antagonist in tissues in 
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which estrogen effects are undesirable (e.g. breast, endometrium) but is an agonist in 
tissues in which estrogen action is important (e.g. the cardiovascular system, bone, 
brain) (Oseni et al., 2008). The agonist activity of tamoxifen in the endometrium is 
undesirable, due to promotion of endometrial cancer. Raloxifene is an estrogen 
antagonist in the breast and in the endometrium (Oseni et al., 2008).  
Raloxifene is a polyphenol which undergoes rapid conjugation in the GI tract and 
liver, but it does not re-enter the enterohepatic circulation, as tamoxifen does, and 
has a lower bioavailability (Oseni et al., 2008). Further, a much smaller proportion of 
raloxifene enters the circulation as only 2% is bound to albumin with a half-life of 27 
hours (Oseni et al., 2008).  
The Multiple Outcomes of Raloxifene Evaluation (MORE) trial demonstrated a 
reduction in vertebral fracture in patients taking raloxifene, but it was also shown to 
decrease the incidence of breast cancer in ER-positive patients by 90%, but had no 
effect on ER-negative patients (Cummings et al., 2002). The prospective, randomized 
controlled Study of Tamoxifen and Raloxifene (STAR) trial, showed no significant 
difference in the incidence of invasive breast cancer in either group after 3.2 years, 
and a trend towards fewer uterine cancers in the raloxifene group (not significant) 
(Vogel, 2009). 
1.6.3 Faslodex (Fulvestrant ICI 182,780) 
Faslodex is a pure steroidal anti-estrogen, which binds with a 100 times greater 
affinity to the estrogen receptor than Tamoxifen (Figure 1.8b) (Wakeling and Bowler, 
1992, Rajah et al., 1996). It is licensed for use in postmenopausal women with 
hormone receptor-positive advanced breast cancer failing on prior antiestrogen 
therapy. It has a distinct mechanism of action, which includes down-regulation of 
ER protein, possibly through stimulation of nuclear export of ER, differing from 
that of tamoxifen or the aromatase inhibitors, which may help to delay the 
development of resistance (Howell, 2006, Dauvois et al., 1993).  
1.6.4 Aromatase inhibitors 
Aromatase Inhibitors (AIs) significantly reduce estrogen production in 
postmenopausal women by inhibiting aromatase activity (Miller, 2003). In 
premenopausal women AIs are ineffective as they produce an increase in 
gonadotrophin secretion, which results in a reduced feedback of estrogen on the 
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pituitary and hypothalamus. AIs present an alternative to tamoxifen for antagonising 
estrogenic effects on the breast, in post-menopausal women. In the 1990s, 3rd 
generation AIs were developed, which included two subgroups: the steroidal 
analogue exemestane, which binds irreversibly to the active site of aromatase thereby 
inactivating the enzyme (type 1 inhibitor) and non-steriodal inhibitors that bind 
reversibly to the haem group of the enzyme (type 2 inhibitor), of which the main 
agents are anastrozole and letrozole (Figure 1.8c) (Osborne and Tripathy, 2005).  
The Arimidex, Tamoxifen Alone or Combination (ATAC) trial showed a 
significantly improved Disease Free Survival (DFS), time to recurrence (TTR) and 
incidence of contralateral breast cancer whilst taking arimidex as compared to 
tamoxifen (median follow-up 68 months) (Baum et al., 2002, Baum et al., 2003, 
Howell et al., 2005). There were significantly fewer disease recurrences in the 
arimidex group, but no difference was seen in overall survival. Similar results were 
seen in the Breast International Group (BIG) 1-98 study comparing letrozole to 
Tamoxifen upfront (Thurlimann et al., 2005). In both the ATAC and BIG 1-98 
studies there were more fractures, less thromboembolic events and less endometrial 
cancers were seen in those taking an AI than tamoxifen. 
A number of trials have looked at sequential endocrine treatment (tamoxifen → AI) 
including ATAC, MA-17, IES, ARNO95 and ABCSG (Howell et al., 2005, Goss et 
al., 2003, Goss et al., 2005, Coombes et al., 2004, Boccardo et al., 2005, Jakesz et al., 
2005). The Intergroup Exemestane Study (IES) showed a 24% improvement in DFS 
in women taking 2-3 years of tamoxifen followed by exemestane compared to 5 years 
of tamoxifen (Coombes et al., 2004). There was also a trend towards improvement in 
overall survival in the sequential group, which was significant in the node positive 
group. These trials clearly demonstrate an improved DFS, and now ASCO advises 
that AIs should be part of the adjuvant treatment of postmenopausal early stage 
breast cancer. Until results from ongoing clinical trials are available, the optimal 
timing, duration and type of AIs remain unanswered. 
AIs have a different side effect profile than tamoxifen, and include hot flushes, 
vaginal dryness, musculoskeletal pain, and headache. AIs are not associated with an  
increase in thromboembolic disease or endometrial carcinoma, but are associated 
with an increase in bone fractures and osteoporosis (BIG 1-98 and ATAC trials). 
Bone monitoring, such as Dual Energy X-ray Absorpitometry (DEXA) scanning  
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should be available for patients taking AIs. All women commencing an AI should be 
advised about calcium and vitamin D supplements, stopping smoking and increasing 
their daily exercise (Hillner et al., 2003). It is advised that for all women taking an AI, 
baseline bone mineral density (BMD) should be obtained and monitored annually. 
The Zometa/Femara Adjuvant Synergy Trial suggests that treatment with a 
bisphosphonate following commencement of an AI may prevent a decline in bone 
mineral density (Brufsky et al., 2005). 
1.6.5 Ovarian ablation 
There are many methods of suppressing ovarian function in premenopausal women 
including surgical oophorectomy, radiation induced ovarian ablation and 
Gonadotrophin Releasing Hormone (GnRH) agonists (McDonald Wade et al., 2008). 
GnRH agonists are increasingly being used to achieve ovarian suppression. GnRH 
over-stimulate and subsequently down-regulate GnRH receptors. Their effect is to 
produce an initial rise in Luteinising Hormone (LH) and Follicle-Stimulating 
Hormone (FSH) in the first 7-10 days of treatment followed by a decrease after 14-
21 days that leads to post-menopausal estrogen and progesterone levels (Williams et 
al., 1986, Cockshott, 2000). After 7.3 years of follow-up the Zoladex Early Breast 
Cancer Research Association (ZEBRA) randomizing 1640 lymph node-negative, pre-
menopausal ER-positive women showed no difference in DFS, overall survival, or 
quality of life comparing the GnRH agonist Goserelin (Zoladex) to CMF 
chemotherapy (Jonat et al., 2002, Kaufmann et al., 2003). A number of trials are 
investigating the role of GnRH agonists in adjuvant treatment of premenopausal, 
early stage breast cancer – Suppression of Ovarian Function Trial (SOFT), 
Tamoxifen and Exemestane Trial (TEXT), and the Premenopausal Endocrine 
Responsive Chemotherapy (PERCHE) trial (Strasser-Weippl and Goss, 2005).  
1.7 Breast cancer and hormone resistance 
Evidence has shown that patients who relapse after a previous response to tamoxifen 
will respond to an aromatase inhibitor (Mouridsen et al., 2003). Although estrogen 
deprivation is more effective in delaying resistance than tamoxifen, resistance will 
eventually develop. 
 44 
1.7.1 Resistance to tamoxifen 
One-third of women treated with tamoxifen for 5 years will develop recurrent 
disease within 15 years (2005). Approximately 15% of patients that develop 
resistance to tamoxifen will lose expression of the ERα, and <1% of ERα-positive 
tumours have mutations in the ERα gene (Riggins et al., 2007, Johnston et al., 1995, 
Gutierrez et al., 2005, Clarke et al., 2003, Herynk and Fuqua, 2004). Expression of a 
truncated form of ERα, ERα36 in the presence of full length ERα has also been 
associated with a reduced response to tamoxifen (Shi et al., 2009). However, in most 
cases, ERα expression persists and evidence suggests that these patients will respond 
to a change in endocrine therapy (Johnston et al., 1997, Massarweh et al., 2006). A 
number of mechanisms have been proposed for resistance to tamoxifen including 
intrinsic (de novo) and acquired resistance. 
One mechanism of intrinsic resistance involves the enzyme CYP2D6. The 
cytochrome P450s (CYPs) are membrane-bound haem-thiolate enzymes involved in 
the oxidative, perioxidative and reductive metabolism of various molecules, and 
more than 50 CYP genes have been identified in humans, each of which encodes a 
different CYP protein product (Nelson et al., 2004). CYP2D6 is the dominant CYP 
iso-enzyme involved in the metabolism of tamoxifen to its clinically active form 
endoxifen (Figure 1.7a) (Desta et al., 2004). CYP2D6, together with CYP2B6, 
CYP2C9, CYP2C19 and CYP3A4 are involved in the metabolism of 4-
hydroxytamoxifen. Four different CYP2D6 phenotypes have been identified – 
Extensive Metaboliser (EM), Intermediate Metaboliser (IM), Poor Metaboliser (PM) 
and Ultrarapid Metaboliser (UM) (Griese et al., 1998, Raimundo et al., 2004, Sachse 
et al., 1997). Over 80 different SNPs have been identified for this gene (Beverage et 
al., 2007, Bradford, 2002). Goetz et. al. were the first to link CYP2D6 
polymorphisms with treatment response, where in a 11.4 year median follow-up they 
demonstrated that the *4/*4 genotype was associated with a poor relapse free or 
disease-free survival period, without any affect on overall survival (Goetz et al., 2005, 
Schroth et al., 2007). Subsequently patients with the *10/*10 genotype were shown 
to have a lower plasma concentration of endoxifen and 4-hydroxytamoxifen than 
those with other genotypes and a significantly worse time-to-progression (5.0 vs. 21.8 
months) and disease-free survival (Lim et al., 2007, Xu et al., 2008).  
There is growing evidence that hot flushes are an indicator of tamoxifen efficacy, as 
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the Women’s Healthy Eating and Living (WHEL) trial showed that those patients 
reporting hot flushes were less likely to develop recurrent breast cancer (12.9% vs. 
21%) than those who did not (Mortimer et al., 2008). Patients are often prescribed 
selective serotonin re-uptake inhibitors (SSRIs) to aid compliance by reducing 
menopausal symptoms, however it has now been shown that SSRIs have a high 
compliance for the CYP2D6 enzyme, therefore reducing the efficacy of tamoxifen to 
endoxifen (Figure 1.5a) (Crewe et al., 1992, Jeppesen et al., 1996, Loprinzi et al., 
2000, Loprinzi et al., 2002, Stearns et al., 2003). This endoxifen lowering effect has 
subsequently been linked to the CYP2D6 genotype (Jin et al., 2005). It has been 
advised that if treatment is required for menopausal vasomotor symptoms, then an 
SSRI such as citalopram or escitalopram or a serotonine nor-adrenaline re-uptake 
inhibitor (SNRI) such as venlafaxine should be used, as these substances show no 
significant inhibition of CYP2D6 (Jin et al., 2005). Potent SSRIs such as paroxetine 
and fluoxetine should be avoided (Borges et al., 2006). Approximately 50% of ERα-
positive breast cancer patients do not respond to tamoxifen therapy (Osborne, 
1998b).  
A number of different molecules have been identified which can affect anti-estrogen 
sensitivity in vitro (Figure 1.9). Overexpression of transmembrane peptide growth-
factor receptors, such as the epidermal growth factor receptor (EGFR), human 
epidermal growth factor receptor 2 (HER-2) and insulin-like growth factor receptors 
(IGFRs) are associated with resistance to endocrine therapy (Kurokawa et al., 2000, 
Ellis et al., 2001, Koga et al., 1989, Faridi et al., 2003, DeGraffenried et al., 2003, 
deGraffenried et al., 2004, Miller et al., 2009). Activation of downstream intracellular 
signalling via the Ras-Raf-mitogen-activated protein kinase (MAPK) pathway and the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway have also been implicated in 
endocrine resistance (Sivaraman et al., 1997, Gee et al., 2001, Tokunaga et al., 2006, 
Martin et al., 2005). These pathways activate downstream targets, which 
phosphorylate ERα (at serine 118 or serine 167) and its coactivators, such as 
amplified in breast cancer 1 (AIB-1) (Font de Mora and Brown, 2000, Joel et al., 
1998, Bunone et al., 1996, Kato et al., 1995). High expression of both HER2 and 
SRC1, a p160 co-activator closely related to AIB-1, is associated with resistance to 
tamoxifen in breast cancer (Myers et al., 2004, Dowsett et al., 2001, Dowsett, 2001). 
Growth factor stimulated receptor tyrosine kinase signalling results in resistance to  
tamoxifen due to enhancement of the agonistic properties of tamoxifen in breast  
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Figure 1.9 Molecular mechanisms of endocrine resistance. Acquired tamoxifen 
resistance in breast cancer cells is mediated by either modulation of the estrogen receptor 
(ER) pathway or aberrant or compensatory cellular signaling pathways controlled by 
growth factor receptors that negate the anti-proliferative and pro-apoptotic effects of 
tamoxifen. In tamoxifen-resistant cells, these end points are regulated by nuclear receptors 
(ER and EERα) and their co-activators, for example nuclear receptor co-activator 3 
(NCOA3; also known as AIB1 or SRC3); receptor tyrosine kinases (RTKs), including the 
epidermal growth factor receptor (EGFR), ERBB2, insulin-like growth factor receptor 
(IGFR) and fibroblast growth factor receptor (FGFR); RTK ligands, including 
transforming growth factor-α (TGFα) and heregulin (HRG), and downstream signalling 
pathways; and cellular stress responses, including those downstream of reactive oxygen 
species (ROS). CDK10, cyclin-dependent kinase 10; JNK, Jun N-terminal kinase; P, 
phosphorylation; PAK1, p21-activated kinase 1; PAX2, paired box 2 transcription factor; 
NF-κB, nuclear factor-κB; XBP1, X-box-binding protein 1. Taken from Musgrove, EA 
and Sutherland RL. Biological determinants of endocrine resistances in breast cancer. Nat 
Rev Cancer 2009; 631-643 
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cancer cells (Massarweh and Schiff, 2007). HER2 driven phosphorylation of AIB1 
has been demonstrated to enhance AIB-1 co-activator function (Shou et al., 2004). 
More recently tamoxifen resistance has been shown to develop when AIB1 levels are 
high and the transcriptional repressor PAX-2 low, thereby inducing high HER-2-
expression (Hurtado et al., 2008). The tumour suppressor FOXP3 and the zinc finger 
transcription factor GATA4 have been shown to repress transcription of HER-2 
(Hua et al., 2009, Zuo et al., 2007). Inhibiting HER-2 signalling combined with 
endocrine treatment in HER-2+ve xenografts re-establishes sensitivity to tamoxifen 
and delays resistance to low levels of estrogen (Shou et al., 2004). BCAR1, has been 
shown to induce tamoxifen resistance in vitro when overexpressed (Dorssers et al., 
1993, van der Flier et al., 2000). BCAR3, synergizes with BCAR1 and activates 
PAK1, both resulting in tamoxifen resistance (Riggins et al., 2003, van Agthoven et 
al., 1998 Cai, 2003 #14696, Rayala et al., 2006). 
MCF-7 cells treated with tamoxifen and fulvestrant become increasingly dependent 
on EGFR as they become resistant (Gee et al., 2003, McClelland et al., 2001). 
Tamoxifen resistance in invasive lobular carcinoma is associated with an increased 
expression of the Estrogen-Related Receptor (ERRγ) (Riggins et al., 2008). Increased 
expression of Activator Protein 1 (AP1) and Nuclear Factor-κB (NF-κB) have also 
been associated with endocrine resistance (Schiff et al., 2000, Zhou et al., 2007).  
Anti-estrogens administered in the neoadjuvant setting result in decreased 
proliferation and G1 cell cycle arrest (Dowsett et al., 2006, Doisneau-Sixou et al., 
2003). Increased expression of c-MYC, cyclin D1, cyclin E1 and a reduction in the 
expression of Rb or the CDK inhibitors p21/p27 results in decreased antiestrogen 
sensitivity (Figure 1.5a) (Prall et al., 1998, Venditti et al., 2002, Hui et al., 2002, 
Dhillon and Mudryj, 2002, Cariou et al., 2000, Carroll et al., 2000, Bosco et al., 2007, 
Varma et al., 2007, Wang et al., 2008b, Butt et al., 2005, Caldon et al., 2006). 
Similarly, microRNAs (miRNAs) mi-221 and miRNA-222 reduce p27 expression and 
confer resistance to tamoxifen. These miRNAs also reduce ERα expression and are 
overexpressed in HER-2-positive breast cancers (Miller et al., 2008, Zhao et al., 
2008). There is increasing evidence that overexpression of the antiapoptotic 
molecules BCL-2 and BCL-XL, and reduced expression of pro-apoptotic molecules 
BAK, BIK and caspase 9 results in a decreased response to tamoxifen (Figure 1.5b) 
(Siddiqa et al., 2008, Riggins et al., 2005). Increased expression of the splice variant 
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form XBP-1 is associated with tamoxifen resistance and worse survival (Gu et al., 
2002, Gomez et al., 2007, Davies et al., 2008). Differential responses to tamoxifen 
have also been observed in different subtypes of ER-positive breast cancers (Sorlie et 
al., 2001, Sotiriou et al., 2003). The luminal A breast cancers have a higher ER-
expression and lower proliferation index and better outcome than the luminal B 
subtypes (Sorlie et al., 2003). 
Gene expression signatures, improving upon current prognostic tools, such as 
immunohistochemistry, histological analysis of tumour biopsies and clinical 
evaluation of tumour characteristics may enable physicians to predict risk of 
recurrence and the response to a specific therapy. Paik et al in collaboration with 
Genomic Health Incorporated developed a recurrence score based on 21 genes that 
appeared to predict accurately the likelihood of distant recurrence in tamoxifen 
treated patients with node negative, ERα-positive breast cancer (Paik et al., 2004). 
The process of clinical validation is ongoing for Oncotype DX™ in the clinical trial 
TAILORx – Trial Assigning IndividuaLized Options for Treatment (Rx). This trial 
will evaluate whether women with node-negative, ER-positive breast cancer need 
chemotherapy based on their recurrence score (RS).  
1.7.2 Resistance to aromatase inhibitors 
The mechanism for resistance to AIs has elements in common with tamoxifen 
resistance. AIB1 mRNA levels are increased in MCF-7 cells treated with anti-
estrogens (ICI 182,780, and tamoxifen), but reduced by estrogen (Lauritsen et al., 
2002). The increase in AIB1 levels following treatment with antiestrogens, 
contributes to resistance by promoting hormone independent pathways. Variability 
in clinical response to AIs raises the possibility that genetic variation may play a role. 
Recently the aromatase gene was sequenced in 60 patients identifying 88 
polymorphisms. Functional genomic studies of three non-synchronous coding single 
nucleotide polymorphisms (cSNP) showed a significantly lower immunoreactive 
protein than wild-type aromatase enzyme (Ma et al., 2005). It is therefore possible 
that patients with decreased aromatase activity would have reduced benefit from 
treatment with aromatase inhibitors. Currently several large studies are evaluating 
pharmacogenomics (the relation between a patient’s genetic make up and response to 
a given therapy) of aromatase inhibitors under the auspices of the Pharmacogenetics 
Research Network (PGRN) (Giacomini et al., 2007).  
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Previous research on endocrine resistance has highlighted many molecules and 
pathways contributing to endocrine resistance (see above), the importance of which 
is presently unclear. The importance of HER-2 and downstream kinases has been 
established and therefore ongoing clinical studies are evaluating whether combining 
endocrine therapy with a variety of novel targeted therapies (monocloncal antibodies, 
tyrosine kinase inhibitors, Raf kinase inhibitors and mTOR inhibitors) may help 
overcome endocrine resistance (Johnston, 2005). 
1.8 The nuclear receptor superfamily 
The nuclear receptor (NR) superfamily comprises a very large family of transcription 
factors, with 48 members in man. These transcription factors are characterised by a 
highly conserved DNA binding domain (DBD) and a conserved ligand binding 
domain (LBD) (Figure 1.10a) (Blumberg and Evans, 1998, Mangelsdorf et al., 1995, 
Chawla et al., 2001). The NR superfamily members are activated upon binding their 
cognate ligand(s) to regulate the expression of target genes. 
NRs can be grouped into four subfamilies on the basis of their DNA binding and 
dimerisation properties (Figure 1.10b). Class I NRs include the steroid hormone 
receptors: estrogen receptors α and β (ERα and ERβ), progesterone receptor (PR), 
glucocorticoid receptor (GR), mineralocorticoid receptor (MR), and the androgen 
receptor (AR). These receptors bind as homodimers to palindromic response 
elements. In the case of ERα and ERβ the palindromes are based on the sequence 
“AGGTCA” present as half-sites separated by 3 bases. The other Class I receptors 
bind to palindrome sequences, the half-sites separated by three bases. Class II NRs, 
which include the retinoic acid receptor (RARα/β/γ), retinoid X receptor (RXRα, β, 
γ), vitamin D3 receptor (VDR), peroxisome proliferator activated receptor (PPARα, 
γ, δ) and the thyroid receptor (TRα/β) bind to direct repeats of the “AGGTCA” 
half-site. Binding occurs as heterodimers, with members of the retinoid X receptor 
family (RXRα, β, γ). Class III receptors bind primarily to a direct repeat of the 
sequence “AGGTCA”. Binding by Class III receptors to these sites occurs as 
homodimers, with examples including binding by the retinoid X receptors 
themselves (RXR α, β, γ). Class IV receptors typically bind to extended “AGGTCA” 
core sites, where they bind as monomers.  
On the basis of ligand binding the human NR can also be subdivided into three 
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Figure 1.10 Nuclear Receptors Share Common Structure/Function Domains  (a) A 
typical nuclear receptor contains a variable N-terminal region (A/B), a conserved DBD (C), a 
variable hinge region (D), a conserved LBD (E), and a variable C-terminal region (F).  (b)
Nuclear receptors can be grouped into four  classes according to their ligand binding, DNA 
binding, and dimerisation properties: steroid receptors, RXR heterodimers, homodimeric-
orphan receptors, and monomeric orphan receptors. Shown are representative receptors for 
each group. Question marks refer to orphan receptors for which ligands are not known. Taken 
from Magelsdorf DJ et. al. The Nuclear Receptor Superfamily: The Second Decade. Cell . 
1995. 83, 835-839 
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subclasses, the so-called “endocrine receptors”, the “adopted orphan receptors” and 
the “orphan receptors” (Figure 1.11) (Chawla et al., 2001). Endocrine receptors 
include NRs, which bind with a high affinity to a specific group of small molecule 
ligands and include the steroid hormone receptors AR, ER, GR, MR and PR, the 
retinoid acid, vitamin D3 and thyroid receptors.  
The second group of NRs encompasses those receptors which bind with lower 
affinity to a wide variety of ligands and whilst these receptors have been termed 
“adopted orphan receptors”, it is likely that the identified ligands for these receptors 
are indeed bona fide and the lower affinity is a reflection of the greater diversity of 
ligands to which each receptor type in this group can bind, as well as the fact that 
many of the ligands for these receptors are highly abundant. For example, the liver 
FXR (Farnesoid X Receptor) and LXR (Liver X Receptor) bind to bile acids, some 
of which are present in huge quantities (Chiang, 2002, Mohan and Heyman, 2003).  
Orphan receptors are grouped together on the basis that they have no identified 
ligand, although it is possible that some orphan receptors may not require a ligand 
for their activity. Recent examples of orphan receptors where putative ligands have 
been found include Steroidogenic Factor 1 (SF-1) and Liver Receptor Homolog-1 
(LRH-1), both of which have been shown to be activated upon binding phosphatidyl 
inositol (Krylova et al., 2005, Li et al., 2005a), and the Drosophila E75 NR, which 
has been shown to bind heme (Reinking et al., 2005). 
Upon binding ligand NRs stimulate the expression of regulated genes through 
concerted action of two transcription activation functions, AF-1 and AF-2. AF-1 is 
located at the N-terminal to the DNA binding domain, is poorly conserved in the 
NR family and is often subject to regulation by phosphorylation (Le Goff et al., 
1994, Ali et al., 1993). AF-2 is intrinsic to the LBD and requires a conformational 
change for activity, primarily through ligand binding. Transcription activation by 
NRs requires the ordered recruitment of transcriptional coregulator complexes, 
which facilitate RNA polymerase II recruitment to promoters of regulated genes. 
These co-regulator complexes remodel and modify chromatin to promote the 
regulation of gene expression by NRs. The structure and activity of ER and LRH-1 
are described below, as these receptors are the subject of the work presented in this 
thesis. 
Figure 1.11 The nuclear receptor superfamily. (a) Schematic structure of a typical 
nuclear receptor is shown. (b) Nuclear receptors can be subdivided into three or four 
groups, depending on the source and type of their ligand. Taken from Chawla et. al. 
Nuclear Receptors and lipid physiology opening the X-files. Science. 2001 294(30). 
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1.9 The estrogen receptor (ER) 
1.9.1 Structure and function 
17β-estradiol (E2), the principal ligand binding to ERα and ERβ was identified in 
1962, with the ERα cDNA being described in 1986 and the gene mapped to the long 
arm of chromosome 6 (6q24-q27; now 6q25.1) cloned the same year (Jensen, 1962, 
Greene et al., 1986, Green et al., 1986, Gosden et al., 1986).  The ERβ gene was not 
described until much later (Kuiper et al., 1996, Mosselman et al., 1996, Tremblay et 
al., 1997) and has been mapped to chromosome 14 (14q.23.2) (Enmark et al., 1997). 
The ERα gene is encoded within eight exons separated by seven intronic regions and 
spans more than 140 kilobases (Ponglikitmongkol et al., 1988). The ERβ gene is also 
encoded within eight exons, spanning approximately 40 kilobases (Enmark et al., 
1997). 
Deletion analyses and structural studies have shown that the most conserved, near 
central region, region C, encodes the DNA Binding Domain (DBD) (Figure 1.12) 
(Zajchowski et al., 1997, Mader et al., 1993). Region E is also highly conserved 
between ERα and ERβ and across the nuclear receptor superfamily, and encodes the 
Ligand Binding Domain (LBD). Structural studies have shown that the ER LBD 
forms a wedge-shaped pocket into which the ligand is accommodated (Pike et al., 
2000). Estrogen binding causes a conformational change that allows transcriptional 
coactivator binding to a coactivator binding groove, which is required for chromatin 
remodelling and modification and for preinitiation complex formation at gene 
promoters, for initiation of gene expression by ER (Shiau et al., 1998, Darimont et 
al., 1998, Rachez and Freedman, 2001). 
The A/B regions are highly divergent and found to be variable in length in the 
different NRs. The exact mechanism underlying transcriptional regulation by AF-1 is 
unclear, although many coactivators have been shown to interact with AF-1 
sequences. ERα AF-1 activity is regulated by the LBD, which allows the unliganded 
ERα to interact with the hsp90 complex, thereby maintaining ERα in an inactive 
state (Sabbah et al., 1996, Baulieu, 1987, Groyer et al., 1987). ERα AF-1 activity is 
further regulated by phosphorylation at several sites, resulting in increased ERα 
activity (Rochette-Egly, 2003). Tamoxifen is an antagonist in the breast, but acts as 
an agonist (i.e. have estrogenic activity) in the uterus, and has been termed  
hERα 
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Figure 1.12 Domain-structure representation of human ERα and ERβ isoforms.  
Adapted from Kong E.H et. al. Structure and mechanism of the estrogen receptor.  
Biochemical Society Transactions. 2003. 31(1), 56-59. 
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a selective estrogen receptor modulator (SERM) (MacGregor and Jordan, 1998). The 
antagonistic activity derives from inhibition of AF-2, together with activation of AF-
1. Therefore, where AF-2 activity is predominant, tamoxifen is found to act as an 
antagonist, while in tissues where AF-1 is predominant, tamoxifen acts in an 
agonistic manner (Berry et al., 1990, Murphy, 1998, Osborne, 1998a). The A/B 
region, located amino-terminal to the DBD is variable in length and sequence 
between ERα from different species, with 28% amino acid sequence homology. 
Region C (amino acids 181-263) of the estrogen receptor encodes the DBD, which is 
the most highly conserved region across the NR superfamily (Figure 1.12). The DBD 
contains two functionally distinct zinc-finger motifs within 66-70 amino acids, which 
are responsible for DNA binding and dimerization of the receptors (Mader et al., 
1993). Each zinc finger binds one zinc ion co-ordinated by four cysteine residues. 
Two α-helical motifs within the DBD enable interaction with the DNA major grove 
(first α-helix), leading to stabilization of the complex by mediating dimerization 
between DBDs, through amino acid residues in the D-box (second α-helix) (Bain et 
al., 2007, Perlmann et al., 1993, Zechel et al., 1994). ERα and ERβ bind DNA with 
equal affinity as either homodimers or as heterodimers to EREs (Ogawa et al., 1998, 
Pace et al., 1997, Kuiper and Gustafsson, 1997, Cowley et al., 1997, Klein-Hitpass et 
al., 1989, Kumar and Chambon, 1988). Amino acids located at the C-terminal end of 
the first zinc finger, the P-box determine the specificity of NR for its response 
element. This was demonstrated by substitution of three amino acids in human ERα 
(E, G and V) by the analogous amino acids in the glucocorticoid receptor (GR) (G, 
S, V) thus enabling the ERα to bind to a glucocorticoid response element (GRE). 
Reciprocal substitutions of amino acids G-S in GR by E-G, in contrast, enabled GR 
to bind to EREs (Green et al., 1988, Mader et al., 1989, Danielsen et al., 1989). 
Region D (amino acids 264-302) also referred to as the flexible hinge region, is 
involved in nuclear localisation and dimerization and is also important in the 
interaction of unliganded ERα with the hsp90 complex maintaining ERα in an 
inactive state (Klinge et al., 1997). Phosphorylation of serine residue 305 in the hinge 
region of ERα increases binding to target gene promoters, which has been shown to 
lead to increased cell growth in the absence of estradiol. It has also been implicated 
as a role in tamoxifen resistance (Giordano et al., 2009, Tharakan et al., 2008). 
The LBD in region E (also called AF-2) (amino acids 303-552) is the second most 
conserved domain in the NR superfamily (figure 1.12). The LBD is encoded within a 
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peptide region of approximately 250 amino acids and is required for ligand binding, 
and also facilitates receptor homodimerization and heterodimerization, and mediates 
gene regulation by directly interacting with coactivators and corepressors. The LBD 
is formed by 12 α-helices arranged in an anti-parallel α-helical ‘sandwich’ fold, 
forming a wedge-shaped structure that was first described for the human RXRα 
LBD and is a structure common to the LBD of most NRs (Bourguet et al., 1995, 
Moras and Gronemeyer, 1998). Hence, the ligand bound ERα LBD is seen to be a 
structure of 12 α-helices (H1-H12) organised in a three-layered sandwich with H4, 
H5, H6 and H9 flanked on one side by H1 and H3 and on the other side by H7, H10 
and H11. The ligand pocket is closed on one side by an anti-parallel β sheet and on 
the other by H12. The ERα LBD structure has been determined in complex with 
estrogen, estrogen agonists and anti-estrogens (Brzozowski et al., 1997, Kong et al., 
2003, Shiau et al., 1998). The AF-2 ligand-binding pocket of ERα can bind a wide 
variety of compounds, including polycyclic aromatic hydrocarbons, pesticides and a 
class of estrogen like substances termed xenoestrogens (Bolger et al., 1998). The 
orientation of H12 is highly sensitive to the nature of the bound ligand, but the 
overall conformation of the ERα LBD is remarkably similar. In addition to binding 
ligand, the NR LBDs direct transcriptional regulation by the recruitment of 
transcriptional coactivators and corepressors (Glass and Rosenfeld, 2000). The 
interaction of coactivators with LBD of NR is mediated by a two-turn α-helix having 
the sequence LXXLL (L is a leucine and X is any amino acid) (Le Douarin et al., 
1996b, Heery et al., 1997). This α-helical motif is accommodated in the H3, H4 and 
H5 groove, with H12 also participating in the interaction with the LXXLL motif. 
The large side chains of the antiestrogens, tamoxifen, faslodex and raloxifene prevent 
H12 from adopting an agonist-bound conformation, thus antagonizing recruitment 
to by the LBD. Compounds lacking a large side chains, such as genistein, inhibit 
ERα activation by stabilizing the ligand-binding pocket (Shiau et al., 2002, Pike et al., 
1999).  
The F region (amino acids 553-595) at the C-terminus of ERα, represents the last 45 
amino acids in ERα and approximately the last 30 amino acids in ERβ (Figure 1.13). 
The F region functions to internally restrain dimerization of ER, thus protecting 
against improper ligand activation (Skafar and Koide, 2006, Yang et al., 2008). 
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1.9.2 Estrogen receptor isoforms 
The ERα gene coding sequence is encoded within eight exons separated by seven 
intronic regions spanning more than 140 kilobases. Up to five different ERα 
transcript isoforms/variants have been noted in humans due to alternative usage of 
eight 5’ untranslated exons, exonic duplications, alternative splicing and intronic 
exons (Hirata et al., 2003). The human ERα gene encodes a polypeptide of 595 
amino acids. However in different cell lines, variant polypeptides have been 
identified and include ERα-36 (hERα-36 kDa), hERα-46 kDa and hERα-66 kDa 
(Flouriot et al., 2000, Wang et al., 2005). hERα-36 lacks both the transcriptional 
activations domains (AF1 and AF-2)  (Figure 1.13) (Wang et al., 2005). The hERα-46 
kDa also lacks AF-1 and demonstrates an antagonistic activity on the proliferative 
action of the hERα-66 kDa in MCF-7 cells (Penot et al., 2005).  
ERβ is a polypeptide of 530 amino acids and is structurally and genetically distinct 
from ERα. Human ERβ is also encoded within an 8 exon gene, located in a 40 
kilobase region of chromosome 14q22-24 (Enmark et al., 1997). ERβ exists as five 
distinct isoforms, termed ERβ1-5, each distinguished by a unique exon 8 sequence. 
These variants are usually found in greater abundance than full-length ERβ (ERβ1) 
in terms of RNA expression (Leygue et al., 1999, Tong et al., 2002, Iwao et al., 2000). 
Ethnic differences in expression of ERβ isoforms have been reported with ERβ and 
in particular, ERβ5 expressed at significantly higher levels in African Americans 
compared to Caucasians (Poola et al., 2005). Tumours from African American and 
Latin American women are often ERα-negative and associated with a poorer survival 
(Chu et al., 2003). This high expression of ERβ isoforms suggests that these patients 
may well benefit from a specific ERβ-targeted therapies. 
1.9.3 Transcriptional regulation by estrogen receptors 
Unliganded ERα exists in an inactive repressed complex, bound by the hsp90 
complex (Klinge et al., 1997). Binding of a ligand allows dissociation from these heat 
shock proteins, receptor dimerization and binding to EREs in promoters of estrogen 
responsive genes. Regulation of gene expression by ERα requires the ordered 
recruitment and dissociation of a series of coactivator complexes, resulting in 
chromatin remodelling and cycles of histone acetylation and methylation, 
deacetylation and demethylation, to facilitate RNA Polymerase II recruitment and 
Figure 1.13 Domain structure and expression of hERs in HEK 293 cells. Domain structure 
representation of human hER-α isoforms. Domains (labeled A– F), amino acid sequence numbers, 
and activation function domains (AF-1 and -2) are shown. The function of each domain is indicated. 
The last 27 amino acids of hER-a36 are indicated as a filled box. Adapted from  Wang ZY et al. 
Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human 
estrogen receptor-α66. Biochemical and Biophysical Research Communications 336 (2005) 1023–
1027. 
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initiation of transcription (Glass and Rosenfeld, 2000, Metivier et al., 2003).  
1.10 Estrogen receptor cofactors 
It is well known that ER function is tissue specific and ligand dependent, indicating 
that ERα alone could not account for its diverse functions, therefore requiring other 
signalling factors (Halachmi et al., 1994). Since the description of the first ER 
cofactors in 1995, more than 300 NR cofactors have been described (Onate et al., 
1995, McKenna et al., 1999) (McKenna and O'Malley, 2002). These factors are 
generally categorized as coactivators that enhance ER transcriptional activity by 
interacting with the basal transcription machinery and/or by altering chromatin 
structure by chromatin remodelling and chromatin modification, generally 
functioning as large, high-molecular weight complexes comprised of approximately 
six to seven coregulator proteins (Jordan and O'Malley, 2007). Cofactors do not bind 
to DNA directly but do so by association with sequence-specific DNA-binding 
proteins. Following recruitment to the promoter complex, cofactors may affect 
transcription directly or via further cofactor recruitment. 
1.10.1 Coactivators 
These proteins were originally identified as NR interacting proteins in yeast 2-hybrid 
and bacterial expression library screens (McKenna and O'Malley, 2002). The most 
extensively characterised and studied of the NR interacting proteins are the p160 
(Steroid Receptor Coactivator- SRC) family of coactivators. The three highly 
homologous members of the p160 family, named SRC1 (also called Nuclear 
Receptor Coactivator-1 (NCoA1)), SRC2 (also called Glucocorticoid Receptor 
Interacting Protein 1(GRIP1), Transcriptional Intermediary Factor 2 (TIF-2) or 
NCoA2) and SRC3 (also known as Retinoic Acid Receptor interacting protein 
(RAC3), mouse homolog CBP-Interacting Protein (p/CIP), hRARβ-stimulatory 
protein (ACTR), Amplified In Breast cancer (AIB-1) and TR-interacting protein 
(TRAM1)) (Onate et al., 1995, McInerney et al., 1996, Voegel et al., 1996, Anzick et 
al., 1997, Chen et al., 1997, Hong et al., 1997, Li et al., 1997). These p160 
coactivators are characterized by a basic helix-loop-helix, and PAS (per/Arnt/Sim 
homology) domains, which mediate homo- and heterodimeric interactions with 
proteins containing similar domains. All three are recruited to NR by interaction with 
liganded LBD through the LXXLL α-helical motif (Heery et al., 1997). Three 
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LXXLL motifs are present in each p160 and even though the leucine residues are 
critical for interaction, sequences flanking the motif influence NR specificity (Heery 
et al., 2001, Mak et al., 1999, Needham et al., 2000). The p160 proteins act as scaffold 
proteins for the recruitment of other coactivators to NR. They interact with the p300 
and CBP histone acteyltransferase complexes to facilitate histone modification upon 
ligand stimulation and NR recruitment to promoters of regulated genes (Glass and 
Rosenfeld, 2000). 
SRC-1 was the first steroid receptor coactivator cloned which enhanced the 
transcriptional activity of ERα when cells were treated with estrogen (Onate et al., 
1995). SRC-1 has been shown to be involved in ligand-independent activation of 
ERα. SRC-1 expression has been noted in invasive ductal and lobular breast 
carcinomas, but is not expressed in normal tissue (Fleming et al., 2004b). SRC-1 
expression is associated with HER-2 expression, increased risk of recurrence and 
poor response to endocrine therapy and axillary nodal positivity (Fleming et al., 
2004b, Fleming et al., 2004a). One clinical study showed that SRC-1 and AIB-1 was 
expressed in 22% and 54% of breast tumours respectively, and in a subset of patients 
their expression was associated with growth factor expression, suggesting a link 
between growth factor and coactivator expression (Myers et al., 2005). Localisation 
studies have shown SRC-1 and SMRT to be colocalised with the nuclear receptors 
ERα and ERβ (Myers et al., 2005). SRC-1 knockout mice (SRC-1-/-) have revealed 
partial resistance to several hormones (Weiss et al., 1999). 
The second member of the coactivator family is SRC-2 (GRIP1/TIF-2) (Voegel et 
al., 1998, Hong et al., 1996). SRC-2 is regulated by sumoylation, phosphorylation and 
ubiquitination. Sumoylation of SRC-2 modulates its subnuclear localisation and its 
interaction with NRs (Kotaja et al., 2002a, Kotaja et al., 2002b). SRC-2 
phosphorylation by MAPKs potentiates ER-dependent transcription (Gregory et al., 
2004, Lopez et al., 2001). Activation of PKA down-regulates SRC-2 post-
transcriptionally, but has no effect on expression of SRC-2 mRNA (Borud et al., 
2002). Disruption of SRC-2 expression in mice results in reduced fatty acid 
metabolism, and SRC-2 knockout mice have reduced fertility (Picard et al., 2002, 
Gehin et al., 2002). SRC-2 and ERα expression correlates in breast cancer tissue, 
with higher mRNA levels in breast cancer than normal mammary tissue 
(Kurebayashi et al., 2000). To date, there is little data on the predictive or prognostic 
role of SRC-2 in cancer. 
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SRC-3 (AIB1) stimulates ERα transcriptional activity in reporter gene assays (Anzick 
et al., 1997, Li et al., 1997). It has been implicated in cellular proliferation, 
differentiation, and migration and is overexpressed in a variety of human epithelial 
tumours including breast and prostate cancer (Anzick et al., 1997, McKenna et al., 
1999, Kirkegaard et al., 2007, Gnanapragasam et al., 2001). The gene for AIB-1 is 
located on chromosome 20q and is amplified in 5-10% of breast cancers (Bautista et 
al., 1998). Increased expression of AIB-1 in mice is associated with tumour 
development, whereas silencing of AIB-1 impairs mammary tumourigenesis (Torres-
Arzayus et al., 2004, Kuang et al., 2004). AIB-1 is regulated by post-translational 
modifications including methylation, phosphorylation, acetylation, ubiquitination, 
and sumoylation. Increased AIB-1 and ERα expression are associated with a better 
outcome in untreated patients, however in patients treated with tamoxifen AIB-1 
expression is associated with a worse disease free survival (Kirkegaard et al., 2007, 
Osborne et al., 2003). In vitro data suggests that elevated levels of ERα co-activators 
may increase the agonistic activity of tamoxifen, thereby leading to endocrine 
resistance (Kurebayashi et al., 2000). 
Sequence analysis of one of the first ER interacting proteins, RIP140 (Cavailles et al., 
1995) showed the presence of ten copies of a motif with the consensus sequence 
LXXLL (where L=leucine, although isoleucine, or other large hydrophobic amino 
acid residues can substitute). This motif was also present in a region of SRC-2/TIF2 
already shown to be important for its activity (Le Douarin et al., 1996a). Mutational 
analysis and yeast 2-hybrid assays showed that sequences surrounding and including 
these LXXLL motifs are sufficient for interaction with the LBD of NR (Heery et al 
1997). Structural studies have shown that these motifs form α-helices and interact 
with NR LBD at a groove formed by α-helices H3, H4, H5 and H12 (Shiau et al., 
1998). LXXLL motifs also mediated interaction of NR with other coactivators such 
as CBP/p300 and TRAP220 (Chang et al., 1999). Other co-activators directly interact 
with the ERα AF-1 region (e.g. p68 RNA helicase), hinge domain (e.g. PGC-1α), or 
the DBD (e.g. Ciz1) (Endoh et al., 1999, Tcherepanova et al., 2000, den Hollander et 
al., 2006). Other cofactors such as protein arginine methyl transferase, CARM1 and 
PRMT2 affect ERα transcriptional activity through indirect association with SRC 
family of coactivators (Chen et al., 2000). 
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1.10.2 Corepressors 
Far fewer corepressors have been identified than coactivators. Corepressors inhibit 
transcription of NR target genes by either directly or indirectly interacting with the 
receptors. Sequence analysis of the nuclear corepressors including NCoR1 (Nuclear 
receptor corepressor 1) and SMRT (silencing mediator for retinoid and thyroid 
receptors)/TRAC-2 has identified an LxxxI/HIxxxI/L conserved nuclear 
corepressor-binding motif (the so called CoRNR box), which has been demonstrated 
to mediate either ligand-independent or anti-estrogen stimulated association with the 
AF-2 domain of ERα (Perissi et al., 1999, Leers et al., 1998, Chen and Evans, 1995, 
Sande and Privalsky, 1996, Hu and Lazar, 1999). The CoRNR-box occupies the 
coactivator-binding groove in the LBD, but being a more extended α-helix, pushes 
H12 away from its normal position in the coactivator occupied LBD (Xu et al., 
2002). Corepressors also interact with other domains of ERα, including the AF-1 
(HDAC4) and hinge domains (SAFB and MTA-2) (Leong et al., 2005, Oesterreich et 
al., 2000, Cui et al., 2006). Overexpression of the nuclear corepressors NCoR and 
SMRT potentiates tamoxifen antagonist activity, and decreased NCoR levels 
correlate with hormone resistance (Smith et al., 1997, Scott et al., 2007). In addition 
to associating with nuclear receptors on DNA, NCoR and SMRT form complexes 
with mammalian suppressor mSin3 and with histone deacetylases (Alland et al., 1997, 
Heinzel et al., 1997, Nagy et al., 1997). Therefore corepressors mediate gene 
repression by recruiting histone deacetylases leading to histone tail deacetylation. 
Liganded ERα inhibits the expression of some genes, and one potential mechanism 
is through the recruitment of other cofactors, such as Receptor-Interacting Protein 
140 (RIP140) and Ligand dependent nuclear receptor Corepressor (LCoR) to the 
LBDs through LXXLL coactivator motifs, rather than the CoNR-box motif 
(Cavailles et al., 1995, Fernandes et al., 2003). These corepressors also recruit histone 
deacetylases, as well as the Carboxy-terminal Binding Protein (CtBP). CtBP has been 
shown to act as a corepressor for a number of transcription factors, and is recruited 
by the sequence PXDLS in the interacting protein (Chinnadurai, 2002, Nibu et al., 
1998).  Increased expression of corepressor MTA-2, results in hormone-independent 
and anti-estrogen resistant cell growth (Cui et al., 2006). 
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1.11 Chromatin remodelling 
Methylation and/or acetylation of histones promote decondensation of chromatin 
structure, thereby favouring gene transcription. Demethylation and/or deacetylation 
lead to chromatin condensation, thus inhibiting transcription. A large number of 
steroid receptor cofactors are involved either directly modifying histones (e.g. 
CBP/p300, P/CAF, SRC-1, CARM-1, and HDAC1) or indirectly deacetylating 
histones through the recruitment of histone deacetylases (e.g. MTA1/2 or SIN-3) 
(McKenna et al., 1999). These cofactor/cofactor complexes are recruited to 
estrogen-responsive promoters in an ordered and cyclical fashion. Evidence suggests 
that histone premodification is essential to direct the recruitment of individual 
cofactors (Metivier et al., 2003). Additionally ERα and cofactors are also modified 
during transcriptional activation e.g. acetylation of ERα results from agonist-induced 
interactions with certain coactivators that result in decreased transcriptional activity 
(Aye et al., 2004). SCR3 an ERα coactivator with histone acetyl transferase activity 
loses its coactivator activity following acetylation by p300 (Chen et al., 1999). 
1.12 Non-classical mechanisms for transcriptional regulation by ERα  
ERα has been shown to regulate the expression of several target genes through an 
indirect mechanism of interaction with other transcription factors, notably AP-1, SP-
1, NF-kB, STAT5, GATA-1 and GATA-3 (Kushner et al., 2000, Safe, 2001, 
Eeckhoute et al., 2007). Whilst indirect regulation of gene expression by ERα does 
not require its binding to DNA, the DBD is often required for the regulation of 
these genes. Mutational analysis has shown that specific residues within the second 
zinc finger play a key role in this process. Genes regulated by this mechanism include 
VEGF, IGF-1, BCL-2, cyclin D1, c-MYC, c-Fos and DNA polymerase α. 
1.13 Non-genomic signalling of ERα  
There is a great deal of recent evidence which demonstrates that in addition to a 
nuclear role for ERα through regulation of gene expression, ERα also causes rapid 
activation of protein kinase cascades through direct interaction with protein kinase 
signalling cascades. Thus, addition of estrogen rapidly stimulates ERK1/2 MAPK 
activity through a process requiring ERα (Klinge et al., 2005). Activation of Akt 
mediates many effects of PI3K, including phosphorylation and inactivation of BAD 
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to prevent BAD-mediated apoptosis and rapid activation of the endothelial isoform 
of eNOS (Chambliss and Shaul, 2002). Evidence for localisation of a small 
proportion of ERα to the cell membrane has been reported (Levin, 1999, Levin, 
2002, Razandi et al., 2003a) and seems to be involved in rapid activation of MAPK, 
Akt, p21ras, Raf-1 and protein kinase C, increase in intracelluar Ca2+ levels, alteration 
in maxi-K channels, and release of nitric oxide and stimulation of prolactin secretion 
(Cheskis, 2004, Levin, 2005, Shupnik, 2004). The adapter protein, Modulator of 
Non-genomic Activity of estrogen Receptor (MNAR) has been identified to be 
required for membrane estrogen action (Wong et al., 2002, Barletta et al., 2004). 
Recently, a model has been proposed for the formation of a multiprotein-based 
activating particle, involving ERα, SRC, MNAR, p85α, SHC and G proteins in 
ERα-responsive cells. In this model MNAR, p85α, SHC and G proteins act to 
mediate ERα and SRC activation (Song et al., 2005). Crosstalk with growth factor 
receptors, such as IGF-1R and EGFR has also been described in activation of these 
signalling cascades (Kahlert et al., 2000, Razandi et al., 2003b). Expression of this so-
called membrane ER (mER) is correlated with less differentiated and more 
aggressive breast tumours (Pelekanou et al., 2007). 
1.14 Regulation of ERα  gene expression through the use of alternative 
promoters 
The original description of the cloning of the human ERα gene identified one gene 
promoter (Ponglikitmongkol et al., 1988). Subsequent comparisons of the human, 
mouse and chicken ERα gene 5` untranslated regions (5`UTR) showed poor 
sequence conservation in the region proximal to the first exon, suggesting the 
possibility of other alternative 5` exons and promoters located further upstream. 
Further analysis of the human genomic sequences indicated the presence of 
sequences about 2 kb upstream of the initially described ERα gene promoter with 
substantial homology in mouse and rat ERα genes (Keaveney et al., 1991). These 
regions encoded sequences that potentially defined a second gene promoter, 
transcribing an exon that could splice to an acceptor splice site within the first coding 
exon of the ERα  gene. This arrangement was subsequently confirmed by the 
identification of a transcript from human uterine mRNA with the predicted 
structure. Moreover, the presence of a splice acceptor site in the first coding exon 
suggested the possibility of the presence of other promoters and exons. To date, 
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Figure 1.14 Genomic Organization of the Promoter Region of the Human ERα 
Gene Demonstrating the genomic location of multiple promoters and upstream 
exons. Boxes represent upstream exons with names according to the suggested 
nomenclature. Promoters are depicted as broken arrows. Numbers below exons 
correspond to the distance from the originally described transcription start site +1 in 
base pairs. Numbers between exons show the size of major introns in kilobase pairs. 
The common acceptor splice site in exon 1 is represented by an open triangle.Taken 
from Kos M. et al. Minirview: Genomic organisation of the human ERα gene 
promoter region. Mol Endocrinol. 2001 15(2) 2057-2063  
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seven promoters have been identified in the ERα gene, with several of these 
showing tissue specific activity (Figure 1.14) (Flouriot et al., 1998, Kos et al., 2001). 
Promoter A, the most proximal promoter to exon 1 is the most common promoter 
utilised in tissues and cell lines. Additional promoters, B-E have been described, and 
have been shown to work in reporter gene assays (Keaveney et al., 1991, Piva and 
Del Senno, 1993, Kos et al., 2002).  
One hypothesis that has been suggested for this complex arrangement of gene 
promoters and 5`UTR exons, is that the numerous AUG start codons found in these 
potentially have a regulatory role, primarily by inhibiting scanning ribosomes from 
reaching the start codon in exon 1, thereby inhibiting ERα protein expression (Kos 
et al., 2002). The promoters found within 2 kb of the acceptor splice site (A, B and 
C) are preferentially used in cells highly expressing ERα, whereas the more distal 
promoters E and F are used in tissues where ERα expression is lower, such as the 
liver and in osteoblasts (Reid et al., 2002). While these alternative promoters can 
account for tissue specific expression of ERα they may also play a role in the 
regulation of ERα levels. Increased use of promoter A has been demonstrated in 
breast cancer cells compared with normal breast epithelium (Grandien et al., 1995). 
Further, promoters that are not used in normal mammary epithelium are seen to be 
active in breast cancer cells (Weigel et al., 1995). 
1.15 Post-translational regulation of ERα  
Post-translational modifications are thought to play a key role in the regulation of 
ERα. Post-translational regulation of NRs includes methylation, phosphorylation, 
acetylation, ubiquitination and sumoylation. Post-translational regulation of nuclear 
receptors results in the protein being differentially affected by modifications either 
singly or in combination, therefore affecting receptor conformations, ligand binding, 
DNA binding and coactivator interactions (Likhite et al., 2006).  
1.16 ERα  mutations 
A number of mutations and polymorphisms of ERα have been identified in 
precocious puberty conditions and also in cancer (Herynk and Fuqua, 2004). More 
than 20 mutations of ERα have been described, with the most frequent being 
mutations A86V, K303R and Y537S/N. Further, a Y86V mutation has also been 
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reported to occur in 12% of breast cancer specimens, where it has been associated 
with a reduced ERα expression and spontaneous abortions (Garcia et al., 1988, 
Lehrer et al., 1990). The tyrosine residue Y537 is known to be a target residue for 
phosphorylation by c-SRC and related kinases and is located at the amino cap of 
H12. Importantly, mutation of this site to asparagine (Y537N) has been seen in 
breast tumours (Zhang et al., 1997) and has been shown to cause ligand-independent 
ERα activity (Weis et al., 1996). The K303R mutation, also reported in breast 
cancers, results in a receptor with greater sensitivity to low concentrations of 
estrogen, increased binding to the coactivator TIF2, and inhibition of corepressor 
MTA2 on the activity of the receptor (Fuqua et al., 2000, Cui et al., 2006). Transgenic 
mice expressing the K303R mutant in the mammary gland show precocious alveolar 
development, greater alveolar budding, increased β-casein production and more 
dilated ducts compared with control transgenic mice expressing ERα, although there 
was no evidence for an increased rate of tumour formation or hyperplasia (Herynk et 
al., 2009). Further, the K303R mutant ERα mice delayed tumourigenesis when 
crossed with HER-2 expressing transgenic mice. Hence, a role for this mutation in 
breast cancer development remains unclear.  
1.17 Estrogen responsive genes 
The major actions of estrogen are mediated by binding to ER and the consequent 
transcriptional activation of target genes by the DNA-bound ER. Prior to the advent 
of gene expression microarray profiling, relatively few estrogen-regulated genes in the 
breast had been identified, with these largely coming from differential display and 
subtractive hybridisation methodologies. Such genes include the PR, pS2, Cathepsin 
D and Gene Regulated by Estrogen in Breast Cancer (GREB-1), all of which are 
regulated by direct binding of ERα to EREs in the promoters of their genes. Other 
estrogen regulated genes include c-myc and cyclin D1 where no ERE involvement 
has been identified and ERα activation occurs through recruitment by interaction 
with other transcription factors (see section 1.8). Recent gene expression microarray 
studies have shown that the expression of a large number of genes is estrogen-
regulated in estrogen-responsive cell lines. Frasor et al. (2004) identified 438 
estrogen-regulated genes in an array set of 12,000 (Affymetrix human U95A) (Frasor 
et al., 2004). Other studies similarly identified large numbers of estrogen-responsive 
genes breast cancer cell lines and in other cell types (Soulez and Parker, 2001, Inoue 
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et al., 2002). These studies further show that the majority of estrogen-regulated genes 
(approximately 70%) are inhibited by estrogen, with only 30% of the genes showing 
stimulation. Importantly, these studies show that many of the estrogen-regulated 
genes in breast cancer cell lines are important for cell cycle progression and 
apoptosis, and include genes encoding transcription factors, cell growth factors and 
genes associated with DNA damage recognition and repair (Frasor et al., 2004).  
1.18 Liver receptor homolog-1 (LRH-1) 
On the basis of homology, the NR superfamily can be divided into seven subfamilies 
(NR0-NR6), representing ancestral relationships (Schwabe and Teichmann, 2004). 
The Liver Receptor Homolog-1 (LRH-1; also called NR5A2, α-fetoprotein 
transcription factor, human B1-binding factor, Ftz-F1-related factor, and CYP7A1 
promoter binding factor) is an orphan member of the NR5A2, or Ftz-F1 subfamily, 
which comprises four members (NR5A1-NR5A4). Mouse LRH-1 was the first 
NR5A member to be cloned and was identified as a result of its homology to the 
Drosophila Fushi tarazu factor-1 (Ftz-F1;NR5A3). Further LRH-1 orthologs have been 
identified in several species, including in humans (Galarneau et al., 1996, Kudo and 
Sutou, 1997, Boerboom et al., 2000, Liu et al., 1997, Ellinger-Ziegelbauer et al., 1994, 
Nakajima et al., 2000, Becker-Andre et al., 1993, Galarneau et al., 1998, Li et al., 
1998, Nitta et al., 1999). A second member of the family and, a close homologue of 
LRH-1 in mammals, is the Steroidogenic Factor-1 (SF-1; NR5A1), which is seen to 
be highly expressed in steroidogenic and hypothalamo-pituitary-adrenal axis tissues 
(Val et al., 2003).  
1.18.1 LRH-1 structure and isoforms 
LRH-1 has a similar structure to other NRs, and includes transcription activation 
functions (AF1 and AF2), DBD and an LBD (Robinson-Rechavi et al., 2003, 
Warnmark et al., 2003). The LRH-1 LBD structure has been determined by 
molecular replacement methods, using an atomic model of the hormone-bound 
RXRα LBD, and was found to share a common protein fold seen in other NRs but 
arranged into a sandwich structure with four layers, instead of the typical three-
layered sandwich of eleven α-helices and two short β-strands (Sablin et al., 2003, 
Egea et al., 2000). Further, comparison of LRH-1 with hormone-bound RXRα, 
revealed a conformation that resembled an active, agonist bound state, where the C-
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terminal helix H12 is tightly packed against the H3-H4-H5-H11 region of the LBD. 
The LRH-1 LBD also showed three distinct features not present in other LBD 
structure. Firstly, a rigid, long helix H2 forming the fourth outer layer in the 
receptor’s structure, the positioning of the preceding helix H1 which is translated by 
one helical turn towards H9, and thirdly as a result of the positioning of H1, the N-
terminal proline is configured on the opposite face of H1, which influences the 
direction of the N-terminal linker, which runs along helix H9 (Sablin et al., 2003).  
LRH-1 has a large (~820Å3), well-defined, fully enveloped hormone pocket. Sablin et 
al. tested whether the activity of LRH-1 may be ligand dependent, by creating 
specific amino acid mutations in the LRH-1 pocket (Sablin et al., 2003). All four H11 
pocket mutants (A368W, A368M, A532W and A532M) exhibited comparable activity 
with wild type LRH-1 in HepG2 liver cells, which implies that the activity of LRH-1 
is preserved even after disrupting the size and shape of the ligand-binding pocket. 
Substitution of external facing residues of the helix H2 (Q336, Q346, and Q347) 
with alanines or histidines was shown to diminish activity of LRH-1 in HepG2 when 
co-transfected with either AIB-1 (coactivator) or SHP (corepressor). Mutation of the 
internal residues on helix H2 (R352E) demonstrated diminished activity by GRIP1 
but not SHP. This confirms that an incorrectly packed or misplaced H2 in LRH-1 
therefore destabilizes the active conformation of H12. 
Members of the NR5A family bind to DNA with a high affinity as monomers to the 
Ftz-F1-consensus binding site YCA AGG YCR (where Y is any pyrimidine and R is 
purine) similar to other NRs such as Rev-Erbα (NR1D1), Nerve Growth Factor-
inducible Factor B (NGFI-B; NR4A1) and estrogen-related receptor 2 (ERR2; 
NR3B2) (Ueda et al., 1992). The NR5A subfamily is unique, as family members 
contain 20 amino acid long motifs located at the C-terminal end of the DBD, 
sometimes referred to as the C-terminal extension (CTE) or called the Ftz-F1 motif 
after Ftz-F1, the Drosophila NR first identified as a coactivator of the Fushi tarazu 
(Ftz) transcription factor (Fayard et al., 2004, Ueda et al., 1990). This 20-residue Ftz-
F1 motif in hLRH-1 binds to the small (16.4kDa) Multi-protein Bridging Factor 
(MBF-1), which also interacts with the TATA-Binding Protein (TBP) component 
(Brendel et al., 2002). Crystal structural analysis of the LRH-1 DBD-DNA complex 
indicate that positioning of the non-DNA-binding Ftz-F1 helix affects receptor 
activity and coactivation by transcriptional enhancer GRIP1 (Solomon et al., 2005). It 
is suggested that correct packing of the Ftz-F1 helix may be required to orientate the 
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LBD and binding of coactivators relative to DNA for transcriptional control and 
binding of transcriptional enhancer proteins.  
The LRH-1 gene is organised into eight exons, and spans more than 150 kilobases of 
chromosome 1, 1q32.11 (Figure 1.14) (Galarneau et al., 1998, Li et al., 1998, Zhang 
et al., 2001). Three isoforms of LRH-1 have been identified, all resulting from 
alternative splicing, with the most common isoform being one that encodes an LRH-
1 variant that lacks exon 2 sequences and, thereby, encodes a smaller A/B domain 
when compared to the form in which this exon is used (Galarneau et al., 1998, Li et 
al., 1998, Nitta et al., 1999, Zhang et al., 2001). The third, and, smallest variant of 
LRH-1, contains a deletion in the D and E region as a result of alternative splicing 
involving exon 5, and subsequently encodes an isoform that does not activate 
transcription (Nitta et al., 1999, Zhang et al., 2001).  
1.18.2 Modulation of LRH-1 activity by phospholipids 
Structural analysis of hLRH-1 LBD demonstrated an electron density map consistent 
with the presence of bound phospholipid, the nature of which was further 
characterised by nondenaturing mass spectrometry (Krylova et al., 2005, Ortlund et 
al., 2005). Quantification of the hLRH-1 and phospholipid showed a ligand/receptor 
complex, with nearly all of the protein bound by a phospholipid (Krylova et al., 
2005), however another study revealed only 20% of the LBD bound to a 
phospholipid (Ortlund et al., 2005). The most abundant species were found to be 
747-721Da consistent with the phospholipids phosphatidyl glycerol (PG) and 
phosphatidyl ethanolamine (PE). hLRH-1 was shown to selectively bind to 
Phosphatidyl Inositol Phosphate-2 (PIP2) and PIP3 phosphatidyl inositol with an 
efficacy of 2-3 fold better than LRH-1 with a pocket mutation (Ortlund et al., 2005, 
Krylova et al., 2005). Mutant forms of hLRH-1, with substantially impaired 
phospholipid binding, were also shown to decrease interaction with coactivators 
SRC-2 (GRIP-1) and SRC-3, as determined by GST-fusion pull down and 
mammalian two-hybrid experiments.  
1.18.3 Kinase activation of LRH-1 
LRH-1 has been seen to be regulated by various phosphorylation pathways. MAPK 
kinase (ERK) phosphorylation has been shown to stimulate LRH-1 activity. This is 
primarily seen to occur through two hinge domain serine residues, Ser-238 and Ser- 
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Figure 1.15 Structure of the gene, mRNAs and protein isoforms of Human Liver  
Receptor Homolog-1 (hLRH-1). The hLRH-1 genomic sequence spans more than 150 kilobases 
and consists of eight exons. The hLRH-1 isoform is identical to hLRH-1v1 except for a deletion 
in the A/B domain, due to splicing of exon 2. The hLRH-1v2 isoform contains a deletion within 
the D or E domain, resulting from an alternative splicing event in exon 5, in addition to the 
splicing of exon 2. As shown, specific exons encode particular hLRH-1 protein domains. Taken 
from Fayard E et al. LRH-1: an orphan nuclear receptor involved in development, metabolism 
and steroidogenesis. TRENDS in Cell Biology. 2004. 14(5), 251-260. 
71	  
 72 
243 as mutation of these to alanines (S238A and S243A) results in decreased ERK 
mediated phosphorylation of LRH-1 (Lee et al., 2006). Further, the potent MEK1/2 
inhibitor U0126 is seen to completely inhibit the PMA and EGF mediated 
stimulation of LRH-1 activity (Lee et al., 2006). The p38 kinase-signalling pathway 
has also been seen to regulate LRH-1 activity in granulosa cells (GCs) (Falender et 
al., 2003). Follicle stimulating hormone (FSH) and forskolin promote p38 
phosphorylation in GCs (Yu et al., 2005, Maizels et al., 1998).  Furthermore, SB 
203580 a highly specific inhibitor for p38 MAPK, markedly reduced both the basal 
and FSH stimulated expression of LRH-1 (Yu et al., 2005). Bile acid (BA) and TNF-
α activation of the stress-activated protein kinase c-Jun N-terminal (JNK) pathway in 
hepatoctypes inhibits CYP7A1 expression, a known target gene of LRH-1, 
suggesting the possibility of LRH-1 phosphorylation through this pathway (Li et al., 
2006, Gupta et al., 2001).  
1.18.4 Synthetic small molecule agonists of LRH-1 
The knowledge that LRH-1 and SF-1 can bind phospholipids, suggests that these 
receptors are chemically tractable. The identification of such synthetic ligands is 
potentially useful in further studies of receptor function. Recently, Whitby et. al. 
described the use of a fluorescence resonance energy transfer (FRET)-based assay to 
detect the interaction between the ligand binding domain of LRH-1 and a peptide 
derived from the coactivator TIF-2, and used this as the basis of a screen for small 
molecule agonist of LRH-1, thereby resulting in the identification of compound 5a 
(GSK8470) (Whitby et al., 2006). In a FRET-based assay for recruitment of a peptide 
derived from DAX-1, compound 5a was able to displace the phospholipid in the 
LBD. The potent binding of compound 5a, and the rigid cis-bicyclo[3.3.0]oct-2-ene 
structure provided a template for further compound development designed to define 
the ligand-receptor pharmacophore at three positions (R1-R3). Reporter assays 
demonstrated a dose dependent increase in LRH-1 reporter activity, with increasing 
concentrations of compound 5a. Cell lines HepG2 and primary hepatocytes treated 
with 10µM of compound 5a significantly increased the expression of SHP mRNA as 
measured by quantitative RT-PCR (Whitby et al., 2006). 
1.18.5 SHP, DAX-1 and Prox1 as co-repressors of LRH-1 
LRH-1 activity results from the stabilization of the LBD by the extended helix H2. 
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In vivo, the constitutive activity of LRH-1 is regulated by the orphan nuclear receptor 
Small Heterodimer Partner (SHP, NR0B2), which contains a putative LBD but, lacks 
a classical DBD (Goodwin et al., 2000, Lu et al., 2000, Lee and Moore, 2002). SHP 
was discovered as a corepressor interacting with several nuclear receptors including 
ER, RXR and LRH-1 (Seol et al., 1996, Nishizawa et al., 2002, Lee et al., 2000, Seol 
et al., 1998). The significance of the LRH-1/SHP interaction is seen in the role of the 
regulation of the cholesterol 7-α-hydroxylase gene (CYP7A1), which is the rate-
limiting enzyme in the conversion of hepatic cholesterol to BAs (Lu et al., 2000, 
Goodwin et al., 2000). Mice, in which the SHP gene has been deleted by homologous 
recombination, have an imbalance in BA metabolism and abnormal responses when 
challenged with diets rich in cholesterol (Wang et al., 2002, Kerr et al., 2002). 
Activation of FXR results in an increase in SHP, which interacts with LRH-1 bound 
to the CYP7A1 promoter, blocking its stimulatory effects on transcription (Goodwin 
et al., 2000, Lu et al., 2000).  
SHP has two functional AF-2-binding motifs, ID1 and ID2, which resemble the 
LXXLL motifs in a number of NR coactivators (Sablin et al., 2003). The binding of 
wild-type SHP has been shown to repress LRH-1 reporter activity to baseline levels, 
but only mutation of the SHP ID2 motif abolished the ability of SHP to repress 
LRH-1, demonstrating that the functional interaction between LRH-1 and SHP is 
mediated by the SHP ID2 motif (Li et al., 2005a).  This is consistent with other 
studies that have shown that mutations in the SHP ID2 motif but not the ID1 motif 
prevents SHP inhibition of AR and GR (Borgius et al., 2002, Gobinet et al., 2001). 
SHP has been shown to bind preferentially to LRH-1 over several other NRs, 
including PPARs, ERs and oxosteriod hormone receptors. SHP inhibits the activity 
of most NRs with which it binds, the exceptions being SF-1 and PPARα and 
PPARγ, where interaction results in activation (Seol et al., 1997, Kassam et al., 2001, 
Nishizawa et al., 2002). Gupta et. al. have shown that SHP expression is regulated by 
the JNK pathway, as overexpression of c-Jun augmented SHP activity whose effects 
were abrogated by mutation of the c-Jun response element in the SHP promoter 
(Gupta et al., 2001). 
DAX-1/Dax-1 (dosage-sensitive sex-reversible adrenal hypoplasia congenital critical 
region on the X chromosome gene 1 also known as dosage sensitive sex reversal, and 
Adrenal Hypoplasia Congenital (AHC) critical region on the X chromosome, gene 1) 
encoded by the gene NR0B1, is an orphan nuclear receptor, which if mutated results 
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in the inherited condition AHC (frequency 1:12,500 live births) with associated 
hypogonadotropic-hypogonadism (HH) and, when duplicated causes phenotypic sex-
reversal in XY individuals (Lalli and Sassone-Corsi, 2003, Bardoni et al., 1994, Lin et 
al., 2006). DAX-1 is expressed throughout the hypothalamic-pituitary-adrenal-
gonadal (HPAG) axis during development and in adult tissues. During 
embryogenesis, DAX-1 directs cell differentiation in the testes and adrenal tissues 
(Lalli and Sassone-Corsi, 2003). In the adult, DAX-1 acts to repress several nuclear 
receptors including SF-1, ERRγ, AR, PR, GR and LRH-1 (Ito et al., 1997, Crawford 
et al., 1998, Nachtigal et al., 1998, Song et al., 2004, Park et al., 2005, Zhang et al., 
2000, Holter et al., 2002, Agoulnik et al., 2003, Suzuki et al., 2002, Fayard et al., 
2004). NR0B1 has a simple genomic structure with two exons (exon 1 168bp, and 
exon 2 245bp), separated by a single intron (3385bp) (Zanaria et al., 1994, Guo et al., 
1995, Guo et al., 1996). The 1413 nucleotide cDNA encodes a protein of 470 amino 
acids and a spliced isoform of DAX-1 designated DAX-1α specifies a protein of 401 
amino acids encoded by exon1 and exon2α (Hossain et al., 2004). The domain 
structure of DAX-1 is unusual, in that it lacks a DBD, modular domain and hinge 
region. The DAX-1 N-terminus consists of three sequence repeats that include the 
LXXL/ML motif, which has no known homology to any other proteins except the 
nuclear receptor SHP (Seol et al., 1996). DAX-1 has been shown to colocalize with 
SF-1 and has been shown to act as an inhibitor of SF-1 mediated transactivation 
(Ikeda et al., 1996, Ikeda et al., 2001, Ito et al., 1997, Suzuki et al., 2003). As stated 
above, SF-1 is not repressed by SHP (Li et al., 2005b). Peptide binding assay have 
shown that the two DAX-1 LXXLL motifs bind to SF-1, but the SHP ID2 interacts 
poorly.  Replacing the SHP ID2 motif with the DAX-1 motif, enabled SHP to 
repress SF-1 (Li et al., 2005b). The coactivator-binding site in LRH-1 is wide and 
well formed enabling LRH-1 to interact with many LXXLL motifs with a great 
affinity, however the coactivator-binding site of SF-1 is deeper and narrower, which 
explains why SF-1 interacts with a more limited spectrum of LXXLL motifs.  
DAX-1 has been shown to interact with LRH-1, by binding in and around the 
coactivator groove of LRH-1 (Sablin et al., 2008). DAX-1 binds to LRH-1 as a 
heterotrimer with a stoichiometry of two molecules of DAX-1 to one molecule of 
LRH-1. One molecule of DAX-1 binds in the coactivator groove of LRH-1 and the 
second binds close by, so that it becomes positioned outside the LBD of LRH-1 
(Sablin et al., 2008). Dimeric DAX-1 binds to LRH-1 with a significantly greater 
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affinity compared to monomeric DAX-1 and it has been suggested that the 
association between the two DAX-1 molecules may facilitate the binding of NRs. 
There have been reports of >30 missense mutations of DAX-1 associated with 
adrenal disease, with almost all mutations affecting evolutionarily conserved residues 
positioned within the visible structure, which suggests that this corresponds to a 
critical functional domain (Lin et al., 2006). Mutations of the residues L280P and 
I279A in the LBD resulted in a diminished repression of LRH-1 by DAX-1 and a 
significantly reduced binding of DAX-1 to LRH-1 respectively (Sablin et al., 2008). 
The double mutant I279A/L280A reduced the ability of DAX-1 to act as a 
corepressor of LRH-1. DAX-1 has been proposed to be involved in the 
development of a number of cancers including the adrenal, pituitary, breast, ovarian 
and prostate cancer (Reincke et al., 1998, Shibata et al., 2001, Ikuyama et al., 1998, 
Aylwin et al., 2001, Conde et al., 2004, Abd-Elaziz et al., 2003, Agoulnik et al., 2003). 
DAX-1, therefore may have a role as a tissue specific coregulator of ER, AR, PR, 
LRH-1 and SF-1 target genes. 
Prox-1 is a transcription factor related to Drosophila melanogaster Prospero. Prox-1 
was initially described as a cofactor for FF1b, the Drosophila homologue of SF11 
during development of the interrenal primordium in zebrafish (Liu et al., 2003b). Its 
subsequent corepressor activity was then described (Qin et al., 2004). Mammalian 
Prox-1 is expressed in pancreas, liver, lens, and lymphocytes (Oliver et al., 1993, 
Ryter et al., 2002, Li et al., 1998, Nitta et al., 1999, Rausa et al., 1999). Co-expression 
of Prox-1 and LRH-1 is seen in the liver and pancreas, where expression is high, and 
at low levels in the ovary and small intestine, with a splice variant of Prox-1 seen in 
the testis (Steffensen et al., 2004). Prox-1 inhibits LRH-1 activation of an LRH-1 
regulated reporter gene in COS-7 cells and Prox-1 has also been shown to reduce the 
expression of SHP mRNA levels in HuH7 liver cell lines overexpressing LRH-1. 
Domain mapping has confirmed the N-terminal of Prox-1 as the dominant repressor 
domain (aa 108-337) (Steffensen et al., 2004). 
1.18.6 Potentiation of LRH-1 by steroid receptor coactivator-1 (SRC-1) 
SRC-1 has been shown to interact directly with the LBD of LRH-1, significantly 
potentiating its transcriptional activity (Xu et al., 2004). The interaction between 
SRC-1 and LRH-1 involves a region containing the glutamine-rich domain of SRC-1, 
and helix 1 and AF-2 of the LRH-1 LBD. This provides stability, enhancing the 
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recruitment of SRC-1. Point mutations, IL260AA and LL263AA in helix 1 of LRH-1 
have been shown to impair the interaction with SRC-1, and reduce transcriptional 
activity (Xu et al., 2004). Protein Inhibitor of Activated STAT (PIAS) has been 
shown to interact with LRH-1 via the C-terminus to repress LRH-1-stimulated 
transcriptional activity of the CYP11A1 promoter in HEK293T cells (Hsieh et al., 
2009). This inhibitory effect can be partly overcome by over-expression of SRC-1. A 
motif in the LBD was found to be key to the interaction between LRH-1 PIASγ, and 
is the same region required for the interaction between SRC- 1 as well as SHP and 
DAX-1 (Xu et al., 2004, Suzuki et al., 2003, Lee and Moore, 2002, Hsieh et al., 2009). 
1.18.7 Sumoylation of LRH-1 
SUMO modification is important in regulating the activity and subcellular 
localization of transcription factors (Gill, 2003). LRH-1 has been shown to be a 
target protein of SUMO modification, with the hinge region lysine residue 224 in 
LRH-1 being the major conjugation site (Chalkiadaki and Talianidis, 2005, Lee et al., 
2005). Sumoylation of LRH-1 represses transcriptional activity and localization in 
promyelocytic leukaemia protein nuclear bodies. Mutation of target lysines 173 
(K173) or 289 (K289) indicated that both were vital for transactivation of LRH-1 
and SUMO-1-mediated subcellular localization (Yang et al., 2009). Forskolin and 
cholera toxin reduced the accumulation of LRH-1 in nuclear bodies, suggesting that 
cAMP may be important in regulating the sumoylation pathway and LRH-1 activity. 
1.18.8 Regulation of LRH-1 by sphingosine-1-phosphate 
Sphingolipid signalling mediators are a family of extracellular and intracellular 
signalling molecules mediating cell reactions such as differentiation, apoptosis, 
calcium homeostasis, proliferation and growth arrest. These mediators include 
TNFα, IL-1, Fas (Apo-1, CD95) agonists, CD-40, CD-28, CD5, DR-5 lymphocyte 
function-associated antigen-1 (LFA-1) CD-32, progesterone, Vitamin D3, protein 
kinase C, PDGF, EGF, NGF and infection (Gulbins and Li, 2006). The key elements 
in the sphingolipid-signalling cascade include Ceramides (CER), Ceramide-1-
Phosphate (C1P), Sphingosine (SPH) and Sphingosine-1-Phosphate (S1P). S1P is a 
bioactive sphingolipid that acts on a number of signalling pathways and acts as a 
second messenger in mitogenesis, calcium mobilization and call migration (Pyne and 
Pyne, 2000, Spiegel and Milstien, 2003). The effects on cell survival or cell death are 
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dependent upon a balance between levels of CER (pro-apoptotic) and S1P (anti-
apoptotic).  CER activates c-Jun kinase (JNK) stress activated protein kinases 
(SAPK), and caspase 3 which are important in cell membrane and cytoskeleton 
destruction (Llacuna et al., 2006). CER also stimulates release of reactive oxygen 
species (ROS) and cytochrome-c activating apoptotic proteases (Hearps et al., 2002). 
CER finally decreases expression of the BCL-2 family of anti-apoptotic proteins and 
the activity of anti-apoptotic enzymes such as PKC. SPH is produced from 
hydrolysis of CER by ceramidases (CDases) resulting in stimulation of ROS and 
activation of caspase 3, 7 and 8 as well as inhibiting Akt (Chang et al., 2003, Chang et 
al., 2001). Increased levels of SPHK have been shown to be elevated in lung, ovarian, 
uterine, breast and colon cancer (French et al., 2003). An elevated level of SPHK has 
been shown to promote estrogen dependent growth in MCF7 breast cancer cells, 
with no effect seen by increased expression of the point mutation of SPHK1, 
SPHKG82D (Sukocheva et al., 2003, Nava et al., 2002). SPHK activity is rapidly 
increased (within minutes) following treatment with estrogen in MCF7 cells, but not 
in the ERα-negative cell line MDA-MB 231 (Sukocheva et al., 2003). Estrogen 
stimulated activation of the Erk was increased in MCF-7 cells transfected with 
SPHK, and blocked by PD098095 an inhibitor of MEK, the upstream activator of 
Erk (Sukocheva et al., 2003). 
The major source of S1P is from phosphorylation of SPH by the highly conserved 
enzyme Sphingosine Kinase (SPHK), which is activated by many agonists and stimuli 
(Taha et al., 2006, Spiegel and Milstien, 2002, Olivera and Spiegel, 2001). The effects 
of S1P are mediated intracellularly and extracellular by specific plasma membrane G-
Protein-Coupled Receptors (GPCRs), S1P1-S1P5 (Fukushima et al., 2001, Hla et al., 
2001, Chun et al., 2002). The effects of S1P are anti-apoptotic, activating cell 
proliferation, decreasing the time for cell division, mobilizing Ca2+ and increasing the 
cell survival (Davaille et al., 2002). S1P has been shown to increase PGE2, whose 
expression in breast and colon cancer is attributed to cyclooxygenase-2 (COX-2) 
expression (Pettus et al., 2005). Hadizadeh et. al. demonstrated that S1P induces 
LRH-1 mRNA expression via a Pertussis Toxin (PT)-sensitive, PGE2 dependent 
pathway (Hadizadeh et al., 2008). S1P rapidly activates (within 15 minutes) PGE2 
production as measured by Enzyme-Linked Immunoassay (EIA). This increase in 
LRH-1 expression following treatment with S1P was significantly reduced with the 
specific COX-2 inhibitor NS-398. Both S1P and PGE2 increase binding of LRH-1, 
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CCAAT/enhancer binding protein (C/EBP), and CREB to the LRH-1 promoter 
(Hadizadeh et al., 2008). LRH-1 was also shown to increase transcription from the 
LRH-1 gene promoter in a positive regulatory loop.  
1.18.9 Function of LRH-1 in development 
LRH-1 is predominantly expressed in tissues derived from the gut endoderm such as 
the liver, small intestine, preadipocytes, adrenal gland testes and ovary (Galarneau et 
al., 1996, Boerboom et al., 2000, Becker-Andre et al., 1993, Li et al., 1998, Wang et 
al., 2001, Schoonjans et al., 2002, Hinshelwood et al., 2003, Liu et al., 2003a, Falender 
et al., 2003, Sirianni et al., 2002, Clyne et al., 2002, Lambard et al., 2005, Pezzi et al., 
2004). LRH-1 plays an important role in development, as LRH-1 null mice die at 
embryonic day 6.5-7.5 due to impaired node formation and gastrulation (Pare et al., 
2004). As previously mentioned Ftz-F1 was first identified in Drosophila as a direct 
activator of the homeo-box-segmentation ftz gene during early development, and as a 
prerequisite for ecdysone-induced, stage specific responses (Lavorgna et al., 1991, 
Broadus et al., 1999). Murine embryos express abundant amounts of LRH-1 in the 
foregut endoderm at E7.5 and the yolk-sac endoderm, branchial arch and neural 
crest by E8.5 (Galarneau et al., 1996, Pare et al., 2001). Expression of LRH-1 
continues in the foregut endoderm during liver and pancreas development (E9.5), 
reaching levels found in adult mice by E17.5 (Rausa et al., 1999, Annicotte et al., 
2003). LRH-1 has been shown to regulate early expression of α1-fetoprotein, a 
marker of visceral endoderm and liver differentiation (Galarneau et al., 1996). Three 
genes integral to early hepatic differentiation – HNF-1α, HNF-3β, and HNF-4α 
contain LRH-1 binding elements in their gene promoters (Pare et al., 2001, Rausa et 
al., 1999). The conservation of GATA elements in the LRH-1 promoter and the 
general role of GATA factors in endodermal derivatives suggest a close link between 
GATA and LRH-1 signalling (Zhang et al., 2001, Pare et al., 2001). LRH-1 is 
coexpressed in the developing embryonic pancreas with PDX-1, a homeobox factor 
essential for pancreatic development (Annicotte et al., 2003). PDX-1 has been shown 
to induce LRH-1 expression during this time (E8.5-E16.5). In later development 
LRH-1 regulation by PDX-1 does not occur due to their separate expression in the 
exocrine and endocrine pancreas respectively (Annicotte et al., 2003). LRH-1 is also 
expressed in breast stroma, which is predominantly comprised of undifferentiated 
adipose tissue (Clyne et al., 2002). Transformation of preadipocytes into mature 
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adipocytes is associated with induction of PPARγ and rapid loss of P450 aromatase. 
LRH-1 controls aromatase expression in preadipocytes by binding to response 
elements in the CYP19 promoter II: an effect, which is inhibited by SHP (Kovacic et 
al., 2004, Clyne et al., 2002, Michael et al., 1995). 
1.18.10 LRH-1 function in cholesterol homeostasis 
LRH-1 binding sites have been identified in the regulatory regions of several genes 
involved in cholesterol and BA homeostasis, which include: ATP-Binding Cassette 
(ABC) transporters ABCG5 and ABCG8, the organic solute transporters (OST) α 
and β, and the ileal apical sodium-dependent BA transporter (ASBT) (Freeman et al., 
2004, Frankenberg et al., 2006, Chen et al., 2003). Cholesterol 7α-hydroxylase 
(CYP7A1) is involved in the first rate limiting step in bile acid synthesis, and 
cholesterol 12α-hydroxylase (CYP8B1), which converts chenodeoxycholic acid to 
cholic acid, are among the genes in the liver for which LRH-1 binding sites have 
been identified (Russell, 2003). LRH-1 enhances the transcription of these two genes 
and is involved in the feedback repression of CYP7A1 and CYP8B1 through a 
signalling pathway involving the Farnesoid X Receptor (FXR) and SHP (Goodwin et 
al., 2000, Lu et al., 2000). Development of a selective FXR activator GW4064, 
identified SHP-1 as an FXR regulated gene. Expression of SHP, directly binds to 
LRH-1 as described in a Glutathione S-Transferase (GST) pull-down assay 
(Goodwin et al., 2000). The binding of SHP to LRH-1 inhibits its transcription and 
hence represses CYP7A1 and CYP8B1 expression. LRH-1-1- mice die in vivo, but 
LRH-1+/- mice overexpress CYP7A1 and CYP8B1, suggesting that the main effect of 
LRH-1 on CYP7A1 and CYP8B1 is the recruitment of SHP and not their basal 
induction (Pare et al., 2004, del Castillo-Olivares et al., 2004). Targeted mouse gene 
knockouts of LRH-1 in hepatocytes and intestinal epithelia demonstrated that a lack 
of LRH-1 in either of these tissues affected the levels of genes involved in 
cholesterol and BA homeostasis. LRH-1 deficiency in hepatocytes was found to have 
no effect on CYP7A1 expression or its repression by FXR (Lee et al., 2008). 
CYP8B1 levels were significantly reduced in mice deficient for LRH-1 in 
hepatocytes. This reduction was found to effect the composition of the bile acid 
pool. It is thought that in these Hepatocyte Knockout (HepKO) mice, LRH-1 may 
either not regulate or only play a minor role in the regulation of CYP7A1 or that a 
redundant factor may maintain CYP7A1 expression in the absence of LRH-1. One 
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such factor could be HNF4α, which binds to the same response element in the 
CYP7A1 promoter, and is inhibited by SHP in vitro (Lee et al., 2008, Crestani et al., 
1998, Lee et al., 2000).  
LRH-1 expression is increased at the RNA and the protein and following bile duct 
ligation and is associated with the increased expression of Multidrug Resistance 
associated Protein-3 (MRP3), which is key to the transportation of bile salts, 17β-
estradiol and cisplatin (Uchiumi et al., 1998, Kool et al., 1999). Upregulation of 
MRP3 is seen in primary biliary cirrhosis, congenital biliary atresia and familial 
intraheptic cholestasis (Jansen and Muller, 2000, Shoda et al., 2001, Ogawa et al., 
2000). In HepG2 cells the upregulation of MRP3 is due to the TNF-α activation of 
LRH-1 (Bohan et al., 2003).  
1.18.11 LRH-1 in the gastrointestinal tract  
In the intestinal mucosa, LRH-1 is mostly expressed in the crypt cells where it 
regulates expression of cyclin D1 and cyclin E1, promoting epithelial proliferation 
and crypt renewal (Schoonjans et al., 2005). LRH-1 acts as a tissue-restricted 
coactivator of β-catenin on cyclin D1 and c-MYC promoters. β-catenin is key in the 
pathogenesis of colon cancer, and is closely controlled through an interaction of a 
multi protein complex comprising conductin/axin, the adenomatous polyposis coli 
(APC) and the serine/threonine kinase GSK-3β, which phosphorylates β-catenin, 
thereby inducing its degradation (Kinzler and Vogelstein, 1996). β-catenin levels 
accumulate in patients with mutations of the APC gene, which predisposes carriers 
to familial adenomatous polyposis, a syndrome associated with multiple colonic 
polyps at a young age (Nishisho et al., 1991, Groden et al., 1991, Miyoshi et al., 1992, 
Powell et al., 1993). Also in 80% of sporadic colon cancer both APC alleles are 
inactivated, indicating the key role of APC in the maintaining a balance between 
differentiation and proliferation in intestinal crypts (Kinzler and Vogelstein, 1996, 
Miyoshi et al., 1992). LRH-1 overexpression has been reported in 47.6% of patients 
with gastric carcinoma, with proliferation of the gastric carcinoma cell line SGC-7901 
induced through cyclin E1 (Wang et al., 2008a). 
Expression of LRH-1 in the intestine is more than 200 times that of the expression 
in the adrenal gland (Mueller et al., 2006). Overexpression of LRH-1 in murine 
intestinal epithelium induces the transcription of CYP11A1 and CYP11B1 which 
encode for the enzymes P450ss and 11β-hydroxylase, important in the rate limiting 
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step of converting cholesterol to pregnenolone and the conversion of inactive 11-
deoxycorticosterone to corticosterone respectively (Mueller et al., 2006). Mice 
deficient in LRH-1 are predisposed to intestinal inflammation as a result of a defect 
in local glucocorticoid production. In patients with inflammatory bowel disease 
(IBD), inflammation is negatively correlated with LRH-1 expression, suggesting a 
protective effect of LRH-1 against the onset of IBD (Coste et al., 2007).  
1.18.12 LRH-1 and the ovary 
SF-1 and LRH-1 are involved in the development and physiology of steroidogenic 
tissues. LRH-1 is found in granulosa cells of the follicles in all stages of development 
and the luteal cells of the corpus luteum (Hinshelwood et al., 2003, Liu et al., 2003a, 
Falender et al., 2003). Expression of SF-1 and LRH-1 in the ovary during the 
menstrual cycle is regulated by estradiol and FSH during follicular growth, LH in 
ovulation and LH and prolactin during luteinisation and maturation of the corpus 
luteum (Boerboom et al., 2000, Falender et al., 2003). The expression of LRH-1 is 
significantly increased during pregnancy, unlike that of SF-1 (Hinshelwood et al., 
2003, Liu et al., 2003a). SF-1 regulates aromatase expression in the ovary through the 
two conserved Ftz-F1 sites (Hinshelwood et al., 2003, Michael et al., 1995, 
Fitzpatrick and Richards, 1993). Absence of SF-1 in the corpus luteum during 
pregnancy suggests that LRH-1 is the key factor in regulating CYP19 expression and 
hence estrogen synthesis during pregnancy. Chromatin Immunoprecipitation (CHIP) 
assays have shown that LRH-1 is associated with the inhibin-α promoter in the 
primary granulosa GRMO2 cells (Weck and Mayo, 2006). Inhibins are heterodimeric 
glycoprotein hormones, which are part of the Transforming Growth Factor β (TGF-
β) family. They are comprised of a common α-subunit (inhibin-α) or β -subunit 
(inhibin-β), and are synthesized by Sertoli cells and Leydig cells of the testes and 
ovary respectively. Inhibins function to suppress FSH secretions by the pituitary, and 
are involved in spermatogenesis, oocyte maturation, granulosa cell function and 
steroid hormone production (O'Connor and De Kretser, 2004, Woodruff et al., 
1988, Meunier et al., 1988, Matzuk et al., 1996). Inhibins may also have tumour 
suppressor activity in both the ovary and the testis. Overexpression of LRH-1 
increases inhibin-α promoter activity, only in the presence of GATA4 or GATA6 
(Robert et al., 2006). LRH-1 could not increase inhibin-α activity in cell lines devoid 
of GATA factors such as CV-1 cell line (Robert et al., 2006). This activation of 
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inhibin-α by the GATA/LRH-1 complex is significantly enhanced by PKA, but did 
not affect the protein-protein interaction between GATA/LRH-1. 
1.18.13 Regulation of aromatase by LRH-1 in the breast 
Synthesis of estrogen is catalyzed by the enzyme aromatase cytochrome P450, 
CYP19 that is expressed in a number of tissues including ovary, testes, placenta, 
brain, bone and adipose. The CYP19 gene is 120kb in length, with nine coding exons 
spanning 30kb. Several untranslated first exons are found located upstream of the 
first coding exon (exon2), with splicing occurring to a common acceptor site in this 
exon (Clyne et al., 2004). Each 5’ exon has a unique promoter region, and this 
alternative promoter usage results in tissue specific regulation of CYP19. In the 
ovary, aromatase expression is regulated by FSH through promoter II in the 
placenta, retinoids regulate aromatase using promoter I.1 and in adipose tissue 
glucocorticoids, class 1 cytokines and TNFα control aromatase using promoter I.4 
(Simpson et al., 2000, Michael et al., 1995, Sun et al., 1998, Zhao et al., 1995a, Zhao 
et al., 1995b, Zhao et al., 1996b). Quantification of promoter usage using exon-1 
specific RT-PCR showed that in the normal breast aromatase expression is low 
through promoter 1.4, whereas the expression of aromatase in adipose surrounding a 
breast tumour is increased by 4-fold with a switch in promoter usage from the 
normal I.4 cytokine-responsive promoter to the cAMP-dependent gonadal promoter 
II (Agarwal et al., 1996, Harada, 1997, Zhou et al., 1997). Aromatase expression in 
breast carcinoma tissue is also elevated compared with normal adipose tissue 
(Harada, 1997, Zhou et al., 1997). 
Regulation of aromatase promoter II by SF-1 was first described in ovarian cells 
(Fitzpatrick and Richards, 1993, Lynch et al., 1993). Whilst SF-1 is not expressed in 
adipose tissue, LRH-1 is highly expressed (Clyne et al., 2004). LRH-1 and aromatase 
are both expressed in preadipocytes, and levels fall significantly with differentiation 
(Clyne et al., 2002). Gel shift assays confirmed that LRH-1 binds to the SF-1 site in 
the aromatase promoter II. Treatment of preadipocytes with forskolin (FSK) and 
phorbol ester (PMA) (activating the PKA and PKC pathways respectively resulted in 
a significant increase in LRH-1 expression and subsequent aromatase Promoter II 
expression, which suggests that phosphorylation regulates LRH-1 activity in these 
cells.  
Experimental viral transduction of LRH-1 into primary adipose stromal cells results 
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in a large increase in aromatase expression, which can be further augmented by the 
addition of FSK and PMA (Zhou et al., 2005). Quantification of aromatase 
transcripts, confirm that the predominant aromatase promoter in adipose tissue was 
promoter II. DAX-1 is not expressed in pre-adipocytes, however pre-adipocytes do 
express SHP, which inhibits aromatase promoter expression when transfected into 
3T3-L1 preadipocyte cells regardless of treatment with PMA or FSK (Clyne et al., 
2004). SHP inhibits aromatase promoter activity by inhibiting LRH-1 DNA binding 
and transcriptional activity (Kovacic et al., 2004). Loss of SHP activity in patients 
expressing a mutant SHP gene results in mild obesity (Nishizawa et al., 2002, 
Nishigori et al., 2001). The mutations include two frameshift mutations, one 
nonsense mutation that was seen in two subjects, and three missense mutations. 
PGE2 is known to bind to Prostaglandin E receptors EP1 and EP2 on adipose 
stromal cells thereby activating the PKC and PKA pathways stimulating aromatase 
expression (Zhao et al., 1996a, Richards and Brueggemeier, 2003).  
PGE2 is a secretory product of breast cancer epithelial and fibroblast cells, as well as 
macrophages at tumour sites (Simpson et al., 1997). COX-2 overexpression in mice 
induces tumourigenesis, which is dependent upon PGE2 (Chang et al., 2005). 
Treatment of adipose stromal cells with PGE2 resulted in a dose dependent increase 
in LRH-1 and aromatase, suggesting that one mechanism by which aromatase 
expression is regulated is through PGE2 mediated activation of LRH-1 (Zhou et al., 
2005). COX-2 inhibitors suppress CYP19 expression and activity in breast cancer 
cells (Diaz-Cruz et al., 2005). The activity of the murine aromatase promoter II is 
significantly up-regulated by GATA factors in the gonads and in breast tumours 
(Tremblay and Viger, 2001, Bouchard et al., 2005). The GATA proteins are a family 
of vertebrate transcription factors named after the consensus nucleotide sequence 
(A/T)GATA(A/G), which they bind to, and can be sub-divided into two groups 
based on tissue distribution and sequence homology: GATA1/2/3 and 
GATA4/5/6. Mouse knockout models have shown that these are key regulators of 
cell fate specification, cell differentiation, organogenesis and tissue specific gene 
expression (LaVoie, 2003, Molkentin, 2000, Orkin, 1992). GATA factors have been 
associated with several cancers including breast cancer (Bertucci et al., 2004, Hoch et 
al., 1999, Ketola et al., 2000, Kiiveri et al., 1999, Lin et al., 2000). GATA2 and 
GATA3 are involved in adipocyte differentiation, and GATA3 and GATA4 are up 
regulated in breast tumours and the breast cancer cell lines BT20, MCF-7, T47D and 
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ZR-75-1 (Jin et al., 2000, Bertucci et al., 2004, Hoch et al., 1999, Usary et al., 2004, 
Bouchard et al., 2005). One potential role of GATA factors in breast tumours may 
be to keep preadipocytes in an undifferentiated state. Human aromatase promoter II 
activation in MCF7 cells by GATA3 or GATA4 with/without LRH-1 is strongly 
dependent upon stimulation of PKA (Bouchard et al., 2005). The proximal LRH-1 
gene promoter contains three consensus GATA binding motifs, which are highly 
conserved. GATA mediated activation of LRH-1 activity in MCF7 cells is 
significantly enhanced by PKA (Bouchard et al., 2005). GATA factors together with 
LRH-1 are important regulators of aromatase expression. 
Co-transfection of the coactivators SRC-1 (GRIP1) or PGC-1α (both expressed in 
preadipocytes) in Hela cells with LRH-1 was found to increase aromatase activity 
(Safi et al., 2005). This effect was abrogated by mutation of the GRIP1 NR box and 
the PGC-1α LXXLL major binding sites, and augmented by addition of FSK (Safi et 
al., 2005). PGC-1α is predominantly expressed in adipose tissue, liver and muscle, 
and was identified as a specific coactivator of PPARγ, but has subsequently been 
shown to coactivate many NRs (Puigserver et al., 1998, Lin et al., 2002, Knutti et al., 
2000). Retinoid X receptor α (RXRα) can also inhibit LRH-1 activity by 
competitively binding LRH-1 coactivators GRIP1 and PCG1α (Safi et al., 2005). 
RXR ligands have demonstrated efficacy in suppressing breast cancer in in vitro 
models (Gottardis et al., 1996, Wu et al., 2002). Inhibition of aromotase promoters II 
and 1.4 in human preadipocytes has also been shown to occur in response to RXR 
and PPARγ ligands (Rubin et al., 2002). One mechanism that has been suggested, 
involves the RXR sequestation of LRH-1 coactivators thereby inhibiting local 
aromotase expression, however retinoids have also been shown to inhibit growth in 
ER-negative tumours also (Safi et al., 2005, Wu et al., 2002).  
1.18.14 LRH-1 is an estrogen-regulated gene 
Annicotte et. al. first described the estrogen regulation of LRH-1, whose expression 
was increased (8-9 fold) 6 hours following addition of estrogen (Annicotte et al., 
2005). The expression of LRH-1 was also increased by the ERα-specific agonist 
Propyl Pyrazole Triol (PPT) (4-5 fold) and reduced by the anti-estrogens tamoxifen, 
raloxifene and ICI 182,780 (8-, 10- and 4.5 fold respectively. LRH-1 expression was 
seen to be highest in several ERα-positive breast cancer cell lines, whereas LRH-1 
was minimally expressed in ERα-negative cell lines. Chromatin immunoprecipitation 
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and gel shift assays confirmed that transcriptional regulation is a result of direct 
binding of ERα to the LRH-1 promoter, and siRNA-mediated knockdown of LRH-
1 decreased the estrogen dependent proliferation of MCF-7 cells (Annicotte et al., 
2005). Immunostaining demonstrated that LRH-1 is co-localised with ERα and PR 
in infiltrating ductal carcinomas in both the nucleus and the cytoplasm.  
In a larger series (n=106), LRH-1 was expressed in the nuclei of 43.2% of infiltrating 
ductal carcinomas (n=88) and 27.8% of DCIS (n=18) (Miki et al., 2006). LRH-1 was 
also detected in adipocytes adjacent to the tumour but not intratumoural stromal 
cells or epithelia of normal mammary glands. LRH-1 mRNA expression was also 
significantly correlated with immunoreactivity in 22 cases of IDC, and ERα status 
(p=0.0157, p=0.0041 respectively) (Miki et al., 2006). LRH-1 immunoreactivity was 
negatively correlated with stage (p=0.0247) and histological grade (p<0.0001), HER2 
status (p=0.0036), but there was no association with tumour size or overall survival. 
No correlation was noted between LRH-1 immunoreactivity and patient age, 
menopausal status, nodal involvement, Ki67 histological grade (by Van Nuys 
classification) in DCIS, risk of recurrence. LRH-1 immunoreactivity was associated 
with a better prognosis in those patients with PR-positive breast cancer (Miki et al., 
2006). 
1.19 Promyelocytic leukaemia zinc finger –estrogen eeceptor (PLZF-ER) 
In order to identify the genes key to estrogen-regulated growth, our laboratory 
previously developed a strategy to obtain silencing of genes directly regulated by ER 
binding to promoters. In a small percentage of acute promyelocytic leukaemias, a 
t(11:17) translocation generates a novel gene, PLZF-RARα in which the majority of 
the PLZF gene is fused 5’ to exons 2-8 of the RARα gene, resulting in a polypeptide 
containing the N-terminal part of PLZF and the N-terminal-most two zinc fingers of 
PLZF with the DBD and LBD of RARα (Chen et al., 1993a, Chen et al., 1993b). 
PLZF is a transcriptional repressor that interacts with NCoR/SMRT, mSin3A and 
HDACs to recruit histone deacetylases resulting in the repression of RARα-regulated 
gene expression and consequent block in promyelocytic differentiation (Chen et al., 
1994). 
By replacing the RARα portion of PLZF-RARα with the homologous sequences 
from ERα, PLZF-ERα was generated (Figure 1.16) (Buluwela et al., 2005). In order 
 86 
to explore the repression of estrogen-regulated gene expression in breast cancer cell 
lines, with a view to identifying estrogen-regulated genes, which mediate the 
estrogen-regulated growth of breast cancer cells, the estrogen-responsive, ERα-
positive MCF-7 breast cancer cell line was used to generate cell lines stably 
expressing PLZF-ERα in a tetracycline-inducible manner. For this, an MCF-7 line 
stably expressing the bacterial tetracycline repressor fused to the herpes simplex virus 
VP16 Transcriptional Activator (tTa) was used (Clontech). tTA binds to the 
Tetracycline Operator sequence (TetO), enabling activation of the expression of 
genes under the control of promoters encoding TetO sites (pRevTRE; BD 
Biosciences). Tetracycline, or the more stable analogue doxycycline (Dox), prevents tTa 
binding to the TetO, preventing expression of the gene of interest (Gossen et al., 
1995, Baron et al., 1997, Gossen and Bujard, 1992).  
This MCF-7 Tetracycline-Off (MCF-7-TO) cell line was used to generate stable lines 
expressing PLZF-ERα under the regulation of a tTa-regulated promoter. Of the 
lines generated, two were taken forward (JP13, JP23) on the basis of good repression 
of an estrogen-responsive reporter gene. In these lines, expression of the estrogen-
regulated PR, pS2 and CTSD genes were reduced to levels observed in the parental 
cells in the absence of estrogen. However the expression of these genes was similarly 
reduced in these lines in the presence of Dox, the reason for which is currently 
unclear, but may be due to reduced levels of the ERα in the cloned lines, or may be 
due to ‘leaky’ PLZF-ERα expression in these lines in the presence of Dox. 
Notwithstanding the constitutive repression of some estrogen-regulated genes in the 
JP13 and JP23 cells, both lines exhibited an inhibition of estrogen regulated growth 
when PLZF-ERα expression was induced (Buluwela et al., 2005). These observations 
suggest that there are at least two classes of estrogen-responsive genes in MCF-7 
cells, firstly those like PR, pS2 and CTSD, which show constitutive repression and 
other estrogen-responsive genes whose expression is only inhibited by high-level 
PLZF-ERα expression, and which presumably include genes which are required for 
estrogen-regulated growth in MCF-7 cells. As such, these MCF-7-TO-PLZF-ERα 
lines potentially provide a means of distinguishing those estrogen-regulated genes 
that may be critical for estrogen regulated growth in MCF-7 cells.  
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1.20 Identification of estrogen-regulated genes whose expression is inducibly 
repressed by PLZF-ERα  in MCF-7 cells 
In order to identify estrogen-regulated genes using these lines, our laboratory carried 
out gene expression microarray analysis using Affymetrix arrays (with near complete 
human gene coverage), under the auspices of the CRUK microarray facility, The 
Patterson Institute for Cancer Research, Manchester. Cells were grown in estrogen-
deprived conditions for 72 hours, in the presence and absence of tetracycline (for 
regulated PLZF-ERα expression), and RNA prepared following the addition of 
estrogen for 16 hours. This was used for carrying out gene expression microarray 
analysis using the Affymetrix U132 plus 2-array format. Of the 55,000 transcripts 
represented on the array, more than 3000 showed estrogen regulation (by more than 
1.5 fold) at the 16-hour time point. Importantly, only 149 of these genes showed 
PLZF-ERα mediated repression, and since PLZF-ERα expression blocks estrogen- 
stimulated growth of MCF-7 cells, it is likely that these genes are particularly 
important for estrogen-stimulated growth responses of MCF-7 cells. One of these 
genes, LRH-1 is a member of the nuclear receptor superfamily of transcription 
factors and this has become the focus of the work reported in this thesis. 
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Figure 1.16 Organization of the PLZF-ER fusion protein. The positions of the DNA binding 
domain (DBD), the ligand binding domain (LBD) and transcription activation functions AF-1 
and AF-2 of RARα and ER are shown. PLZF is also shown, with the POZ domain, required for 
mediating recruitment of the Sin3A HDAC complex and the nine zinc fingers (ovals) present in 
PLZF being highlighted. PLZF-RARα is the protein product resulting from a t(11;17) 
translocation in APL. Replacement of the RARα sequences by the analogous 
portion of ER resulted in PLZF-ER.  
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1.21 Project aims 
In breast cancer cells, the growth stimulatory effect of estrogens is mediated through 
the ER, a member of the superfamily of transcription factors. Currently treatment 
strategies to inhibit ER activity include endocrine therapies such as SERMS, AIs, 
pure anti-estrogens, and GnRH agonists. Eventually, resistance will develop to all 
treatment options currently available demonstrating a need to identify new diagnostic 
and therapeutic targets.  
Previous studies using gene expression microarrays have identified a large number of 
estrogen-regulated genes in estrogen responsive cell lines. Microarray analysis using a 
cell line generated in our laboratory, enabled identification of those estrogen-
regulated genes, which potentially mediate the estrogen regulated growth of the ER-
positive MCF-7 breast cancer cell line. One of the genes identified was LRH-1, a 
nuclear receptor, recently identified as an estrogen responsive gene. The aim of the 
current study was to further evaluate the role of LRH-1 in breast cancer cells. 
Specifically, these studies aim to; 
• Confirm and further characterise the estrogen regulation of LRH-1 
• Investigate the activity of LRH-1 in mediating growth in breast cancer cell 
lines using RNA interference with siRNAs.  
• Evaluate several synthetic small molecule agonists of LRH-1 on breast cancer 
cell growth.  
Collectively these studies aim to provide a better understanding of LRH-1 expression 
in breast cancer, and its effect on the estrogen dependent growth of breast cancer 
cells. 
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2 MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. Reagents 
Reagents and chemicals were supplied by Sigma-Aldrich (Poole, UK) and VWR 
International (Leicestershire, UK), unless otherwise stated. DNA ladders and reverse 
transcriptase were obtained from Fermentas, Helena Biosciences Europe 
(Sunderland, UK). ReddyMix™ PCR mastermix was supplied by ABgene (Epsom, 
UK). Taqman Real-time PCR reagents and Gene Expression Assays were supplied 
by Applied Biosystems (Cheshire, UK). Additional real-time RT-PCR was performed 
using primers purchased from PrimerDesign Ltd (Southampton, UK), or Eurofins 
MWG Operon (Ebersberg, Germany). Primer details are given in Tables 2.1 and 2.2. 
Kits for DNA and RNA preparation were obtained from Qiagen Ltd (Crawley, UK). 
Antibodies used and suppliers are listed in Table 2.3.  
2.1.2. General stock solutions 
Solutions were made in double distilled, de-ionised water (DDW) by dissolving the 
appropriate quantity of reagent. The solution was then autoclaved and stored at 
room temperature. 
 
X10 phosphate buffered saline (PBS) 136mM NaCl; 3mM KCl; 8mM 
Na2HPO4; 1.5mM KH2PO4. Stored at 
4oC 
X10 TBE 89mM Tris-base; 89mM Boric acid; 2mM 
Na-EDTA, pH 8.0 
10% Lauryl sodium dodecyl sulphate 
(SDS) 
10% w/v SDS, pH 7.0. Not autoclaved. 
TE Buffer 10mM Tris-HCl; 1mM Na-EDTA, pH 
8.0 
Sodium ethylene diamine Tetra-acetate 
(Na-EDTA) 
0.5M Na-EDTA, pH 8.0 
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2.1.3. Tissue culture reagents 
All mammalian cell lines were cultured at 37°C in a humidified atmosphere gassed 
with 5% CO2. Tissue culture was carried out in a NuAIRE class II, ducted laminar 
flow safety cabinet (NuAIRE DH Autoflow, Oxon, UK). Dulbecco’s Modified 
Eagle’s Medium (DMEM), 5mg penicillin/streptomycin/L-glutamine solution 
(P/S/G), 0.02%Na ethylenediaminetetra-acetic acid (EDTA) solution and 10X 
trypsin solution were supplied by Sigma-Aldrich (Poole, UK). DMEM without L-
glutamine, and phenol red, foetal calf serum (FCS), and 0.4% trypan blue solution 
were supplied by Invitrogen (Paisley, UK). Dextran-coated, charcoal treated FCS 
(DSS) was purchased from First Link (Birmingham, UK). 17β-estradiol (E2) and 4-
hydroxytamoxifen were purchased from Sigma-Aldrich (Poole, UK). ICI 182, 720 
(ICI) was purchased from Tocris (Bristol, UK). Compound 5a (Whitby ref) was a 
kind gift of Dr R. J. Whitby (School of Chemistry, University of Southampton, UK). 
Compounds 5b and 5L (Whitby paper) were kindly provided by Mr A. Bayly and 
Prof A. Spivey (Department of Chemistry, Imperial College, UK). 
2.1.4. Sundries 
Eppendorf tubes were purchased from Anachem (Bedfordshire, UK). Saran Wrap 
was purchased from the Dow Chemical Company (London, UK) and Whatman filter 
paper from Whatman International Ltd (Kent, UK). General laboratory and tissue 
culture plastics were purchased from Triple Red (Oxon, UK) and Corning (supplier 
Appleton woods, Birmingham, UK). Sterilin plates were supplied by Barloworld 
Scientific (Staffordshire, UK). Hybond-ECL nitrocellulose was obtained from 
Amersham Biosciences UK Ltd (Little Chalfont, UK). Kodak BioMax light film was 
supplied by Sigma-Aldrich (Poole, UK).  
2.2. METHODS 
2.2.1. Cell culture 
The MCF-7, ZR-75-1, T47D, MDA-MB-231, BT474 and MDA-MB-231 cell lines 
were obtained from the American Type Culture Collection (ATCC) (LGC 
promochem, Middlesex, UK). HepG2 cells were kindly provided by Dr Tahereh 
Kamalati (Imperial College, London), and had been purchased from European 
Collection of Cell Cultures (ECACC) (Salisbury, UK). All cell lines were maintained 
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in DMEM, supplemented with 10% FCS (Gibco-Invitrogen, UK), together with a 
solution of penicillin (100U/ml), streptomycin (100mg/ml) and L-glutamine (3 mM) 
(P/S/G), at 37°C in a humidified atmosphere gassed with 5% CO2. Cell cultures 
were grown to 70-80% confluency, at which time the adherent monolayer of cells 
were passaged by washing in phosphate buffered saline (PBS). Trypsin (1x trypsin) in 
0.02% EDTA was added and the cells placed in an incubator at 37°C in a humidified 
atmosphere gased with 5% CO2 for approximately 5 minutes to promote cell 
detachment and disaggregation. The action of the trypin was halted by the addition 
of culture media and the cells passaged into tissue culture flasks at ratios of 1:3-1:4.  
Aliquots of cells were regularly frozen in order to maintain stocks. For freezing, 5-10 
x 106 cells were trypsinised and centrifuged at 13,000 rpm in a bench top centrifuge, 
to form a cell pellet. The pellet was resuspended in 1.5ml of freezing medium (90% 
FCS, 10% DMSO). The suspension was then transferred into 2.5ml cryovials and 
placed -80°C for a minimum of 24 hours prior to being placed in liquid nitrogen 
storage.  
When frozen stocks were required, the frozen cells were thawed rapidly at 37°C in a 
water bath followed by slowly adding 25ml culture medium in a 50ml falcon tube and 
pelleted by centrifugation at 13,000rpm. On removing the supernatant, the cells were 
resuspended in 5ml of media and placed in a T25 tissue culture flask, which was 
placed in an incubator set at 37°C with humidified 5% CO2.  
For experiments investigating the effects of ligands, cells were cultured in phenol 
red-free DMEM supplemented with 10% DSS for 3 days prior to the addition of 
17ß-estradiol (E2; 10 nM), or the anti-estrogens OHT (100 nM) or ICI (100 nM), as 
appropriate. Since estrogen and anti-estrogens were prepared in ethanol, an equal 
volume of ethanol was added to the no ligand controls. Cells were harvested for 
RNA or protein lysate preparation, or for fixation to carry out sulphorhodamine B 
(SRB) estimation of cell number at varying times following the addition of ligand, as 
described in the appropriate figure legends in the results section. Compound 5a, 5b 
and 5L were prepared in DMSO, hence an equal volume of DMSO was added to the 
no ligand controls.  
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2.2.2. Cell counting and trypan blue exclusion 
Following trypsinisation, cells were resuspended in culture medium. 100µl of cell 
suspension was mixed with an equal volume of 0.4% trypan blue (Invitrogen, UK) to 
assess viability. 15µl of the trypan blue/cell suspension mixture was loaded into a 
haemocytometer chamber. The chamber was viewed under 10x objective on an 
inverted phase contrast microscope (Zeiss, Germany). Only viable bright cells, which 
had not taken up the dye, were included in the count. The cell concentration 
(cell/ml) was calculated as the number of cells counted per grid (9 squares) x dilution 
factor (2) x 104. To increase accuracy, two independent cell samples were taken. 
2.2.3. RNA preparation  
Cell culture medium was removed from the tissue culture plates by aspiration. The 
cells were washed twice with warm PBS and collected by scrapping the plate using a 
rubber policeman following the addition of RLT buffer (buffer containing guanidine 
isothiocyanate and β-mercaptoethanol) from the RNeasy Mini Preparation kit 
(Qiagen Ltd, UK). Cells were homogenised by centrifugation (13,000 rpm for 2 
minutes) through a QIAShredder (Qiagen Ltd, UK). Total RNA was extracted using 
the RNeasy Mini Preparation kit (Qiagen, Ltd) following manufacturer’s instructions, 
as described (Bonham and Danielpour, 1996). Prior to extraction, the columns were 
treated with DNaseI to remove residual DNA (Qiagen, Ltd, UK). Following 
homogenisation, 600µl of 70% ethanol was added to the homogenised lysate and 
thoroughly mixed. 700µl of the sample was then added to the RNeasy mini spin 
column placed in a 2ml collection tube. The sample was then centrifuged at 13,000 
rpm for 15 seconds and the flow-through discarded. The remainder of the sample 
was then added to the column and the centrifugation step repeated. 350µl of buffer 
RW1 was then pipetted onto the column and centrifuged for 15-30 seconds at 13,000 
rpm. DNaseI incubation mix (70µl Buffer RDD plus 10µl DNaseI stock solution) 
was then added onto the RNase silica-gel membrane and incubated at room 
temperature for 15 minutes. A further 350µl of buffer RW1 was added to the 
column and centrifuged at 13,000 rpm for 15-30 seconds to wash the column. The 
flow-through was discarded. The RNeasy column was then transferred to a new 2ml 
collection tube and 500µl RPE buffer added. The sample was centrifuged again at 
13,000 rpm for 15-30 seconds to wash the column, and the flow-through discarded. 
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A further 500µl of RPE buffer was added and centrifuged again at 13,000 rpm for 2 
minutes to dry the column. To complete the drying stage, the column was transferred 
to a new 2ml collection tube and centrifuged for 1 minute. In the final step, the 
RNeasy column was then transferred to a new 1.5ml microcentrifuge collection tube 
and 50µl of RNase-free water added to the column. The column was centrifuged for 
1 minute at 13,000 rpm to elute the RNA.  
2.2.4. Spectrophotometry 
RNA concentration and purity were determined by using either a Shimadzu UV-VIS 
spectrophotometer 1201 (Milton Keynes, UK) or the nano-drop ND10000 
spectrophotometer (Lab Tech International, East Sussex, UK). With the UV 
spectrophotometer a quartz cuvette (Hellma, UK) was used. 5µl of RNA was diluted 
in 995µl of RNase free water. An optical density (OD) value of 1.0 at 260 nm 
corresponds to a concentration of 40µg/ml for RNA. An estimate of purity was 
obtained by measuring the absorption at 260nm and 280nm. The ratio of these two 
readings (OD260nm/OD280nm) should be 2.0 for RNA. Readings significantly less 
than this indicate contamination with protein or phenol. The quality of the RNA was 
confirmed by running 2µg of RNA on a 1.5% agarose gel. 
2.2.5. Agarose gel electrophoresis of RNA and DNA 
RNA and PCR products were resolved on agarose gels prepared in 1x TBE buffer 
using a horizontal gel electrophoresis apparatus (24 x 24 cm gel HU13 (Thistle 
Scientific, Glasgow, UK)) and visualised using a UVIpro Platinum Gel Doc System 
ultraviolet transilluminator (UVItec, UK). The concentration of the agarose gel (1-
1.5%) used was dependent on the expected size of the products to be resolved and 
contained either 0.25µl/ml ethidium bromide (Sigma, UK) or 0.1µl/ml SYBR Safe 
DNA gel stain (Invitrogen, UK). The size markers used included: Low or High 
Range, ready to use, MassRuler DNA ladder (Helena Biosciences Europe, UK). 
Low range fragment size (bp): 1031, 900, 800, 700, 600, 500, 400, 300, 200, 100, 80. 
High range fragment size (bp): 10000, 8000, 6000, 5000, 4000, 3500, 3000, 2500, 
2000, 1500. 
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2.2.6. cDNA preparation by reverse transcription 
cDNAs were prepared from total RNA using thin-walled PCR tubes, as below: 
 
• 4µl 5x RT buffer (250mM Tris HCl, 200mM KCl, 30mM MgCl2), containing 
50mM DTT (Helena Biosciences Europe, UK) pre-warmed to 37ºC for 15 
minutes 
• 2µl 10mM dNTP stock (Helena Biosciences Europe, UK) 
• 1µl random hexamers p (dN)6 (200ng) (Helena Biosciences Europe, UK) 
• 2µg RNA 
• Sterile water to a total volume of 19µl 
• 1µl RT stock RevertAid ™ Moloney Murine Leukaemia Virus (M-MuLV) 
 Reverse Transcriptase (200U/µl) (Helena Biosciences Europe, UK) 
 
The reaction was incubated at room temperature for 5 minutes, then at 42ºC for 1 
hour and heat inactivated at 95ºC for 5minutes. The cDNA was then diluted 1:10 
with sterile ddH2O and 2µl of cDNA was subsequently used as a template in each 
PCR reaction. 
 
2.2.7. Polymerase chain reaction (PCR) 
 
25µl PCR reactions were set up in 0.2µl domed cap Thermo-PCR tubes, containing 
12.5µl of PCR master mix (2x Pre-aliquoted ReddyMix™ (Abgene,UK), containing 
0.625 units of Thermoprime Plus DNA Polymerase, 75 mM Tris-HCl (pH 8.8 at 
25ºC), 20mM (NH4)2SO4, 1.5mM MgCl2, 0.01% Tween-20, 0.2mM each of dATP, 
dCTP, dGTP, dTTP), together with 2.5µl sense and anti-sense PCR primers 
(10pmol/µl), 2µl cDNA from the RT reaction and 5.5µl autoclaved DDW to make 
up a total of 25µl. Primer list Table 2.1. 
 
The PCR mixture was centrifuged for 30 seconds prior to loading onto a GeneAmp® 
9700 PCR machine (Applied Biosystems, UK). PCR was carried out over 23-40 
cycles using the following conditions. 
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• Initial Denaturing  94ºC 5 minutes 1x cycle 
• Denaturing   94ºC 1 minute 
• Annealing   XºC 1 minute (X denotes optimal        
           annealing temperature) 
• Extension   72ºC 1 minutes 
• Final Extension  72ºC 5 minutes 1  x cycle 
 
2.2.8. Real-time qRT-PCR (SyBr Green) 
 
Real-time qRT-PCR was carried out according to manufacturer’s protocols on an 
Applied Biosystems ABI 7900HT fast real-time PCR system using SyBr green 
primers and mastermix from Primer Design. Each PCR reaction was carried out in 
triplicate, in a Microamp® fast optical 96-well reaction plate (Applied Biosystems, 
UK). Sybr green reactions (40-50 repeats): 
 
•  Denaturing 95°- 10 minutes 
•  Annealing 95°- 15 seconds 
•  Extension 60°- 1 minute 
•  Melt Curve 95°- 15 seconds 
                50°- 15secs 
                95°- 15secs  
 
2.2.9. Real-time qRT-PCR (ABI Taqman Assays) 
 
Real-time qRT-PCR was performed according to manufacturer’s instructions 
(Applied Biosystems) on a Taqman 7900 HT Fast machine using validated Gene 
Expression for the gene of interest (Table 2.2). Each PCR reaction was carried out in 
triplicate, in a MicroAmp® optical 96-well reaction plate (Applied Biosystems, UK). 
Each reaction consisted of 10µl 1xTaqman® Universal PCR Master Mix (Applied 
Biosystems, UK), 1µl Gene Expression Assay primers (Applied Biosystems, UK), 8µl 
distilled autoclaved water and 2µl cDNA from the RT reaction.  
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The PCR settings were:  
 
• Stage 1 (repeat 1x) 95°C for 0.20 seconds,  
• Stage 2 (repeat 40x) 95°C for 0.03 seconds,  
• 60°C for 0.30 seconds.  
 
Target gene was determined by normalising to expression of the control gene 
(GAPDH), and represented relative to the vehicle control, using the 2-ΔΔCT method as 
described by Livak et. al. (Livak and Schmittgen, 2001). The Taqman® universal 
mastermix consists of AmpliTaq Gold® DNA Polymerase, dNTPs and optimized 
buffer components. The fluorescent reporter dye of the Taqman® probes chosen 
was 6-carboxyfluorescein (FAM™). Negative controls were set up using ddH2O 
instead of cDNA. PCR and fluorescence analysis were performed using the ABI 
Prism 7900HT Fast sequence detection system (Applied Biosystems).  
 
2.2.10. Preparation of protein lysates for western blotting 
 
Cells were washed twice with pre-warmed (37°C) PBS. 0.5ml of hot lysis buffer 
(0.12M Tris-HCl pH 6.8, 4% w/v SDS, 20% w/v glycerol, 0.2M DTT, 0.008% 
bromophenol blue), pre-heated to 100°C, was added to the plates. The cells were 
collected into 1.5 ml microcentrifuge tubes using a rubber policeman, placed for 5 
minutes at 100°C, cooled on ice, aliquoted and stored at -80°C until required. 
 
2.2.11. Western blotting 
 
Reagents:   
Upper Buffer 0.5M Tris-HCl (pH 6.8); 0.4% SDS 
Lower Buffer 1.5M Tris-HCl (pH8.8); 0.4% SDS 
SDS Polyacrylamide resolving gel 
(10%) 
10ml lower buffer; 13.3ml 30% 
acrylamide: bis-acrylamide; 40µl 
TEMED, 400µl 10% ammonium 
persulphate (APS); 17.7ml DDW 
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SDS Polyacrylamide resolving gel 
(10%) 
2.5ml upper buffer; 1.5ml 30% 
acrylamide: bis-acrylamide; 100µl APS; 
10µl TEMED; 5ml DDW 
SDS-PAGE running buffer 25mM Tris-Base; 192mM glycine; 0.1% 
SDS 
Transfer buffer 5mM Tris-Base; 38mM glycine; 20% 
methanol 
Stripping buffer 15g glycine; 10ml 10% Tween; 83ml 1M 
HCl 
 
Protein lysates were heated at 100°C for 5 minutes prior to loading on a gel and 5-
20µl of the lysates were loaded on an SDS-polyacrylamide gel with a 5% upper or 
stacking gel using a Bio-Rad mini-gel system (Hoeffer Scientific Instruments, UK). 
The percentage of the SDS-polyacrylamide was varied (8-12%) depending on the 
molecular mass of the protein of interest. Coloured recombinant protein molecular 
weight marker (Full Range Rainbow marker, having coloured markers with molecular 
masses (kDa) 250000, 160000, 105000, 75000, 50000, 35000, 25000, 15000, 10000) 
(Amersham Life Sciences, UK), was also loaded onto the gels to quantify protein 
size. The gels were electrophoresed in 1x SDS-PAGE running buffer at 60V for 30 
minutes until the dye front had progressed through the stacking gel, and then at 
100V for 1.5 to 2 hours until the dye had reached the bottom of the gel.  
 
The resolved protein gels were transferred onto a nitrocellulose membrane 
(Hybond-ECL Nitrocellulose membrane (Amersham Biosciences, UK)) for 
immunodetection, using a TE22 transfer unit (Amersham Biosciences, UK) set at 
100V, for 1.5 hours with 1x transfer buffer. The membrane was then incubated in 
5% Marvel/PBS-0.05% Tween20 for 1 hour at room temperature, in order to block 
non-specific binding of the antibody and then incubated overnight at 4°C with the 
appropriate primary antibody (diluted in PBS containing 5% dried skimmed milk 
(w/v) and 0.05% (v/v) Tween-20). The membrane was then washed 4x in PBS 
containing 0.05% Tween-20 (v/v), each wash being 15 minutes. The membrane was 
then incubated with the appropriate HRP-conjugated secondary antibody in PBS 
containing 5% dried skimmed milk and 0.05% Tween-20 for 1 hour. The membrane 
was then washed again 4x in wash buffer for a total of 1 hour. SuperSignal West Pico 
Chemoilluminescent Substrate (Pierce Biotechnology, UK) was added to the 
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membrane, followed by autoradiography using Kodak Biomax Light film (Sigma, 
UK) and film development using a Konica SRX-1001A X-ray developer. 
 
2.2.12.  Sulphordamine B (SRB) growth assay 
 
For studies where estrogen, anti-estrogens or the LRH-1 activator (compounds 5a, 
5b, 5l) action was to be determined, cells routinely grown in DMEM containing 10% 
FCS were transferred by trypsinisation to DMEM containing 10% FCS, or to phenol 
red-free DMEM supplemented with 10% DSS. Following 72 hours in dextran-coated 
charcoal-stripped DMEM, 1 x 104 cells were then plated in flat-bottomed 96-well 
plates in media (200µl/well). Five wells were plated per treatment condition. Ligands 
were added as appropriate on the day following plating (Day 0). Cell growth was 
assessed every 72 hours using the sulphorodiamine B (SRB) assay, a colorimetric 
assay that measures cell mass by staining basic amino acids, as previously described 
(Skehan et al., 1990). Media were changed every 72 hours for the remaining wells, 
until the end of the growth study period. The SRB assay involved fixing the cells by 
adding 100µl ice-cold 40% trichloroacetic acid (TCA) to each well and incubation at 
4°C for 1 hour. The wells were then washed 5x in distilled water, 0.4% SRB (Sigma, 
UK) prepared in 1% acetic acid was added and the plates inclubated for 30 minutes 
at room temperature. Following this, the wells were washed 5x in 1% acetic acid and 
allowed to air-dry overnight. The bound dye was then solubilised by adding 100µl of 
10mM Tris-base to the wells and placed in a plate-shaker for 15 minutes at room 
temperature. The absorbance of the dye was then read using the Anthos 2001 plate 
reader (Jencons Scientific, Leighton Buzzard, UK) or Tecan Sunrise Optical Plate 
Reader (Tecan-UK, Reading, UK) at 492 nm and the readings adjusted for 
background staining. 
 
2.2.13. Transient transfections 
 
MCF-7 and COS-1 cells, maintained in DMEM, supplemented with 10% FCS plus 
P/S/G were plated into 10cm dishes at 1.5 x 106 cells per plate, 24 hours prior to 
transfection with 6µg of each expression plasmid using FuGENE 6 Reagent (Roche 
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Diagnostics, UK), as previously described (Uyttersprot et al., 1998), following the 
manufacturer’s instructions. On the day of transfection, 18µl of FuGENE 6 was 
added to 500µl DMEM, vortexed briefly and incubated for 5 minutes at room 
temperature. 6µg of the DNA mix was added to the reaction mixture and the final 
reaction made up to 600µl with DMEM. The mixture was vortexed briefly and 
incubated for 15 minutes at room temperature. Cell culture medium was removed 
from the plates and the cells were washed twice with pre-warmed PBS. 600µl of the 
DNA/FuGENE 6 mixture was then added to the cells drop-wise and incubated for 
4 hours at 37°C in a humidified atmosphere gassed with 5% CO2, with gentle 
agitation every hour. 10ml of DMEM supplemented with 10% FCS was added to 
each plate. Protein lysates and RNA were prepared 72 hours following transfection, 
as described in section 2.2.2 and 2.2.7. 
 
2.2.14. 5' RNA ligase mediated rapid amplification of cDNA ends (RLM 
RACE) 
 
This method is used to extend partial cDNA clones by amplifying the 5' sequences 
of the corresponding mRNAs (Frohman et al., 1988, Schaefer, 1995, Zhang and 
Frohman, 1997). The technique requires knowledge of only a small region of 
sequence within the partial cDNA clone. During PCR, the thermostable DNA 
polymerase is directed to the appropriate target RNA by a single primer derived from 
the region of known sequence; the second primer required for PCR is 
complementary to a general feature of the target; in the case of 5' RACE, to a 
homopolymeric tail added (via terminal transferase) to the 3' termini of cDNAs 
transcribed from a preparation of mRNA. This synthetic tail provides a primer-
binding site upstream of the unknown 5' sequence of the target mRNA. The 
products of the amplification reaction are cloned into a plasmid vector for 
sequencing and subsequent manipulation 
 
2.2.15. RNA processing 
The protocol is optimised for starting with 10µg of total RNA. The following 
components were assembled in an RNase-free microcentrifuge tube:  
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• 10µg of total RNA  
• 2µl Calf Intestine Alkaline Phosphatase (CIP) (ABI, UK)  
• 2µl CIP buffer (ABI, UK) 
• made up to a total reaction mixture of 20µl with nuclease-free water (Sigma-
Aldrich, UK)  
The mixture was gently mixed, centrifuged at 13,000 for 2-3 seconds and incubated 
at 37°C for one hour.  
At this stage the CIP reaction was terminated by the addition of 15µl Ammonium 
Acetate Solution (ABI, UK), 115µl nuclease-free Water (Sigma-Aldrich, UK) and 
75µl acid phenol:chloroform (ABI, UK). The microcentrifuge tube was vortexed 
thoroughly (to make an emulsion) and centrifuged for 5 minutes at room 
temperature at 13,000 rpm. The aqueous phase (top layer) was transferred to a new 
microcentrifuge tube. To the new tube 120µl isopropanol was added and mixed 
thoroughly before being chilled on ice for 10 minutes. The tube was centrifuged at 
13,000 rpm for 20 minutes and the pelleted RNA was rinsed with 0.5ml cold 70% 
ethanol. The ethanol was carefully removed, the pellet was air-dried and resuspended 
in 11µl Nuclease-free Water (Sigma-Aldrich, UK). 5µl of the CIP’d RNA was added 
to a new microcentrifuge tube (Tobacco Acid Pyrophosphate (TAP) treatment) 
containing:  
• 1µl 10x TAP buffer (ABI, UK)  
• 2µl Tobacco Acid Pyrophosphatase (ABI, UK) 
• 2µl Nuclease-free Water (Sigma-Aldrich, UK).  
The mixture was gently pipetted and spun for 2-3 seconds 13,000rpm before being 
incubated at 37°C for one hour. 
The final phase of RNA processing was 5’-RACE Adapter ligation. The following 
components were assembled in an RNase-free microcentrifuge tube:  
• 2µl CIP/TAP-treated RNA,  
• 1µl 5’RACE Adapter (ABI, UK),  
• 1µl 10x RNA Ligase Buffer (ABI, UK; warmed by rolling between gloved hands 
to resuspend an precipitate. Since the buffer contains ATP, it is not 
recommended to heat it over 37°C, as it would compromise the ATP).  
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The mixture was gently mixed and spun for 2-3 seconds at 13,000 rpm. The mixture 
was then incubated at 37°C for one hour.   
2.2.16.  Reverse transcription 
The following were assembled in an RNase-free microfuge tube on ice:  
 
• 2µl Ligated RNA,  
• 4µl dNTP Mix (Helena Biosciences Europe, UK),  
• 2µl Random Decamers (ABI, UK),  
• 2µl 10x RT Buffer (Helena Biosciences Europe, UK),  
• 1µl RNAase Inhibitor (ABI, UK),  
• 1µl M-MLV Reverse Transcriptase,  
• made up to 20µl with Nuclease-free Water (Sigma-Aldrich, UK).  
 
The solutions were gently mixed and spun for 2-3 seconds in a microcentrifuge at 
13,000 rpm and then incubated at 42°C for one hour. The cDNA was then diluted 
1:2 to give a total volume of 40µl.  
 
2.2.17. Nested PCR for 5’RLM-RACE 
For the Outer 5’RLM-RACE PCR the following components were prepared in 0.2µl 
domed cap Thermo-PCR tubes on ice for a reaction made up to 25µl:  
 
• 1µl RT reaction (from the previous step),  
• 12.5µl of PCR master mix (2x Pre-aliquoted ReddyMix™ (Abgene,UK) 
containing 0.625 units of Thermoprime Plus DNA Polymerase, 75 mM Tris-
HCl (pH 8.8 at 25ºC), 20mM (NH4)2SO4, 1.5mM MgCl2, 0.01% Tween 20  
• 1µl 5’RACE gene-specific outer primer (10µM)  
• 1µl 5’RACE Outer Primer (ABI, UK) 
• 9.5µl Nuclease-free Water (Sigma-Aldrich, UK).  
 
The solutions were gently mixed and centrifuged for 2-3 seconds at 13,000 rpm, 
before loading onto a GeneAmp® 9700 PCR machine (Applied Biosystems, UK). 
PCR was carried out with a 3 minute initial denaturation at 94°C, followed by 35 
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cycles at 94°C (1 minute) and 72°C (1 minute). Final extension was at 72°C for 7 
minutes.  
 
For the Inner 5’RLM-RACE PCR the following components were prepared in 0.2µl 
domed cap Thermo-PCR tubes on ice for a reaction made up to 25µl:  
 
• 12.5µl of PCR master mix (2x Pre-aliquoted ReddyMix™ (Abgene,UK), 
containing 0.625 units of Thermoprime Plus DNA Polymerase, 75 mM Tris-
HCl (pH 8.8 at 25ºC), 20mM (NH4)2SO4, 1.5mM MgCl2, 0.01% Tween 20 
• 1µl Outer PCR (from previous step) 
• 1µl 5’RACE gene specific inner primer (10µM) 
• 2µl 5’RACE Inner Primer (ABI,UK) 
• 9.5µl Nuclease-free Water (Sigma-Aldrich, UK) 
 
The solutions were mixed gently, centrifuged at 13,000 rpm for 2-3 seconds, before 
loading onto a GeneAmp® 9700 PCR machine (Applied Biosystems, UK) and PCR 
was carried out using the same PCR cycling prolife as for the outer 5’RLM-RACE 
PCR. 
 
First round PCR amplification: 5’RLM-RACE outer primer and LRH1 exon3 outer 
reverse primer. Second round PCR amplification: 5’RLM-RACE inner primer and 
LRH1 exon3 inner reverse primer  
2.2.18. Gel analysis of products, cloning and sequencing 
Following completion of the PCR steps, 10µl of each of the resulting PCR products 
were visualised by agarose gel electrophoresis and cloned directly into the PCR 
plasmid cloning vector pJet 1.2 (Fermentas). DNA sequencing of twenty plasmid 
clones identified three insert sequences of 152, 289 and 326bp in size. The identity of 
each product observed by gel electrophoresis was confirmed by DNA sequencing.  
 
2.2.19. RNA interference using small interfering RNA (siRNA) (reverse 
transfection) 
siRNAs (purchased from Dharmacon, UK) were resuspended to a stock of 20µM 
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with 1X siRNA Buffer (diluted from 5X siRNA buffer provided by Dharmacon) and 
Nuclease-free water (Sigma-Aldrich, UK) as per manufacturer’s protocol. The siRNA 
was aliquoted into small volumes and stored at -20°C to -80°C, and limited freeze-
thaw events of each tube to no more than five. Cells maintained in DMEM 
supplemented with 10% FCS, or cultured in DMEM lacking phenol red and 
supplemented with 10% DSS were transfected with siRNA oligonucleotides as 
described below. The reverse transfection method using Lipofectamine RNAiMAX 
was used for transfection of siRNAs. 
The following components were gently added to a 10cm tissue culture plate, mixed 
and left to wait for 20-30 minutes:  
 
• 500µl phenol-red free DMEM 
• 40µl Lipofectamine RNAiMAX (Invitrogen, UK) – kept on ice 
• 40µl siRNA – kept on ice (20µM/ml stock) 
 
10ml of cell suspension was added to the siRNA (made up in DMEM supplemented 
with 10% FCS and 2mM/ml L-Glutamine (Gibco, UK)) containing 1 x 106 cells, and 
the plate gently rocked to allow adequate mixing. The cells were then incubated for 
48 hours before harvesting to prepare RNA or protein, as described in Sections 2.2.2, 
and 2.2.7. 
For determining the effect of gene silencing by siRNA on cell numbers, the 
following was prepared in a 24 well plate. The reagents were thoroughly mixed and 
left to wait for 20-30 minutes:  
 
• 250µl phenol-red free DMEM 
• 5µl Lipofectamine RNAiMAX (Invitrogen, UK) – kept on ice  
• 5µl siRNA – kept on ice (20µM/ml stock).  
 
10µl of the siRNA mixture was then added to each well of a 96 well plate (5 
reactions were performed per condition). Following this, a 200µl cell suspension 
(made up in DMEM supplemented with 10% FCS and 2mM/ml L-Glutamine 
(Gibco, UK)) containing 1 x 104 cells was added to each well containing the siRNA 
mix. For growth experiments in which E2 was added, a similar method was followed 
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except that the medium used was phenol red-free DMEM and dextran-coated 
charcoal-stripped FCS (DSS) was added, as appropriate. E2 (10 nM) was added to the 
medium 24 hours after transfection. 
For some experiments, double transfection of siRNA oligonucleotides was carried 
out. For this, the first transfection was performed in 10 cm plates, as described 
above. 72 hours following the first transfection, the adherent cells were trypsinised 
and then resuspended in culture medium. A cell count was performed and a second 
transfection performed as per the original siRNA protocol above reseeding 2 x 106 
cells per plate. Cells were then harvested 72 hours later for RNA and protein lysate 
preparation.  
In order to carry out Fluorescence-activated cell sorting (FACS) analysis of the 
effects of gene silencing, the second siRNA transfection was performed in 6 well 
plates. For this, added 250µl phenol-red free DMEM, 5µl Lipofectamine 
RNAiMAX (Invitrogen, UK) – kept on ice, 5µl siRNA – kept on ice (20µM/ml 
stock), was added to each well and left for 20-30 minutes. To the siRNA mix 3 x 105 
cells in 2 ml of medium was added (DMEM supplemented with 10% DSS and 
2mM/ml L-Glutamine). FACS analysis was performed 96 hours later, as described 
below. 
2.2.20.  Fluorescence-activated cell sorting (FACS) Analysis 
Cells were trypsinized, centrifuged at 1,100 rpm for 5 min, and resuspended in 5 ml 
of ice-cold PBS, centrifuged as above, gently resuspended in 1 ml ice-cold 70% 
ethanol, and incubated at 4°C for 1 h. Cells were washed twice with 5 ml of ice-cold 
PBS and resuspended in 100 µl of PBS containing 100 µg/ml RNase (Sigma-Aldrich) 
and 1 ml of 50 µg/mL propidium iodide (Sigma-Aldrich). Following incubation 
overnight in the dark at 4°C and filtering through 70-µm muslin gauze into 
fluorescence-activated cell sorting tubes (Becton Dickinson) to remove cell clumps, 
stained cells were acquired using the RXP cytomics software on a Beckman Coulter 
Elite ESP (Beckman Coulter, High Wycombe) and data were analyzed using Flow Jo 
v7.2.5 (Tree Star, Inc.).  
For dual labeling with propidium iodide and Annexin V, the cells were trypsinized 
and collected with the culture medium, centrifuged at 1,100 rpm for 5 min, and 
washed twice with 5 ml of ice-cold PBS containing 2% (w/v) bovine serum albumin 
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(Sigma-Aldrich). Cells were labeled with Annexin V-fluorescein-isothiocyanate 
(FITC) using the Annexin V-FITC apoptosis detection kit I (BD Pharmingen), as per 
the manufacturer's instructions. Labeled cells were acquired within 1 hour, by using 
the RXP cytomics software on a Beckman Coulter Elite ESP, and the data were 
analyzed using Flow Jo v7.2.5. Statistical analysis was performed for three 
independent experiments, carried out using the unpaired student's t test to determine 
P values. 
 
2.2.21.  Reporter assay 
All transient transfection for reporter assay were performed in 24-well plate using 
Fugene HD transfection reagent (Roche Diagnostics). MCF-7 cells and COS-1 cells 
were seeded 75, 000 and 50, 000 cells per well respectively with DMEM (Sigma-
Aldrich Ltd.) supplemented with 10% FCS (First Link Ltd.). Prior to transfection, 
culture medium was replaced with serum and antibiotic free Opti-MEM (Invitrogen). 
Cells in each well were co-transfected with 100ng of reporter construct SF-1-
promoter-Luciferase (SF1-LUC) or ERα-promoter-Luciferase (ERP-LUC), 100ng of 
internal control reporter pRL-TK and blue script carrier DNA BSM in combination 
with or without expression vector of LRH-1 and SF-1. 5 hours after transfection, the 
transfection medium was replaced with fresh culture medium with or without 
treatment of ligands. 24 hours after transfection cells were lysed and luciferase 
activity measured using Dual-Glo Luciferase Assay System (Promega). Transfection 
efficiency was normalized using renilla reporter activity.  Luciferase reading 
represents the mean of three individual transfections, and error was shown as SEM. 
2.2.22. Plasmids  
LRH-1 firefly luciferase reporter gene was SF-1-LUC (gifts from Dr Donald 
McDonnell). ERP-Luc was generated by amplifying the genomic region covering the 
ER gene promoter A to LRHRE site 3 as a 5.9 Kb fragment using high fidelity pfu 
DNA polymerase (Fermentas, UK) using DNA prepared from the human ER gene 
Bacterial Artificial Chromosome clone RP3-443C4 (Geneservice Ltd, UK). The PCR 
product was cloned into the BglII site of pGL3 luciferase reporter vector (Promega). 
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For experiments in which the cells were grown in estrogen-depleted conditions, the 
cells were transferred to DMEM lacking phenol red and containing 5% dextran-
coated charcoal-stripped FCS for 72 hours. 
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Table 2.1 Sequences of RT-PCR primers used in this study 
Primer Sequence 
Annealing 
Temp (ºC) 
No. PCR 
cycles 
TAF9-like-F 
5’-CAA TCC AGT GTC GTG CTG 
AC-3‘ 
59.4 25 
TAF9-like-R 
5'-TCC CTT GGT TAG GTC CCT 
TT -3' 
57.3 25 
exonuclease-1-F 
5'-GCT CCC TAT GAA GCT GAT 
GC-3' 
59.4 31 
exonuclease-1-R 
5'-ACA TTC CTA GCC GAG CTT 
GA-3' 
57.3 31 
FOXO-4-F 
5'-CTG TGC TCA CAC CCC CTA 
CT-3' 
61.4 30 
FOXO-4-R 
5'-AGC TTC CAG GCA TGA CTC 
AG-3' 
59.4 30 
FEN-1-F 
5'-CGC TAA GCT GAG AAG GGA 
GA-3' 
59.4 25 
FEN-1-R 
5'-ACG GCC AAA GTA GCT CTT 
GA-3' 
57.3 25 
Mad4-F 
5'-AAG CAC AGA CGA GCC AAA 
CT-3' 
57.3 25 
Mad4-R 
5'-CTG CTC CTT GAT GCT CAG 
TG-3' 
59.4 25 
zfp503-F 
5'-GAT CAG GGT CCT GAA GAT 
GC-3' 
59.4 25 
zfp503-R 
5'-CCG AGT TGA GTT TGG AGG 
AG-3' 
59.4 25 
EGLN-1-F 
5'-TTG CTG ACA TTG AAC CCA 
AA-3' 
53.2 30 
EGLN-1-R 
5'-TTA CCG ACC GAA TCT GAA 
GG-3' 
57.3 30 
LRH-1-F 
5'-TCG ACC ACA TTT ACC GAC 
AA-3' 
55.3 32 
LRH-1-R 
5'-CCA GCT GGA AGT TTT CAA 
GG-3' 
57.3 32 
HELAD1-F 
5'-GGA GTT GAC AGA CGG GGT 
TA-3' 
59.4 30 
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HELAD1-R 
5'-AGG GCA TTT GTG GTA CTT 
GC-3' 
57.3 30 
SRYbox3-F 
5'-AGA CCA GGA CCG TGT GAA 
AC-3' 
59.4 30 
SRYbox3-R 
5'-GTC GAT GAA TGG TCG CTT 
CT-3' 
57.3 30 
SERPINA1-F 
5'-CAC CCA CGA TAT CAT CAC 
CA-3' 
57.3 30 
SERPINA1-R 
5'-CAG CTT CAG TCC CTT TCT 
CG-3' 
59.4 30 
pS2-F (SA1397) 
5'-TTG GAG CAG AGA GGA GGC 
AAT G-3' 
62.1 30 
pS2-R (SA1398) 
5'-TTA GGA TAG AAG CAC CAG 
GGG ACC-3' 
64.4 30 
PR-F (SA1403) 
5'-CCA GAG CCC ACA ATA CAG 
CTT C-3' 
62.1 30 
PR-R (SA1404) 
5'-GCC AGC CTG ACA GCA CTT 
TCT AAG-3' 
64.4 30 
CathD-F 
(SA1399) 
5'-CAT TCC CGA GGT GCT CAA 
GAA C-3' 
62.1 23 
CathD-R 
(SA1400) 
5'-TCT TCA CGT AGG TGC TGG 
ACT TG-3' 
62.4 23 
GAPDH-F 5'-TCC CAT CAC CAT CTT CCA-3' 53.7 22 
GAPDH-R 5'-CAT CAC GCC ACA GTT TCC-3' 56 22 
Sytl5-F 
5'-CGT TAC ATT CCC CCA GAA 
GA-3' 
57.3 30 
Sytl5-R 
5'-AGC AGG TAG CCC TTC ACA 
AA-3' 
57.3 30 
Syt13-F 
5'-TCC TGG TGG TGC TGA TTA 
AA-3' 
55.3 32 
Syt13-R 
5'-AGC ACT TCC AGC TCC ACA 
CT-3' 
59.4 32 
Rab-27A-F 
5'-CCA TAG CAC TCG CAG AGA 
AA-3' 
57.3 32 
Rab-27A-R 
5'-CCG TAG AGG CAT GAC CAT 
TT-3' 
57.3 32 
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Col12a1-F 
5'-TTT GCC AGG AGA GAA AGG 
TG-3' 
57.3 32 
Col12a1-R 
5'-ATA GCC TTG CCC GTT GTA 
TG-3' 
57.3 32 
TADG-12-F 
5'-GTC AAG AGA GGA GGC TGT 
GG-3' 
61.4 30 
TADG-12-R 
5'-TCC CCT TCC TCT TCA GGT 
TT-3' 
57.3 30 
NRG3-F 
5'-GAT CCC AGA CCA GGA TAC 
GA-3' 
59.4 35 
NRG3-R 
5'-AAT AGC CCA CCA GGT CCT 
TT-3' 
57.3 35 
SEMA6D-F 
5'-AAA TAT TTG GCG GTC CAA 
CA-3' 
53.2 35 
SEMA6D-R 
5'-CAG ACT GGA CTT CCC ATC 
GT-3' 
59.4 35 
GDNFR-F 
5'-AGA CCA CCA CTG CCA CTA 
CC-3' 
61.4 32 
GDNFR-R 
5'-TTG TGG TTA TGT GGC TGG 
AA-3' 
55.3 32 
AP1S3-F 
5'-TTG TGC ATC GTT ACG TGG 
AG-3' 
57.3 35 
AP1S3-R 
5'-ATC TCG GCT CAC TGC AAT 
CT-3' 
57.3 35 
CACNG4-F 
5'-CAC GAC AGC TCG GAG TAC 
CT-3' 
61.4 30 
CACNG4-R 
5'-CAC CTG TGT TGC TGG AAA 
TG-3' 
57.3 30 
SLC26A2-F 
5'-CCA TTT TGG CCT CCT GAG 
TA-3' 
57.3 35 
SLC26A2-R 
5'-GGA TGG TCT CGA ACT CCT 
GA-3' 
59.4 35 
SLC35D2-F 
5'-CAG AAA GTG CGT TCG GCT 
AC-3' 
59.4 32 
SLC35D2-R 
5'-GGG CTG AGA GTT GGA GAC 
TG-3' 
61.4 32 
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SLC29A1-F 
5'-GAG CGG AAC TCT CTC AGT 
GC-3' 
61.4 30 
SLC29A1-R 
5'-GGC AGT GAT CAG AAA CAC 
CA-3' 
57.3 30 
GREB1-F 
5'-GGA CCA GCT TCA GTC ACC 
TTT CCA GTG GTG GCC-3' 
74.5 30 
GREB1-R(1C) 
5'-GGG AGT AAA GCT GGT GCC 
TGG GGC ACA GGT CAC G-3' 
69.5 30 
ZNF367-F 
5'-TCC AGG CTC ACA AAA GGA 
CT-3' 
57.3 35 
ZNF367-R 5'-TTC TGA ACC AGC TTG CCT TT-3' 
55.3 35 
SF-1-F (SA2286) 
5'-ATG GTC TTC AAG GAG CTG 
GA-3' 
57.3 35 
SF-1-R (SA2287) 
5'-GCA CAG GGT GTA GTC AAG 
CA-3' 
59.4 35 
SHP-F (SA2274) 
5'-CCC AAG ATG CTG TGA CCT 
TT-3' 
57.3 36 
SHP-R (SA2275) 
5'-TCC AGG ACT TCA CAC AGC 
AC-3' 
59.4 36 
ERα-F (SA1411) 
5'-CAG ATG GTC AGT GCC TTG 
TTG G-3' 
58.8 28 
ERα-R (SA1412) 
5'-CCA AGA GCA AGT TAG GAG 
CAA ACA-3' 
55.3 28 
LRH-1 
RACE289-F 
5'-CCG GAG TTG AAT CTG TGC 
TG-3' 
59.4 31 
LRH-1 
RACE289-R 
5'-GGG ACA AAG CTC TTC CAG 
AT-3' 
57.3 31 
LRH-1 
RACE325-F 
5'-CCA GGT GCA GGC ATA AAA 
GT-3' 
57.3 31 
LRH-1 
RACE325-R 
5'-TAT CTC CAC ACA CGG GAC 
AA-3' 
57.3 31 
LRH-1 Var1/2-F 
5'-TCT TTA AAG CAC GGA CTT 
ACA CC-3' 
58.9 31 
LRH-1 Var1/2-
R 
5'-TAT CTC CAC ACA CGG GAC 
AA-3' 
57.3 31 
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LRH-1-F(480-
461) 
5'-TAT CTC CAC ACA CGG GAC 
AA-3' 
57.3 31 
LRH-1-F(524-
506) 
5'-GCA GCT TTC ACA GGT GAG 
G-3' 
58.8 31 
5’ RLM-RACE 
RNA adapter 
sequence 
5'-GCU GAU GGC GAU GAA 
UGA ACA CUG CGU UUG CUG 
GCU UUG AUG AAA-3' 
65.3 31 
5’RLM-RACE 
outer primer 
5'-GCT GAT GGC GAT GAA TGA 
ACA CTG -3' 
68.2 31 
5’RLM-RACE 
inner primer 
5'-CGC GGA TCC GGA CAC TGC 
GTT TGC TGG CTT TGA TG -3' 
67.4 31 
LRH-1 exon3 
outer reverse 
primer 
5'-GCA GCT TTC ACA GGT GAG 
G -3' 
66.8 31 
LRH-1 exon3 
inner reverse 
primer 
5'-TAT CTC CAC ACA CGG GAC 
AA -3' 
62.4 31 
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Table 2.2: Assay numbers for Gene Expression Assays (ABI) primer sets 
 
Gene Assay identification number 
GAPDH Hs99999905_m1 
GATA3 Hs00231122_m1 
CTSD Hs00157201_m1 
APOM Hs01597780_g1 
NR5A2 (NR5A2) Hs00187067_m1 
MYC Hs00153408_m1 
GREB1 Hs00536409_m1 
VEGFA Hs00173626_m1 
INHA Hs00171410_m1 
LMNA Hs00153462_m1 
SHP (NR0B2) Hs00222677_m1 
DAX1 (NR0B1) Hs00230864_m1 
SF1 (NR5A1) Hs00610436_m1 
CCND1 Hs00277039_m1 
ESR1 Hs00174860_m1 
SERPINA Hs00165475_m1 
PGR Hs00172183_m1 
TFF1 Hs00170216_m1 
CYP19A1 Hs00240671_m1 
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Table 2.3: Details of antibodies used. 
 
Antigen Company Species of Origin 
of Antibody 
Dilution of 
antibody used 
β-actin Abcam Mouse monoclonal 1:50,000 
ERα (6F11) Novacastra Mouse monoclonal 1:2000 
Cathepsin-D Abcam Mouse monoclonal 1:1000 
PR Santa Cruz Rabbit polyclonal 1:300 
pS2 Santa Cruz Rabbit polyclonal 1:300 
NR5A2 (H-75) Santa Cruz Rabbit polyclonal 1:1000 
NR5A2 PPMX Perseus 
Proteomics 
Mouse monoclonal 1:1000 
HRP-conjugated 
goat anti-Mouse 
IgG 
DakoCytomation, 
Ely, UK 
Goat polyclonal 1:2500 
HRP-conjugated 
goat anti-rabbit 
IgG  
DakoCytomation, 
Ely, UK 
Goat polyclonal 1:2500 
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3 RESULTS 
3.1 Functional grouping analysis of estrogen and PLZF-ERα  regulated genes 
in MCF-7 cells  
As described in the Introduction, a chromosomal translocation that fuses most of the 
PLZF transcriptional repressor gene to the DBD and LBD of the RARα NR to generate 
PLZF-RARα, is responsible for a proportion of the cases of acute promyelocytic 
leukaemia by repressing the expression of retinoic acid regulated genes, thereby causing a 
differentiation block in myelocyte differentiation (Guidez et al., 1998). In previous work 
from the laboratory the portion of PLZF present in PLZF-RARα was fused in frame 
with the equivalent regions of ERα homologous to the regions of RARα present in 
PLZF-RARα, to generate PLZF-ERα (Buluwela et al., 2005). PLZF-ERα was cloned 
into a vector that allows tetracycline-inducible expression of the gene of interest. Stable 
lines were generated in the MCF-7 cell line, chosen because it is the most commonly 
used and hence best characterised model cell line for estrogen-responsive and ERα-
positive breast cancer cell line. The tetracycline-inducible MCF-7-PLZF-ERα (MCF-7-
TO-PLZF-ERα) lines express PLZF-ERα in the absence of tetracycline, or the more 
stable doxytetracycline (doxycycline or Dox) in the culture medium. The MCF-7-TO-
PLZF-ERα lines grew in an estrogen-dependent manner in the absence of Dox in the 
medium, but growth was blocked upon induction of PLZF-ERα expression by removal 
of Dox. These lines were used in gene expression microarray analysis to identify 
estrogen-regulated genes and those estrogen-regulated genes whose expression was 
repressed by PLZF-ERα, as a means of identifying estrogen-responsive genes that may 
be particularly important for mediating the estrogen stimulated growth of MCF-7 cells. 
Of the large number of genes showing estrogen-regulation (1.5 fold or greater) at 16 
hours, following estrogen addition (3,226 genes), only 149 genes were repressed 1.5-fold 
or greater by PLZF-ERα expression. Functional group analysis using Genespring 7 
ordered the genes into thirteen functional groups,, the largest group of genes being those 
associated with regulation of gene expression. Thirty-three of the genes were defined as 
having no known function (unknown), and no functional group assignment has been 
made for a further 24 genes (unassigned).  
Gene Symbol MCF-7-
TO -/+ E2 
Fold Repression 
by PLZF-ERα 
Name Gene Functional Group 
SLC26A2 1.462562396 0.571805274 solute carrier family 26, member A2 transmembrane channels 
SLC35D2 0.633952255 0.563934426 solute carrier family 35, member D2 transmembrane channels 
SLC29A1 1.7784522 0.586337761 solute carrier family 29, member A1 transmembrane channels 
CACNG4 
0.484539833 0.657022303 
calcium channel, voltage dependent, 
gamma subunit 4 
transmembrane channels 
SYL-13 2.032388664 0.54875717 synaptotagmin like-13 protein trafficking & secretion 
SYTL-5 10.56493506 0.498993964 synaptotagmin like-5 protein trafficking & secretion 
RAB27A2 1.460328806 0.608760208 ras-asociated protein 27A2 protein trafficking & secretion 
AP1S3 
1.563380282 0.614503817 
adaptor related protein complex 1, sigma 
3 subunit 
protein trafficking & secretion 
SEMA6D 0.345849802 0.583643123 semaphorin 6D signal transduction 
GDNFR 
2.947211155 0.654490107 
glial cell derived neurotrophic factor 
receptor 
signal transduction 
NRG3 1.559322034 0.60756193 neuregulin 3 signal transduction 
Col12A1 1.917086578 0.553505535 collagen, type XII, alpha 1 extracellular matrix 
SerpinA1 
7.52173913 0.592039801 
serpine peptidase inhibitor, clade 1 
(alpha-1 antitrypsin) 
extracellular matrix 
TADG12 
5.071606994 0.619800333 
TMPRSS3 - transmembrane protease, 
serine 3 
extracellular matrix 
FEN-1 2.842696629 0.642857143 flap structure-specific endonuclease-1 DNA repair and replication 
EXO-1 3.370839937 0.624556063 exonuclease-1 DNA repair and replication 
zfp-503 0.651678277 0.44170096 zinc finger protein 503 Gene expression 
Mad-4 0.400119976 0.630517024 MXP4 - max dimerization protein 4 Gene expression 
SRYbox-3 2.309927361 0.586181278 Sry-like HMG box 3 Gene expression 
LRH-1 2.228070175 0.615686275 liver receptor homologue 1 Gene expression 
EGLN-1 1.507462687 0.627906977  egl nine homolog 1 Gene expression 
HELAD-1 4.734597156 0.587810746 helicase, APC down regulated 1 Gene expression 
TAF9-like 0.402906742 0.639386189 apoptosis-inducing TAf9 like domain Gene expression 
znf367 4.186864738 0.561891234 zinc finger protein 367 Gene expression 
a 
b 
Figure 3.1 Functional group analysis of the 149 genes that are regulated by 
estrogen and whose expression is repressed by PLZF-ER in MCF-7 cells. (a) 
Gene Ontology (GO) analysis of the 149 genes breaks the 149 genes into into 14 
functional groups. (b) Table showing the names of the 24 genes estrogen-
regulated genes that showed the greatest repression by PLZF-ER. Also shown 
are the GO functional groups for these genes. 
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3.2 Validation of estrogen PLZF-ERα  regulation of genes identified by 
microarray analysis 
Genes showing the highest estrogen-regulation and the greatest repression by PLZF-
ERα were chosen for further analysis, in order to confirm the results of the microarray 
analysis. RT-PCR primers were generated for the 23 highest ranked genes (Figure 3.1b) 
and RT-PCR was performed using RNAs prepared from MCF-7 cells. For this, MCF-7 
cells were cultured for 72 hours in DMEM lacking phenol red (since phenol red is 
estrogenic) and containing 10% dextran-coated charcoal-stripped FCS (DSS) to remove 
estrogens from FCS (Berthois et al 1986). Estrogen was added for 8, 16, 24 and 48 hours, 
with an equal volume of the vehicle (ethanol) being added to the no ligand controls. 
Expression of the well-defined estrogen-regulated genes, pS2, and the progesterone 
receptor (PR), showed that their expression was stimulated by estrogen within 8 hours, 
with expression increasing over time for pS2 and peaking at 24 hours for PR (Figure 3.2). 
Expression of the genes identified through microarray analysis similarly showed estrogen 
stimulation, although the profile of estrogen-regulation over time was different for the 
different genes, as was the apparent increase over the no ligand control, as well as the 
level of expression in the absence of ligand. Hence, expression of most of the genes, 
including LRH-1, Mad-4 and ZFP-503 was highest at 8-16 hours, whereas pS2 and PR 
expression continued to increase until 24 or 48 hours following estrogen addition. Only a 
few of the genes showed expression profiles similar to that of pS2 and PR, for example 
GDNFR and TADG12. Expression of SEMA6D was inhibited by estrogen treatment, in 
agreement with the microarray data, which showed that unlike the other genes in this 
group, whose expression is stimulated by estrogen, SEMA6D is an estrogen-repressed 
gene. Taken together, these results show that the genes identified through microarray 
analysis are indeed estrogen-regulated in MCF-7 cells. 
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Figure 3.2 Time course of estrogen regulation for estrogen and PLZF-ER regulated 
genes. MCF-7 cells were cultured in media containing DSS for 72 hours, followed by the 
addition of estrogen (10nM) for 8, 16, 24 or 48 hours, with ethanol being added to the no 
ligand (-) controls.  C – lane 9 of gels represents control (Etoh). Total RNA prepared from 
the treated cells was used for RT-PCR analysis. (a) RT-PCR was carried out for the well-
known estrogen-regulated pS2 and PgR genes. (b-g) RT-PCR was carried out for estrogen-
regulated and PLZF-ER repressed genes, with genes in different functional grouping being 
shown together. RT-PCR for GAPDH was used to control for RNA levels as GAPDH is not 
estrogen regulated. The same GAPDH RT-PCR result is shown in all parts a-g. 
d 
f 
c                           
e 
g 
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3.3 LRH-1 is an estrogen-regulated gene in MCF-7 cells 
As described in the Introduction, LRH-1 is a member of the NR superfamily of 
transcription factors that includes ERα, and has been implicated in the regulation of 
aromatase, an enzyme that carries out a key step in the synthesis of estrogen. As such the 
finding that LRH-1 may be estrogen-regulated in breast cancer cells is clearly of great 
interest. Further, at this stage, a publication showing that LRH-1 expression is estrogen-
regulated in MCF-7 cells and that RNAi mediated LRH-1 down-regulation inhibits MCF-
7 cells growth was published (Annicotte et al., 2005), raising the possibility that LRH-1 
may be an important mediator of estrogen-regulated growth of breast cancer cells, which 
would further validate the PLZF-ERα model described above. In order to further 
confirm that LRH-1 is estrogen-regulated in breast cancer cells, real-time, quantitative 
RT-PCR was carried out. Treatment of MCF-7 cells with estrogen for 24 hours resulted 
in a 4-fold stimulation of LRH-1 expression, whereas LRH-1 expression was not 
stimulated by the anti-estrogens 4-hydroxytamoxifen (tamoxifen) or ICI182, 780 (Figure 
3.3). Immunoblotting for LRH-1 showed a considerable increase in LRH-1 protein levels 
in the presence of estrogen, but not in the presence of tamoxifen or ICI182, 780. Levels 
of the previously described estrogen-regulated cathepsin D gene were also stimulated by 
estrogen, whilst ERα levels were reduced in the presence of estrogen, increased by 
tamoxifen treatment and also reduced in the presence of ICI182, 780, as has been 
described previously (for example see Pace et. al. 1997 JBC). 
The results of the endpoint RT-PCR indicated that many of the estrogen-responsive and 
PLZF-ERα repressed genes, including LRH-1, show rapid upregulation by estrogen, 
with expression falling at later time points. In order to investigate this in more detail total 
RNA was prepared from MCF-7 cells treated with estrogen over a 48 hour time course, 
as three biological replicates. Expression of Cathepsin D, PR, pS2 and GREB-1 was 
stimulated within 4 hours of estrogen treatment and expression continued to increase 
over the 48 hour time course (Figure 3.4). Interestingly, LRH-1 expression was 
stimulated at 2 hours, reached maximal expression at 4 hours and started to decline at 8 
hours, reaching near basal levels at 16 hours, indicating that LRH-1 is an early estrogen-
regulated gene. Only c-MYC expression was stimulated more rapidly by estrogen, with 
maximal stimulation within 1 hour, expression declining by 4 hours, although c-MYC 
levels remained high up to 48 hours.  
In order to investigate the expression of known LRH-1 regulated genes Quantitative Real 
 120 
Time Polymerase Chain Reaction (qRT-PCR) was performed for CYP19, CYP7A, Oct4 
genes (Lu et al., 2000, Clyne et al., 2004, Clyne et al., 2002, Fayard et al., 2004, Gu et al., 
2005). However, these genes were not expressed in MCF-7 cells (data not shown). Cyclin 
D1 (CCND1) and inhibin α (INHA) are known LRH-1 regulated genes (Botrugno et al., 
2004, Planas-Silva and Weinberg, 1997, Prall et al., 1997, Annicotte et al., 2005, Robert et 
al., 2006). Expression of both genes was stimulated (Clyne et al., 2002) by estrogen, with 
highest expression being reached at time points at which LRH-1 expression was 
maximal. It is therefore possible that stimulation of the expression of these genes by 
estrogen is mediated through the estrogen stimulation of LRH-1 expression. It is 
important to note, however, that direct regulation of CCND1 expression by ERα has 
previously been described (Wilcken et al., 1997, Prall et al., 1997, Prall et al., 1998).  
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Figure 3.3 LRH-1 is an estrogen-regulated gene. (a) Protein lysates prepared 
from MCF-7 cells treated with 17ß-estradiol (estrogen; 10nM), tamoxifen (4-
hydroxytamoxifen; 100 nM), or ICI 182, 780 (100nM) for 24 hours were 
immunoblotted, as shown. An equal volume of ethanol (vehicle) was added to 
the no ligand controls. (b) Real-time RT-PCR was performed using total RNA 
prepared from MCF-7 cells treated as above. The means of three RNA 
preparations are shown, assayed in triplicate, are shown. Error bars represent 
the standard errors of the mean (SEM).  
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Figure 3.4 Time course of estrogen treatment of MCF-7 cells shows that LRH-1 
expression is stimulated rapidly by estrogen. MCF-7 cells cultured in estrogen-
depleted conditions for 72 hours were treated with estrogen (10 nM) and cells 
harvested for RNA preparation after 1, 2, 4, 6, 8, 16, 24 or 48 hours. No ligand (NL) 
refers to the 0 hour time point. Real-time RT-PCR was performed for three replicates 
RNA preparations, with each RNA being assayed in triplicate. Relative expression 
was determined by normalising against GAPDH and graphs show mean of the fold 
expression relative to the NL control. Error bars depict SEM.  
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3.4 Knockdown of ERα  using RNA interference results in reduction in LRH-1 
expression  
To further confirm that LRH-1 expression is regulated by ERα, ERα knockdown was 
performed using siRNA for ERα. qRT-PCR of total RNA prepared from triplicate 
cultures of MCF-7 cells showed down-regulation of ERα expression, which was 
accompanied by reduction in expression of GREB1, cathepsin D, PR, as well as LRH-1 
(Figure 3.5a). RNAi was also performed following growth of MCF-7 cells in estrogen-
depleted medium, followed by the addition of estrogen for 24 hours. As for the results in 
full medium, ERα downregulation led to a reduction in expression of estrogen-regulated 
genes, as well as LRH-1 (Figure 3.5b). Together, these results and the results presented in 
sections above demonstrate that LRH-1 expression is estrogen-regulated, with LRH-1 
being an early estrogen-regulated gene. 
Figure 3.5 Expression of estrogen responsive genes in MCF-7 cells 
following RNAi mediated knockdown of ERα. RNA prepared from 
MCF-7 cells transfected with siRNA for ERα (siRNA), a non-targeting 
control or transfection with reagent alone, were used for real-time RT-
PCR analysis. RNAi was performed in cells cultured in estrogen-
depleted medium, with RNA being prepared 24 hours following the 
addition of estrogen (E2; 10 nM) (a; left hand column) or for cells 
cultured in DMEM supplemented with 10% FCS (b; right hand column). 
RNAi was performed for triplicate cultures and real-time RT-PCR was 
performed in triplicate for each RNA. The bar charts show the mean 
expression of the genes, as fold relative to the non ligand control for the 
reagent only control, the expression being normalised against GAPDH 
expression. Errors bars show the standard errors of the means. 
a         b 
0	  
1	  
2	  
Reagent	   Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
ERa	   E2-­‐	  
E2+	  
0	  
2	  
4	  
6	  
8	  
10	  
Reagent	   Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
GREB-­‐1	   E2-­‐	  
E2+	  
0	  
1	  
2	  
3	  
4	  
5	  
Reagent	   Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
Cath-­‐D	   E2-­‐	  
E2+	  
0	  
1	  
2	  
3	  
4	  
5	  
6	  
Reagent	   Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
PgR	   E2-­‐	  
E2+	  
0	  
1	  
2	  
3	  
4	  
5	  
Reagent	   Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
LRH-­‐1	   E2-­‐	  
E2+	  
0	  
0.4	  
0.8	  
1.2	  
Reagent	  Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
ERa	  
0	  
0.4	  
0.8	  
1.2	  
Reagent	  Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
GREB-­‐1	  
0	  
0.4	  
0.8	  
1.2	  
Reagent	  Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
Cath-­‐D	  
0	  
0.4	  
0.8	  
1.2	  
Reagent	  Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
PgR	  
0	  
0.4	  
0.8	  
1.2	  
Reagent	  Non	  Targe8ng	   siRNA	  
Ex
pr
es
si
on
	  (f
ol
d)
	  
LRH-­‐1	  
124	  
 125 
3.5 Association between LRH-1 and ERα expression in different tissues and in 
cancer cell lines 
qRT-PCR for LRH-1 was carried out in order to determine if LRH-1 is expressed in 
breast tissue. In agreement with previous findings showing that LRH-1 was expressed in 
tissues derived from the gut endoderm such as the liver, small intestine, preadipocytes, 
adrenal gland, testes, ovary (Galarneau et al., 1996, Boerboom et al., 2000, Becker-Andre 
et al., 1993, Li et al., 1998, Wang et al., 2001, Schoonjans et al., 2002, Hinshelwood et al., 
2003, Liu et al., 2003, Falender et al., 2003, Sirianni et al., 2002, Clyne et al., 2002, 
Lambard et al., 2005, Pezzi et al., 2004), LRH-1 was found to be expressed in the small 
intestine, colon, liver, cervix, ovary and breast, with its expression not clearly being 
associated with ERα expression (Figure 3.6a).  
In a panel of ERα positive and negative breast cancer cell lines (RNA kindly provided by 
Dr R.Thomas, Imperial College) LRH-1 expression was highest in ERα positive lines, i.e. 
MCF-7, ZR-75-1, T47D and BT483 (Figure 3.6b). The only exceptions were BT474, 
which is weakly ER-positive, but did not express LRH-1 and BT20 and MDA-MB-436, 
which are ER-negative, but did express LRH-1, albeit at very low levels. The highest 
expression of LRH-1 was seen in the human hepatocellular carcinoma cell line HepG2, 
where LRH-1 expression was 2.5 fold greater than that in MCF-7 cell line, despite 
HepG2 cells line being ERα negative. Taken together, LRH-1 expression appears to be 
correlated with ERα expression in the breast, but its expression is likely to be 
independent of ERα in other tissues. 
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Figure 3.6 Real-time-qRT-PCR analysis of Estrogen Receptor (ERα) and 
LRH-1 expression in cancer cell lines and RNA from a variety of tissues. 
(a) Real-time qRT-PCR was performed using one RNA preparation from ERα-
positive breast cancer cell lines (MCF-7, ZR-75-1, T47D, BT20, BT474, 
BT483), ERα-negative breast cancer cell lines (SkBr3, MDA-MB-231, MDA-
MB-436, MDA-MB-231, Cal51), immortalised normal breast cell lines 
(HPRSV1.6.1, MCF10A), an endometrial cancer cell line (Ishikawa), prostate 
cancer cell lines (LNCaP, PC3), hepatocellular carcinoma cell line (HepG2) 
and an ovarian cancer cell line (PE04). The MDA-MB-435 cell line was 
believed to be derived from breast cancer cells, but microarray analysis has 
shown that it is a melanoma line. (b) A panel of RNAs from normal tissues 
(purchased from Ambion-ABI) was also used for real-time qRT-PCR analysis. 
The graphs show the means of each cDNA assayed in triplicate, as folds 
relative to expression in MCF-7 cells (a) or breast (b), following normalisation 
of expression relative to GAPDH expression. The errors bars represent the 
standard errors of the mean. 
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3.6 Expression of the LRH-1 homologue SF-1 and the LRH-1 repressors DAX-1 
and SHP 
SF-1 is related to and binds to the same DNA sequence as LRH-1 (Galarneau et al., 
1996), so potentially regulates similar gene sets, at least in tissues where both are 
expressed. SF-1 expression was extremely low in breast and was highest in the LRH-1 
expressing small intestine and ovary, with some expression also being observed in the 
spleen (Ninomiya et al., 1995, Ramayya et al., 1997), in which LRH-1 was absent. Hence, 
the tissue distribution of SF-1 is considerably smaller than that of LRH-1. In agreement 
with the very low levels of SF-1 expression in breast tissue, expression of SF-1 was 
almost undetectable in breast cancer cell lines, with the exception of CAL51 cells 
(Gioanni et al., 1990). CAL51 is an epithelial triple-negative (ER/PR/HER2 negative) 
breast cancer cell line of luminal phenotype (Yuli et al., 2007). SF-1 expression in the 
HepG2 cell line was approximately 1 x104 fold more than in MCF-7 cells. Note that SF-1 
expression in the liver was very low compared with its expression in the intestine and 
ovary. Hence, SF-1 expression in breast cancer cell lines may well be insignificant. 
Expression of the LRH-1 and SF-1 repressors DAX-1 and SHP was also examined with 
qRT-PCR. Expression of DAX-1 was observed in tissues previously shown to express 
DAX-1 (Lalli and Sassone-Corsi, 2003, Ikeda et al., 1996, Ikeda et al., 2001, Suzuki et al., 
2003), with low-level expression in breast tissue being evident. SHP expression was low 
in breast, with a similar profile to that of LRH-1 in the tissue panel. In breast cancer cell 
lines DAX-1 expression was observed in MDA-MB-435, which is now known to be a 
melanoma line and not a breast cancer cell line, as originally believed (Rae et al., 2007, 
Sellappan et al., 2004, Ellison et al., 2002). DAX-1 and SHP expression, therefore, is very 
low in breast cancer cell lines, and therefore LRH-1 activity would not be regulated by 
these important negative regulators of LRH-1. It is interesting to note that SHP 
expression is regulated by LRH-1 (Lee and Moore, 2002). Hence, it is possible that SHP 
is epigenetically silenced in LRH-1 expressing breast cancer cell lines. 
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Figure 3.7. RT-PCR analysis of RNA from cancer cell lines and a tissue panel for 
modulators of LRH-1 activity. End-point (a) and Real-time qRT-PCR (b, d, f) was 
performed for SF-1, Dax-1 and SHP as in Figure 3.6. (c, e, g) Real-time qRT-PCR was 
also performed for the human tissue panel RNAs as in Figure 3.6.  
a 
b                                  c  
d                                  e  
f                                   g  
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3.7 5’RLM-RACE demonstrates three new forms of LRH-1 in MCF-7 cells 
Immunoblotting for LRH-1 in MCF-7 cells using a commercially available antibody that 
was raised to amino acids 1-75 of human LRH-1 (H-75; Santa Cruz) did not detect a 
polypeptide of a size consistent with that obtained by transient transfection of COS-1 
cells (data not shown). Nor was endogenous LRH-1 detected using other antibodies 
from Abcam, also raised against N-terminal peptides (amino acids 2-33 (Abcam 
ab41900) or amino acids 1-67 (Abcam ab18293) of LRH-1) (data not shown). RT-PCR 
carried out using a forward primer in exon 1 of the LRH-1 gene did not show any 
product, whereas RT-PCR using primers across any two or more of the other mapped 
exons in the LRH-1 gene showed that LRH-1 was expressed (see Figure 3.2). Two major 
LRH-1 splice variants have been described, with LRH-1 variant 1 encoding a polypeptide 
of 541 amino acids (Galarneau et al., 1998, Li et al., 1998, Nitta et al., 1999, Zhang et al., 
2001) (Figure 3.9). Variant 2 splices out exon 2, resulting in a polypeptide of 495 amino 
acids due to lack of amino acids encoded within exon 2 (amino acids 22-68). However, 
this variant should be detected with the RT-PCR primers used to amplify exon 1 
sequences. These results suggested that the 5’ end of the LRH-1 mRNA might be 
different in MCF-7 cells from that described in the literature.  
Therefore, in order to define the 5’ end of the LRH-1 mRNA in MCF-7 cells, 5’RNA 
ligase mediated rapid amplification of cDNA ends (5’ RLM-RACE) was performed. In 
this method, calf intestinal alkaline phosphates treatment of RNA is carried out to 
remove the 5’ phosphate group from mRNA lacking the cap, such as degraded mRNA, 
as well as rRNA, tRNA and DNA. Subsequent treatment with Tobacco Acid 
Pyrophosphatase removes the 5’ cap, leaving a 5’ monophosphate, allowing for ligation 
of an RNA adaptor oligonucleotide using RNA ligase, with CIP phosphatased RNA not 
being ligated to the adaptor. Following cDNA preparation using reverse transcription, 
PCR is performed using a 5’ primer specific for the adaptor and a 3’ primer specific for 
the gene of interest. The method used requires a further round of PCR using the 5’ 
adaptor primer and a nested 3’ primer for the gene of interest. Performing 5’ RLM-
RACE with total RNA from MCF-7 cells showed the presence of 3 products, with sizes 
of 152 bp, 289 bp and 326 bp (Figure 3.8a), none of which were consistent with the size 
expected for LRH-1 variant 1. Cloning and sequencing of the three products showed 
that these products code for previously undescribed variants of LRH-1 (Figure 3.8b). 
Aligning the predicted amino acids sequences of variants 289 and 326 with that of LRH-
 130 
1 variants 1 and 2 shows that the 289 variant would encode amino acids 42-541 of LRH-
1 variant 1, whilst the 326 variant would encode amino acids 67-541 of LRH-1 variant 1 
(Figure 3.9).  
Aligning the sequences of the 289 and 326 variants showed that they would encode novel 
mRNAs whose transcription would be initiated from alternative promoters. Variant 289 
would be transcribed from a promoter that includes intron 1 sequences 5’ to the 
described exon 2 (Figure 3.9), whilst the 326 variant would be initiated from a new exon 
located between exons 2 and 3, which we have named exon 2b. There are less than one 
hundred bases between the 3’ end of exon 2 and the 5’ end of exon 2b (Figure 3.9). The 
third variant transcript, LRH-1 152, is contained within the variant 289 transcript, and 
starts 96 nt downstream of the splice acceptor site of exon 2 used to generate variants 1 
and 2 (ie nucleotide position 138 of the Variant 289 transcript). As such, it was not 
possible to use RT-PCR to further study the expression of LRH-1 variant 152, although 
the original 5’ RLM-RACE analysis of LRH-1 suggested this was a minor variant form 
that would encode amino acids 63-541 of LRH-1 variant 1.  The data also suggests the 
possibility that this variant could be an artifact produced from the LRH1-289 variant 
transcript, a conclusion that would require further investigation using techniques such as 
RNAse protection and primer extension.  All transcripts splice to exon 3.  
Figure 3.8 5’ RLM-RACE analysis of LRH-1 transcripts in MCF-7 cells  
Start sites for LRH-1 gene transcription in MCF-7 cells were identified using 
RNA Ligase Mediated (RLM) Rapid Amplification of cDNA ends (RACE) 
analysis. To do this, total RNA made from estrogen treated cells was 
enzymically treated so as to remove the 5’ CAP on mRNA, thereby allowing  
ligation to an RNA linker with the enzyme T4 RNA ligase. The ligation 
modified total RNA was used to make cDNA that was subsequently 
amplified through two rounds of PCR using nested primers directed against 
the original 5’ RNA linker sequence and LRH-1 exon 3 sequences. (a) The 
resulting PCR products were visualised by agarose gel electrophoresis and 
cloned directly into the PCR plasmid cloning vector pJet 1.2 (Fermentas). 
(b) DNA sequencing of twenty plasmid clones identified three insert 
sequences of 152, 289 and 326bp in size, as shown. Sequences derived from 
the RLM RNA adapter are shown in blue (the first 38bp of each sequence).  
LRH-1 exon 3 sequences are shown in green (the last 72bp of each 
sequence). Sequences in uppercase correspond to LRH-1 sequences and 
potentially identify putative transcription start sites giving rise to sequences 
spliced to exon 3. The predicted  size of RLM –RACE products for LRH-1 
Variant 1 and Variant 2 transcripts using these primers would be 518bp and 
380bp respectively. 
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152bp product:!
cgcggatccgaacactgcgtttgctggctttgatgaaaGATCGCATGGGG!
AACAGGGCCAGATGCCGGAAAACATGCAAGtgtctcaatttaaaatggtg!
aattactcctatgatgaagatctggaagagctttgtcccgtgtgtggaga!
ta!
289bp product:!
cgcggatccgaacactgcgtttgctggctttgatgaaaCTTCTTTTCGCC!
GGAGTTGAATCTGTGCTGCCCGTGTCCAGGTGCTGGGCTTCCGGACCGAC!
ACGGATCCCCCATCCCCGCCCGCGGTCGCCTTGTCATGCTGCCCAAAGTG!
GAGACGGAAGCCCTGGGACTGGCTCGATCGCATGGGGAACAGGGCCAGAT!
GCCGGAAAACATGCAAGtgtctcaatttaaaatggtgaattactcctatg!
atgaagatctggaagagctttgtcccgtgtgtggagata!
326bp product:!
cgcggatccgaacactgcgtttgctggctttgatgaaaAGCCTCCCGCCC!
CGCGCGGGCGCGGGAGTAGCCCCGCTGGGCGCTCGCAGCCGCGGGAGTCA!
AGCCCCCTCCCCAGGTGCAGGCATAAAAGTTTATGGCTCTTGAACAATGC!
GGGGCAGAGGTTTTTCCAAGCAACGTCTAATTGGCCGCTTCTAATTAAGG!
AAAGAGAGGCTTCCAGCTCTATGGCAACCCAAGCAGGGCAGCTTCAGGCT!
AAAGtgtctcaatttaaaatggtgaattactcctatgatgaagatctgga!
agagctttgtcccgtgtgtggagata!
0.5	  
0.3	  
0.2	  
0.1	  
a 
b 
326 289 
152 
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Figure 3.9 Identification of variant LRH-1 transcripts originating from 
the use of novel gene promoters. (a) Shown are schematic representations 
of the human NR5A2 (LRH-1) variant mRNA sequences, with positions of 
exons 1-8 boxed. Regions of exons shown in black represent coding 
sequences, the empty blocks representing 5’ or 3’ untranslated regions. The 
angled lines show intronic regions that are spliced out. (b) The region of the 
LRH-1 gene corresponding to exons 1-4 are shown in greater detail 
showing the alternative splicing which generates LRH-1 variants 1, 2, as 
well as the newly identified variants 152, 289 and 326. The arrows represent 
potential transcription initiation sites, based on published 5’ ends for 
variants 1 and 2, and from the 5’ bases for the 152, 289 and 326 variants 
described in this thesis. Also shown is the genomic sequence of a 650 bp 
region of the LRH-1 gene , with the sequence of exon 2 presented in upper-
case (nucleotides 217-138). RLM-RACE identified three new variant 
LRH-1 transcripts expressed in MCF-7 cells that are initiated from 
previously undescribed gene promoters in this genomic region. The first is a 
transcript that originates at base 176 and contains exon 2 sequences 
(highlighted in blue). This we have termed “variant 289”. The second, is 
wholly included in this transcript, and starts at base 163 of exon 2 
(highlighted in blue and underlined). This we have termed “variant 152”. 
The third starts at base 424, and contains a novel exon sequence 
(nucleotides 424-639; highlighted in green) encoded within intron 2. This 
we have termed “Variant 325”. All three variant transcripts were seen to  
splice to exon 3 of the LRH-1 gene. 
133	  
NR5A2	  (LRH-­‐1)	  169.78kb	  
NR5A2-­‐001	  (Var	  1)	  
NR5A2-­‐003	  (Var	  2)	  
NR5A2	  RACE	  LRH-­‐1	  152	  
NR5A2	  RACE	  LRH-­‐1	  326	  
1-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐2-­‐-­‐34-­‐5-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐6-­‐-­‐-­‐-­‐-­‐7-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐8	  Exons	  
Exon	  2b	  
17224-­‐17439	  
Exon	  2	  
17017-­‐17154	  
Exon	  3	  
21133-­‐21251	  
Exon	  4	  
22802-­‐22943	  
RACE	  LRH-­‐1	  326	  
RACE	  LRH-­‐1	  289	  
LRH-­‐1	  Variant	  1	  
LRH-­‐1	  Variant	  2	  
a	  
b	  
134	  
RACE	  LRH-­‐1	  152	  
NR5A2	  RACE	  LRH-­‐1	  289	  
tagcaggcatcccggtcgccccttccttcttttcgccggagttgaatctg 
tgctgcccgtgtccagGTGCTGGGCTTCCGGACCGACACGGATCCCCCAT 
CCCCGCCCGCGGTCGCCTTGTCATGCTGCCCAAAGTGGAGACGGAAGCCC 
TGGGACTGGCTCGATCGCATGGGGAACAGGGCCAGATGCCGGAAAACATG 
CAAGgtaaggaggcgccgcgcggcgctccggctcccgctgcttccccacc 
cccgggctcgccctgcaggcttcagcctcccgccccgcgcgggcgcggga 
gtagccccgctgggcgctcgcagccgcgggagtcaagccccctccccagg 
tgcaggcataaaagtttatggctcttgaacaatgcggggcagaggttttt 
ccaagcaacgtctaattggccgcttctaattaaggaaagagaggcttcca 
gctctatggcaacccaagcagggcagcttcaggctaaaggtactttagaa 
taataagatcattctaagaaatggaatgtctcactggacacccgaacagg 
ttctctgtcattggaattggtgtgtactgtacttcaaccagtactcttgt 
gtggagggaggcgacccagtctaggaaagtcaactacagaaagaggtgac 
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3.8 Expression of the LRH-1 variants in the human cell line and tissue panel 
RT-PCR analysis using 5’ primers in exon 1, exon 2 (5’ untranslated region of the 289 
variant) and exon 2b, with the 3’ primer in exon 3, confirmed the findings of the 5’ 
RLM-RACE, as expression of variants 1 and 2 was undetectable after 32 cycles of PCR, 
although under these conditions, the 326 variant was also not detected. By contrast the 
289 variant was expressed and demonstrated estrogen regulation (Figure 3.10a). 
Moreover, variant 289 expression was also confirmed in HepG2 cells, where variant 1/2 
expression was also low. Real-time RT-PCR of MCF-7 RNA following treatment with 
estrogen confirmed that expression of 289, 326, as well as variants 1/2 is estrogen-
regulated (Figure 3.10b) 
Real-time RT-PCR analysis demonstrated expression of both the 326 and the 289 
variants in LRH-1 positive breast cancer cell lines (Figure 3.11a-d), although as the 
primer sets were not designed to work under similar conditions, it is not possible to 
compare levels of expression of the two variants. Variants 1/2 were expressed at 
considerably lower level than in HepG2 cells.  
The 289 variant was expressed in all of the tissues in which LRH-1 was seen to be 
expressed, as was the 326 variant. Interestingly, expression of variants1/2 was much 
more restricted, being seen mostly in the small intestine, colon and liver, with little 
apparent expression in the breast (Figure 3.12). Together, these show that the 289 and 
326 variants are expressed in all LRH-1 expressing tissues, and that 289 variant is the 
major form of LRH-1 in the breast. As indicated above, however, a direct comparison of 
the relative levels of expression of the new variants and variants 1/2 requires more 
detailed analysis, using qRT-PCR primer sets and/or other techniques such as RNAase 
protection and of course immunoblotting for the relative expression of the different 
forms of LRH-1 to be better defined. In this regard, immunoblotting of MCF-7 lysates 
was performed using an antibody raised against recombinant protein 161-280 (H2325, 
Perseus Proteomics), which would therefore recognise all isoforms of LRH-1. A 
polypeptide of 57 kDa was detected, in agreement with the expected size for the 289 
variant, its levels being increased in lysates from MCF-7 cells transfected with an 
expression plasmid encoding the 289 variant (Figure 3.11e). A larger polypeptide of 
about 62 kDa was detected following transfection with variant 1, the size being that 
expected for variant 1. No polypeptide of this size was detected in MCF-7 untransfected 
MCF-7 cells or in cells transfected with the 289 variant. The smaller polypeptide in the 
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variant 1 transfected cells may arise from use of the internal methionine that forms the 
first amino acid of the 289 variant (Figure 3.11e) or may be a degradation product. 
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Figure 3.10 LRH-1 variants estrogen regulation. Total RNA was 
prepared from  MCF-7 cells treated with 17β-estradiol (estrogen; 
10nM) for 8 hours. End-point (a) and Real-time qRT-PCR (b) was 
performed using RNA from MCF-7 cells treated as above. The means 
of three RNA preparations are shown, assayed in triplicate, are shown. 
Error bars represent the standard errors of the mean (SEM).   
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Figure 3.11 Expression of the LRH-1 variants in a panel of human cell 
lines. Expression of LRH-1 variants was determined by real-time qRT-
PCR in breast cancer cell lines and in a number of lines deriving from 
other tissues. The relative expression of the variants is shown as fold 
relative to the expression in MCF-7 cells, following normalisation against 
GAPDH expression levels, with standard errors of the mean being shown 
by the error bars. The results of three replicate RNA samples, carried out 
in triplicate are shown. As all sequences encoded by variant 2 are also 
present in variant 1, this assay does not distinguish between variants 1 and 
2. Hence the combined expression of variants 1 and 2 is shown. Real-time 
qRT-PCR performed using primers located in exons 6-8 were used to 
determine total LRH-1 levels. (e) Protein lysates prepared from MCF-7 
cells transfected with vector control, variant 1 or variant 289 were 
immunoblotted for LRH-1 and ß-actin. 
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Figure 3.12 Expression of the LRH-1 variants in a panel of human 
tissues. Expression of LRH-1 variants was determined by real-time qRT-PCR 
in RNA from a panel of normal tissues, as in Figure 3.6 (a-d). The relative 
expression of the variants is shown as fold relative to the expression in the 
breast, following normalisation against GAPDH expression levels, with 
standard errors of the mean being shown by the error bars. The results of 
three replicate RNA samples, carried out in triplicate are shown. As all 
sequences encoded by variant 2 are also present in variant 1, this assay does 
not distinguish between variants 1 and 2. Hence the combined expression of 
variants 1 and 2 is shown. Real-time qRT-PCR performed using primers 
located in exons 6-8 were used to determine total LRH-1 levels.  
139	  
 140 
3.9 Down-regulation of LRH-1 using RNAi inhibits the growth of MCF-7 cells 
The ERα transcription factor stimulates breast cancer cell growth upon binding estrogen 
by regulating the expression of estrogen-responsive genes. In order to determine if LRH-
1 is important in mediating the estrogen/ERα growth stimulation of breast cancer cells, 
RNAi mediated LRH-1 downregulation was carried out. For this, MCF-7 cells were 
transfected with a pool of 4 siRNAs for LRH-1 purchased from Dharmacon, Inc. MCF-
7 growth was determined using the sulphorhodamine B (SRB) assay over a period of 4 
days following transfection with the siRNA pool. When cultured in full medium, growth 
of the MCF-7 cells showed a linear increase over the 4 day period if the cells were treated 
with the transfection reagent or if transfected with a non-targeting siRNA. Growth was 
reduced by 30% following transfection with the LRH-1 siRNA pool (Figure 3.13a). In 
order to determine if the individual siRNAs present in the LRH-1 siRNA pool can 
inhibit MCF-7 cell growth, SRB assays were performed for each of the 4 siRNAs. Similar 
levels of growth inhibition were observed for siRNAs nos. 2-4, but siRNA no. 1 did not 
inhibit growth, which suggests that siRNA no. 1 may not be active against LRH-1.  
MCF-7 cells require estrogen for their growth. Culturing the cells in estrogen-depleted 
culture medium prevents their growth. As LRH-1 may be involved in mediating the 
growth effects of estrogen, LRH-1 siRNA was repeated in MCF-7 cells grown in the 
absence of estrogen. Under these conditions, there was little or no growth of MCF-7 
cells over the 4 day period. Addition of estrogen resulted in a linear increase in cell 
numbers. Transfection with the LRH-1 siRNA pool, or with the individual siRNAs 
inhibited MCF-7 growth to a level similar to the growth observed in the absence of 
estrogen, with the exception of siRNA no. 1 which did not greatly inhibit growth (Figure 
3.13). Together, these results demonstrate that LRH-1 regulates MCF-7 cell growth. 
Figure 3.13 LRH-1 siRNA inhibits the estrogen stimulated growth of MCF-7 
cells. MCF-7 cells were transfected with non-targeting siRNA or reagent alone, or 
with a pool of 4 LRH-1 siRNAs, or with each of the 4 LRH-1 siRNAs individually. 
Transfections were carried out by plating cells in estrogen-depleted culture medium 
to which E2 (10 nM) was added, as appropriate (a), or by plating the cells in 
DMEM containing 10% FCS (b). The transfections were carried out as 5 replicates 
and the graphs show the results of sulphorhodamine B (SRB) growth assay, shown 
as mean optical density readings, with errors bars showing the standard errors of the 
mean.   
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3.10 RNAi for LRH-1 inhibits the growth of LRH-1 positive breast cancer cell 
lines  
The above results demonstrate that LRH-1 is important for the growth of MCF-7 cells. 
In order to determine if it is also required for the growth of other breast cancer cell lines, 
RNAi was performed in the other LRH-1-positive cell lines, ZR-75-1 and T47D cells. 
Transfection with the LRH-1 siRNA pool inhibited the growth of both lines when the 
cells were cultured in full medium and when they were cultured in estrogen-depleted 
medium, supplemented with estrogen (Figure 3.14). Similar results were obtained using 
individual siRNAs nos. 2 and 4 (Figures 3.15 and 3.16). Together, these results indicate 
that LRH-1 is important for the growth of ZR-75-1 and T47D cells, in addition to being 
required for MCF-7 cells, although the extent of growth inhibition in ZR-75-1 and T47D 
cells was lower than that observed for MCF-7 cells. This may be a reflection of the 
apparent greater requirement for ERα in MCF-7 cells compared with these lines, as 
suggested by the finding that there was little apparent growth of MCF-7 cells in the 
absence of estrogen (Figure 3.13), whereas substantial growth was observed for ZR-75-1 
and T47D in the absence of estrogen (Figures 3.14-3.16). LRH-1 siRNA did not affect 
the growth of the ERα positive and LRH-1 negative BT474 cells. Nor was growth of the 
ERα negative and LRH-1 negative MDA-MB-231 cells affected by LRH-1 siRNA, 
suggesting that the growth inhibition observed in MCF-7, ZR-75-1 and T47D cells is due 
to specific downregulation of LRH-1. 
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Figure 3.14 LRH-1 siRNA inhibits the estrogen stimulated growth of 
LRH-1 positive, but not LRH-1 negative breast cancer cell lines. The LRH-1 
expression (ZR75-1, T47D) and LRH-1 negative (BT474, MDA-MB-231) cells 
were transfected with non-targeting siRNA or reagent alone, or with a pool of 4 
LRH-1 siRNAs. Transfections were carried out by plating cells in estrogen-
depleted in DMEM containing 10% FCS (b). The transfections were carried out 
as 5 replicates and the graphs show the results of SRB growth assay, shown as 
mean optical density readings, with errors bars showing the standard errors of 
the mean, as described for Figure 3.13.   
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Figure 3.15 LRH-1 siRNA inhibits the estrogen stimulated growth of LRH-1 
positive, but not LRH-1 negative breast cancer cell lines. Transfections were 
carried out as described in Figure 3.13, using the LRH-1 siRNA number 2. 
Growth assays were performed using the SRB assay, as described in Figure 3.13. 
The cells were cultured in estrogen-depleted medium supplemented with E2 (10 
nM), as appropriate (a), or in DMEM containing 10% FCS (b). 
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Figure 3.16 LRH-1 siRNA inhibits the estrogen stimulated growth of LRH-1 
positive, but not LRH-1 negative breast cancer cell lines. Transfections were 
carried out as described in Figure 3.13, using the LRH-1 siRNA number 4. 
Growth assays were performed using the SRB assay, as described in Figure 3.12. 
The cells were cultured in estrogen-depleted medium supplemented with E2 (10 
nM), as appropriate (a), or in DMEM containing 10% FCS (b). 
   a                b 
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3.11 FACS analysis reveals that LRH-1 siRNA causes cell apoptosis in MCF-7 
cells. 
Fluorescence activated cell sorting (FACS) analysis showed that LRH-1 siRNA results in 
an accumulation of cells in the sub-G1 peak, suggestive of apoptosis. Staining for 
annexin V, a marker of apoptosis showed that the sub-G1 peak indeed contains 
apoptotic cells (Figure 3.17). An increase of approximately 25% in apoptotic cells was 
seen following LRH-1 siRNA, compared with the non-targeting or reagent alone 
controls (Figure 3.17c). These findings suggest that LRH-1 is required for stimulating the 
growth of MCF-7 cells and may act by promoting expression of anti-apoptotic genes 
and/or inhibiting pro-apoptotic gene expression.  
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Figure 3.17 LRH-1 siRNA promotes apoptosis in MCF-7 cells. MCF-7 cells were 
transfected with reagent alone, non-targeting siRNA or the LRH-1 siRNA pool. Cells were 
harvested after 72 hours and fixed for FACS analysis. (a) Shown are the FACS profiles 
obtained, with the graph on the right showing the percentage of cells in each phase of the cell 
cycle. (b) The cells were stained with the apoptotic marker Annexin V. Shown are the scatter 
plots, with cells in early and late early and late apoptosis. (c) The results of Annexin V staining 
shown in part (b) are graphed. The results of three replicates are shown, together with standard 
errors of the means. P-values were calculated using the Student’s t-test. Asterisks (*) represent 
a statistically significant (P<0.005) difference from the reagent control and ^ represents a 
statistically significant difference (P<0.005) with the non-targeting control. 
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3.12 LRH-1 regulates ERα expression in breast cancer cell lines 
To determine if the LRH-1 siRNAs do in fact cause LRH-1 downregulation in breast 
cancer cells, total RNA and protein lysates were prepared from MCF-7 cells following 
transfection with the LRH-1 siRNA pool and the individual siRNAs. qRT-PCR for 
LRH-1 showed a 90% reduction in LRH-1 expression following transfection with the 
LRH-1 siRNA pool (Figure 3.18a). Similar LRH-1 knockdown was obtained for siRNAs 
nos. 2 and 3, with 80% knockdown for siRNA no. 4 and only a 50% knockdown for 
siRNA no. 1. In agreement with the qRT-PCR results, immunoblotting for LRH-1 
showed no detectable LRH-1 following transfection with the siRNA pool and siRNAs 
nos. 2-4, whereas LRH-1 protein was detected following transfection with siRNA no. 1. 
The low level knockdown of LRH-1 with siRNA no. 1 observed here provides an 
explanation for the poor MCF-7 growth inhibition observed with this siRNA (Figure 
3.18b).  
Expression of the LRH-1 regulated inhibin α gene (INHA) was reduced following LRH-
1 knockdown. Interestingly, expression of estrogen-regulated genes cathepsin D (CTSD), 
pS2 and PR was also reduced, with reduction in expression apparently being correlated 
with the extent of LRH-1 downregulation. Hence, the greatest reduction in expression of 
these genes was observed with the pool and siRNAs nos. 2 and 3, which gave the 
greatest LRH-1 knockdown. The reduction in expression of estrogen-responsive genes 
suggested that LRH-1 knockdown may affect ERα levels. qRT-PCR and immunoblotting 
for ERα demonstrated that LRH-1 knockdown leads to reduced ERα expression, the 
profile of the reduction mirroring the extent of LRH-1 knockdown by the different 
siRNAs 
In order to confirm these findings in ZR-75-1 and T47D cells, total RNA was prepared 
from T47D and ZR-75-1 cell lines in which LRH-1 was silenced, using ‘Pool’, No.2 and 
No.4 siRNAs for LRH-1. qRT-PCR confirmed a reduction in the expression of LRH-1 
in both cell lines of 70-80%, and an accompanying reduction in ERα expression of 20-
30% (Figure 3.19a). By contrast, transfection of BT474 cell line with LRH-1 siRNAs had 
no effect on ERα expression, or CTSD expression (Figure 3.19b), suggesting that the 
reduction in ERα expression in MCF-7, ZR-75-1 and T47D cells is not due to LRH-1 
siRNAs directly targeting ERα. 
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In order to further show that LRH-1 regulates ERα expression, MCF-7 cells were 
transiently transfected with LRH-1. LRH-1 over-expression led to an increase in ER 
protein and mRNA (Figure 3.20a, b). ERα levels were similarly increased following 
LRH-1 transfection in BT474 cells (Figure 3.20a). By contrast, transfection of the LRH-1 
co-repressor SHP reduced ERα expression at the mRNA levels (Figure 3.20c). 
siRNA LRH-1 
LRH-1 
ERα 
Cathepsin-D 
β-actin 
Figure 3.18 LRH-1 regulates ERα expression in MCF-7 cells. (a) RNAi 
for LRH-1 was performed in MCF-7 cells, using the LRH-1 pool of 4 
siRNAs, the individual LRH-1 siRNAs (1-4) or the non-targeting siRNA 
(NT). RNA and protein preparations were used for real-time qRT-PCR (a) 
and immunoblotting (b), respectively. The real-time qRT-PCR was 
performed on three RNA preparations, in triplicate and the mean fold 
expression of each gene is shown, relative to expression in the NT control, 
following normalisation of expression against expression levels of GAPDH. 
Errors bars represent the standard errors of the means. 
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Figure 3.19 RNAi mediated LRH-1 downregulation reduces ERα 
expression. (a-c) T47D, ZR-75-1 and BT474 cells were transfected with 
LRH-1 siRNA pool, the individual LRH-1 siRNAs 2 or 4 or non-targeting 
siRNA. RNA prepared from the transfections was used for real-time qRT-
PCR for LRH-1 (a-b), ERα (a-c) and cathepsin D (CathD) (c). The real-
time qRT-PCR was performed on three RNA preparations, in triplicate 
and the mean fold expression of each gene is shown, relative to 
expression in the NT control, following normalisation of expression 
against expression levels of GAPDH. Errors bars represent the standard 
errors of the means. 
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Figure 3.20 Transfection of LRH-1 increases ERα expression, whilst 
transfection of SHP reduces ERα expression in breast cancer cells. Protein 
lysates and total RNA was prepared from MCF-7 and BT474 cells transiently 
transfected with LRH-1 (a-b) or SHP (c). Real-time RT-PCR was performed from 
three replicate RNA preparations, carried out in triplicate. The mean of fold 
expression relative to the vector control is shown, together with standard errors of 
the mean. 
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A series of small molecule LRH-1 activators has recently been described (Whitby et al., 
2006). These compounds have previously been shown to stimulate LRH-1 reporter 
activity in hepatocytes and in HepG2 cells. Treatment with compounds 5a, 5b and 5L 
(kind gifts of Prof R Whitby, University of Southampton) (Figure 3.21a) stimulated the 
growth of MCF-7 cultured in the absence of estrogen (Figure 3.21b). The stimulatory 
effect was dose dependent, with the greatest effect on growth in 5a, 5b and 5L seen at 
20µM, 10µM and 10µM, respectively. At these concentrations compounds 5a, 5b and 5L 
stimulated MCF-7 growth by 35%, 65% and 71%, relative to estrogen treatment. By 
contrast, compounds 5a and 5L had no stimulatory effect on growth in BT474 cells, 
although a small stimulation (45% relative to estrogen, for 10µM compound 5b) in 
growth was seen for compound 5b. The compounds also did not stimulate the growth of 
MDA-MB-231 cells. Indeed, the growth of MDA-MB-231 cells was somewhat inhibited 
by treatment with the compounds. The reasons for the growth inhibitory effects are 
unclear.  
In reporter gene assays in which LRH-1 was co-transfected in COS-1 cells, together with 
an LRH-1 responsive luciferase reporter gene, SF-1-luc, showed that compound 5L was 
the most potent activator of LRH-1, with compound 5a being least effective (Figure 
3.22a). MCF-7 cell growth reflected the activation potential of the three compounds seen 
for the reporter gene assay, with 5L being the most potent stimulator of MCF-7 cell 
growth and 5a being the least effective. All three compounds stimulated ERα expression, 
the profile of stimulation being the same as that observed for the reporter and growth 
assays (Figure 3.22b).  
In summary, the siRNA and SHP transfection experiments show that reduction in LRH-
1 levels or activity leads to inhibition of ERα expression, whilst LRH-1 over-expression 
or activation using small molecule agonists stimulates ERα expression. Taken together, 
these results provide strong evidence to support a role for LRH-1 in regulating breast 
cancer cell growth by regulating ERα expression.  
Figure 3.21 LRH-1 agonists stimulate the growth of LRH-1 positive breast 
cancer cells. Structures of the LRH-1 agonists 5a, 5b and 5L (Whitby et al. 2007) 
are shown. MCF-7 (a), MDA-MB-231 (b) and BT474 (c) cells were cultured in 
estrogen-depleted medium for 3 days prior to plating in wells of 96-well plates. 
Estrogen (10 nM E2) or compounds 5a, 5b or 5L were added, as appropriate. Five 
wells were plated per treatment condition. Every 3 days, cell growth was assessed 
using the SRB assay. Shown are the mean optical densities of the five biological 
replicates, with standard errors of the mean represented by error bars. 
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Figure 3.22 Compounds 5a, 5b and 5L stimulate LRH-1 activity and ER 
expression in MCF-7 cells. (a) COS-1 cells were transiently transfected with 
the LRH-1 responsive firefly luciferase reporter gene, (SF-1-luc), a renilla 
luciferase reporter gene (RLTK) and LRH-1. Reporter gene activity following 
treatment of cells with 10 µM compounds 5a, 5b or 5L are shown, following 
correction for transfection efficiency using the renilla luciferase activity. The 
results of three independent experiments is shown, together with standard errors 
of the mean. (b) MCF-7 cells were treated with compounds 5a, 5b or 5L for 24 
hours prior to RNA preparation. Real-time qRT-PCR was performed for ERα 
and GAPDH. Shown is the expression of ERα relative to the vehicle control, 
following normalisation against GAPDH expression. The results of three RNA 
preparations is shown, with standard errors of the mean being shown as error 
bars.  
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3.13 Investigation of LRH-1 regulation of the expression of ERα isoforms 
Silencing of LRH-1 was shown to abrogate the estrogen proliferative effect in cell lines 
that express LRH-1, and that inhibition of LRH-1 inhibits ERα expression at the RNA 
and protein level. Analysis of the human ERα gene has identified six major ERα mRNA 
isoforms that arise from alternative promoter usage (Flouriot et al., 1998). As the 
different promoters only encode 5’ untranslated regions, there is no impact of alternative 
promoter usage on the ERα protein sequence. Furthermore, these transcripts are 
differentially expressed in human tissues or cell types. In order to investigate which of 
the ERα gene promoters are LRH-1 regulated, qRT-PCR was completed to confirm 
which gene promoters are used in breast cancer cell lines. For this, qRT-PCR primers 
specific for each of the six ERα isoforms, named A-F, were designed and qRT-PCR was 
performed using total RNA from MCF-7, ZR75-1, T47D and BT474 cells.  
In MCF-7 cells, about 75% of ERα mRNA contained exon 1A, implying transcription 
from promoter A, the remaining products arising from use of promoters B, C and F, 
with little mRNA arising from usage of promoters D and E (Figure 3.23). This is in 
agreement with previous findings (Flouriot et al., 1998). A similar expression profile was 
obtained for T47D cells, whereas about 70% of ERα transcription was initiated from 
promoter A. Interestingly, only BT474 cells, which do not express LRH-1, showed a 
substantially different profile, with 37% of the ERα mRNA arising from use of 
promoter A and 60% from promoter F, suggestive of a difference in ERα gene 
regulation in BT474, compared with the other lines.  Direct comparison of the relative 
expression of each promoter in the different cell lines shows this more clearly, with 
promoter A transcribed ERα mRNA in BT474 being 0.003% relative to MCF-7 cells, 
whereas promoter F transcribed ERα mRNA levels in BT474 are about 49% compared 
with levels in MCF-7 cells. It is important to note that the differences in expression from 
promoters D and E may not be significant, given that these promoters are poorly utilized 
in breast cancer cell lines.  
qRT-PCR of mRNA prepared from MCF-7 cells following siRNA for LRH-1 showed a 
similar reduction in expression of all isoforms (Figure 3.24), indicating that LRH-1 
regulation of ERα gene expression is important for all promoters in the ERα gene. As 
noted above, the reduction in promoter D and E usage may not be meaningful as 
expression from these promoters was extremely low. 
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Figure 3.23 ER promoter expression in MCF-7, ZR-75-1, T47D and 
BT474 cell lines. Real-time qRT-PCR analysis was performed using primer 
sets that specifically amplify ERα mRNA originating from promoters A to 
F. RNA prepared from MCF-7 cells for the ERα promoters A-F. The results 
are depicted in two formats. (a) Expression of ERα from each promoter, 
with total expression being taken as 100%. (b) The expression of the 
different ERα isoforms is shown relative to the expression in MCF-7 cells. 
The mean of three assays (with standard error bars) are shown as fold 
expression normalised against GAPDH expression. 
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Figure 3.24 Silencing LRH-1 reduces expression of all ERα 
isoforms in MCF-7 cells. Total RNA prepared from MCF-7 
cells transfected with non-targeting siRNA or with the LRH-1 
siRNA pool were analyzed by real-time qRT-PCR using primer 
sets specific for each ERα isoform, as in Figure 3.21.  
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3.14 An ERα  promoter-derived reporter gene is LRH-1 regulated  
The above-described studies clearly show that LRH-1 regulates ERα expression. In 
order to demonstrate that the regulation is due to direct recruitment of LRH-1 to the 
ERα gene promoters, the ERα gene promoter region was analysed for the presence of 
potential LRH-1 binding sites by analyzing the 150 kb sequence including promoters A 
through F using the consensus LRH-1 binding site having the sequence 5’-
YCAAGGYCR-3’. Ten potential LRH-1 binding motifs were identified in this region 
(Figure 3.25a). As two sequences corresponding well to the consensus LRH-1 binding 
site, together with a third sequence which differs from the consensus LRH-1 binding site 
but is highly related to an LRH-1- binding site identified in the mouse Bile Salt Export 
Pump (BSEP) gene, having the sequence 5’-CCAAAGCTTTGG-3’ (Song et al., 2008) 
and which is the most proximal site to promoters A-C, which together are responsible 
for 90% of the ERα mRNA in MCF-7 cells, we generated a reporter gene encoding the 
region of the ERα gene stretching from 7 kb upstream of promoter A, to include the 
promoter A transcription initiation site. Transfection of this reporter gene demonstrated 
in MCF-7 cells 10-fold stimulation of reporter gene activity when co-transfected with 
LRH-1 (Figure 3.23b). A mutant LRH-1 in which the phenylalanine at position 342 and 
isoleucine at position 416 have been mutated, and in which phospholipid binding by 
LRH-1 is reduced (Ortlund et al., 2005) did not activate the ERα gene reporter as well as 
the wild-type LRH-1 (Figure 3.26c). Together, these findings indicate that LRH-1 is 
recruited to this region of the ERα gene. Mutation of the three potential LRH-1 binding 
sites showed that whilst mutation of the consensus LRH-1 binding sites did not greatly 
reduce reporter gene activity, mutation of the non-consensus site (LRHRE1) reduced 
reporter gene activity to about 40% of the activity seen for the wild-type reporter, 
indicating that LRHRE1 is required for LRH-1 binding to the ERα gene promoter. 
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Figure 3.25 LRH-1 regulates the activity of an ER promoter 
reporter gene. (a) Shown is a schematic representation of the ER gene 
promoter showing the positions of promoters A to F. Also shown are the 
positions of putative LRH-1 response elements. The region in orange 
was cloned into a firefly luciferase reporter gene. Shown are the results 
of three independent experiments, with reporter gene activities being 
shown relative to the vector control. (b) Transfection of MCF-7 cells 
with the ER reporter gene, together with increasing amounts of LRH-1 
was carried out. (c) MCF-7 cells were transfected with the ER reporter 
gene, together with 1 ng of LRH-1 or a mutant LRH-1 (LRH-1-F342W/
I416W). Shown are the results of three independent experiments, with 
reporter gene activities being shown relative to the activity obtained for 
wild-type LRH-1. 
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4 DISCUSSION 
4.1 The requirement for novel treatment strategies in breast cancer 
For over thirty years, treatment with anti-estrogens has become the most important 
treatment option in women with ERα-positive breast cancer. In post-menopausal 
women with locally advanced ERα-positive disease, endocrine therapy reduces annual 
death rate more significantly than adjuvant chemotherapy (2005). Current anti-estrogen 
therapies include the use of SERMs, and AIs, which have been shown to improve 
disease free and overall survival (2005, Baum et al., 2002, Coombes et al., 2004, 
Thurlimann et al., 2005). In spite of the advances made in controlling disease 
progression, a large proportion of patients with locally advanced disease and all patients 
with ERα-positive metastatic disease, will eventually develop resistance to therapy. 50% 
of women with metastatic disease will not respond to endocrine therapy (de novo 
resistance) and the remainder will relapse despite initially responding to treatment 
(acquired resistance) (Ring and Dowsett, 2004). A number of mechanisms have been 
implicated in endocrine resistance including loss of ERα expression, ERα gene 
mutation, expression of a truncated form of ERα, abnormal CYP2D6 phenotype, 
expression of mi221 microRNAs, over expression of growth factor receptors (HER-2, 
EGFR), activation of the MAPK and PI3K/Akt pathways and cSNP in the aromatase 
gene (Riggins et al., 2007, Johnston et al., 1995, Gutierrez et al., 2005, Clarke et al., 2003, 
Herynk and Fuqua, 2004, Shi et al., 2009, Nelson et al., 2004, Desta et al., 2004, Lim et 
al., 2007, Xu et al., 2008, Miller et al., 2008, Zhao et al., 2008, Kurokawa et al., 2000, Ellis 
et al., 2001, Gee et al., 2001, Tokunaga et al., 2006, Martin et al., 2005, Ma et al., 2005). 
This study focuses on the role of LRH-1 in the estrogen-dependent growth of breast 
cancer. Hopefully, greater knowledge of this gene may provide a greater understanding 
of the pathways involved in the proliferation of breast cancer, enabling the development 
of new therapies. 
 
4.2 The MCF-7 breast cancer cell line 
The Michigan Cancer Foundation-7 (MCF-7) breast cancer cell line was isolated from the 
pleural effusion of a 69 year old Caucasian woman with metastatic breast cancer in 1970 
(Soule et al., 1973). The patient had undergone a mastectomy of her right breast for a 
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benign tumour and a radical mastectomy of her left breast for a malignant 
adenocarcinoma 7 and 3 years prior respectively. Local recurrences in the patient were 
treated for 3 years with a combination of radiotherapy and hormonal therapy. Expression 
of the ER was later described in MCF-7 cells, and in 1975 Lippman et al demonstrated 
that the antiestrogen tamoxifen inhibited their growth (Brooks et al., 1973, Lippman and 
Bolan, 1975).  
Removal of phenol red from media resulted in significantly increased sensitivity of MCF-
7 cells to estrogen (Berthois et al., 1986). Phenol red, the indicator used in media to 
monitor the oxidative state of cells, has a similar structure to previously described 
nonsteroidal estrogens. A dimerization product, which occurred during manufacture, was 
found to be responsible for its estrogenic effects (Bindal and Katzenellenbogen, 1988, 
Bindal et al., 1988). Following this finding, medium without phenol-red was used to 
determine the estrogenic effects in MCF-7 cells. 
Monoclonal antibodies were raised to human ER from MCF-7 cells in 1980 and 
following this ER was cloned and sequenced in MCF-7s (Greene et al., 1980, Walter et 
al., 1985). An alteration in the cloned MCF-7 ER cDNA was noted [Gly-400 (GGG)  
Val-400 (GTG)] (Tora et al., 1989). The original ER named HEO produced a protein 
with a reduced affinity for estradiol and the mutation of ER was also found to increase 
the estrogenic activity of tamoxifen (Jiang et al., 1992, Levenson and Jordan, 1994). 
Following this, wild-type ERα from MCF-7 cells is now known as HEGO, with G 
referring to the glycine at position 400. The confirmed estrogen-regulation of this cell 
line, and effect demonstrated by antiestrogens make MCF-7 cells an ideal model cell line 
for studies of estrogen-action in breast cancer (Dupont and Le Roith, 2001, Lai et al., 
2001, Ahmad et al., 1999) and this has been used as a model system to identify estrogen-
regulated genes involved in growth in this project.  
 
4.3 The promyelocytic leukemia zinc finger estrogen receptor (PLZF-ERα) 
fusion protein and the inhibition of estrogen-regulated gene expression  
PLZF is known to be a transcriptional repressor, interacting with NCoR, mSin3A and 
HDACs resulting in repression of RARα gene expression in a small percentage of acute 
myeloid leukaemias expressing PLZF-RARα (Guidez et al., 1998). The PLZF-ERα gene 
was modelled on PLZF-RARα, with PLZF-ERα expression, inducible in a tetracycline 
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manner (Buluwela et al., 2005). Stable lines expressing PLZF-ERα were developed using 
the MCF-7 cell line, which is the most commonly used model breast cancer cell line for 
estrogen-responsive and ERα-positive breast cancer, as described in section 4.1. Further 
experiments in our laboratory demonstrated that the MCF-7-TO-PLZF-ERα lines grew 
in an estrogen-dependent manner in the absence of doxycycline, but growth was 
inhibited in the absence of doxyxcyline when PLZF-ERα is expressed (Buluwela et al., 
2005). This MCF-7-TO-PLZF-ERα was therefore be used as a model to distinguish 
between the estrogen-regulated pathways from the estrogen growth response. 
4.4 Use of the PLZF-ERα  system in the identification of estrogen-regulated 
genes in breast cancer 
Gene expression microarray analysis using the MCF-7-TO-PLZF-ERα cell line was 
performed to identify estrogen-regulated genes and those estrogen-regulated genes 
whose expression was repressed by PLZF-ERα, as a way of identifying estrogen-
regulated genes that may be key in the estrogen stimulated growth of MCF-7 cells. Of 
the >55,000 transcripts on the array more than 3000 demonstrated estrogen-regulation at 
16 hours following addition of estrogen (>1.5 fold) and of these only 149 showed PLZF-
ERα mediated conditional repression by 1.5 fold or greater. Of these, 149 genes 24 were 
taken forward for further evaluation having shown to have the greatest repression by 
PLZF-ERα and estrogen-regulation. These genes were further sub-divided into 6 
functional groups: those genes involved in gene expression, protein trafficking and 
secretion, signal transduction, extracellular matrix, DNA repair, DNA replication and 
finally those gene involved in transmembrane channels. A time course of expression 
using end-point RT-PCR analysis, confirmed that the majority of the 23 genes were 
upregulated following treatment with estrogen. Of those that were upregulated a 
significant proportion increased within 8 hours, suggesting that these are early response 
estrogen-regulated genes. This helps to confirm that the genes identified through the 
microarray analysis primarily define a sub-set of estrogen-regulated genes in MCF-7 cells. 
One of the genes located in the “gene expression” functional subgrouping LRH-1, 
demonstrated early estrogen-regulation, with maximum expression being seen 8-16 hours 
following estrogen treatment. LRH-1 was chosen for further analysis because it is a 
nuclear receptor (Robinson-Rechavi et al., 2003), regulates aromatase expression (Clyne 
et al., 2002), and has recently been described to be important in MCF-7 cell growth 
(Annicotte et al., 2005). 
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4.5 LRH-1 expression and regulation by estrogens and anti-estrogens 
LRH-1 (NR5A2) is an orphan member of the NR5 subfamily of nuclear receptors and is 
closely related to the homologue, SF-1 (NR5A1), which functions in the hypothalamo-
pituitary adrenal axis. To date, three isoforms of LRH-1 have been identified. LRH-1 is 
expressed in a wide variety of tissues, but primarily those derived from the gut 
endoderm. LRH-1 has been implicated in a number of processes including early 
embryological development, cholesterol homeostasis, local gastrointestinal glucocorticoid 
production and has been found in a number of cancers including gastric, colorectal and 
breast.  
In our studies, we have shown that LRH-1 expression is subject to estrogen-regulation as 
seen by end-point RT-PCR, qRT-PCR and immunoblotting. The expression of LRH-1 is 
increased following estrogen treatment, and significantly reduced by the anti-estrogens 
ICI 182,780 and tamoxifen. These results are consistent with findings previously 
describing the estrogen-regulation of LRH-1, and the effects of anti-estrogens on its 
expression (Annicotte et al., 2005). Furthermore, a time course of LRH-1 expression 
demonstrated a rapid upregulation following the addition of estrogen. Maximum LRH-1 
expression was demonstrated by 6 hours following estrogen treatment, with expression 
falling at 24 and 48 hours. Of note in this time course, the expression of two previously 
defined LRH-1 regulated genes, CCND1 and INHA increased following expression. 
CCND1 is known to be regulated by LRH-1 and has been described in cancer 
progression (Botrugno et al., 2004, Planas-Silva and Weinberg, 1997, Prall et al., 1997, 
Annicotte et al., 2005). INHA has been shown to be regulated by LRH-1 in ovarian 
granulosa cells and functions in the developing oocyte (Weck and Mayo, 2006). LRH-1 
has been shown to increase INHA promoter activity (Robert et al., 2006), and its 
temporal expression profile raises the possibility that it may be LRH-1 regulated in MCF-
7 cells. Other well-described LRH-1 regulated genes such as CYP19, CYP7A and Oct 4 
were not expressed in MCF-7 cells, at a level that was able to be detected by end-point 
RT-PCR (Lu et al., 2000, Clyne et al., 2004, Clyne et al., 2002, Fayard et al., 2004, Gu et 
al., 2005). Of note, ERα expression was shown to be significantly reduced following 
treatment with estrogen within 1 hour and remained low even 48 hours following 
treatment which is consistent with previous findings (Saceda et al., 1988).  
4.6 LRH-1 expression in human tissues and cancer cell lines 
LRH-1 is most highly expressed in tissues derived from the gut endoderm such as the 
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pancreas (Lu et al., 2000, Annicotte et al., 2003), liver (Nitta et al., 1999, Goodwin et al., 
2000, Lu et al., 2000) and small intestine/colon (Lu et al., 2000) but is also expressed in 
the ovary (Boerboom et al., 2000, Hinshelwood et al., 2003, Liu et al., 2003, Falender et 
al., 2003, Sirianni et al., 2002), testes (Sirianni et al., 2002, Lambard et al., 2005, Pezzi et 
al., 2004), adrenal glands (Wang et al., 2001) and preadipocytes (Clyne et al., 2002). This 
wide tissue distribution and the fact that LRH-1 null mice die in-utero, suggests an 
important role for LRH-1, particularly in embryonic development (Pare et al., 2004). 
Using a panel of human tissue and cell line RNAs together with qRT-PCR we have 
extended these observations and seen that LRH-1 is predominantly expressed in the 
small intestine, ovary, lung, liver colon cervix, adipose and breast. The highest expression 
of LRH-1 was seen in the liver, colon and small intestine. This is not surprising as LRH-
1 expression in the liver is key to the regulation of the enzymes CYP7A1 and CYP8B1, 
which are involved in bile acid synthesis (Russell, 2003, Goodwin et al., 2000, Lu et al., 
2000, Pare et al., 2004, del Castillo-Olivares et al., 2004, Lee et al., 2008). The expression 
of LRH-1 in the intestine regulates the expression of cyclinD1 and E1, promoting 
epithelial renewal (Schoonjans et al., 2005), and through its action as a coactivator for β-
catenin may be involved in the pathogenesis of colorectal cancer (Kinzler and Vogelstein, 
1996, Wanitsuwan et al., 2008). LRH-1 overexpression has been reported in 47.6% of 
patients with gastric carcinoma, and with proliferation of a gastric carcinoma cell line 
through its regulation of cyclinE1 (Wang et al., 2008). LRH-1 expression is also thought 
to be protective against the onset of inflammatory bowel disease as LRH-1 deficient mice 
are more prone to intestinal inflammation (Coste et al., 2007). 
In the cancer cell line panel, LRH-1 was most highly expressed in the liver HepG2 cell 
line, and was also expressed in breast cancer cell lines, which express ERα. In those 
ERα-positive breast cancer cell lines in which LRH-1 was expressed, the relative 
expression often mirrored the expression of ERα in that particular cell line. Annicotte et. 
al. showed previously that LRH-1 was predominantly expressed in ERα-positive breast 
cancer cell lines (Annicotte et al., 2005). LRH-1 was also weakly expressed in two basal-
like ERα-negative cell lines, BT20 and MDA-MB-436. Having demonstrated that LRH-1 
is expressed in the ovary, it was surprising to find no expression in the ERα-positive 
ovarian cell line PE04. This cell line was derived from the malignant pleural effusion of a 
patient with poorly differentiated adenocarcinoma of the ovary, collected after resistance 
to chemotherapy had developed (Langdon et al., 1988). Whilst LRH-1 is important in the 
development and physiology of the ovary, it appears not to be required for the growth of 
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this particular cell line. 
4.7 Expression of SF1, DAX-1 and SHP 
4.7.1 SF-1 expression in breast cancer 
SF-1 is well known to contribute to the development and physiology of steroidogenic 
tissues, and was originally identified as a key regulator of the expression of cytochrome 
P450 steroid hydroxylases in the adrenocortical and gondal cell line. Studies in mice 
homologous for a null allele of SF-1 confirmed this essential role in steroidogensis 
(Morohashi and Omura, 1996, Parker and Schimmer, 1997). Although the initial stages 
of adrenal and gonadal development can take place in the absence of SF-1, newborn SF-
1 knockout mice are seen to have adrenal and gonadal agenesis and die shortly after birth 
(Bakke et al., 2001). SF-1 knockout mice also exhibit defects in their splenic parenchyma 
(Morohashi et al., 1999). 
Having shown that LRH-1 is predominantly expressed in ERα-positive breast cancer cell 
lines, further studies looking at SF1 expression found no detectable expression of this in 
either ERα-positive breast cancer cell lines and the majority of ERα-negative breast 
cancer cell lines. The notable exception to this was the ERα-negative breast cancer cell 
line CAL51, where low level expression of SF1 could be detected by qRT-PCR. CAL51 
is an ERα/PR-negative breast cancer cell line derived from the malignant pleural 
effusion of a 45 year old woman in 1985 (Gioanni et al., 1990). This cell line has been 
shown to have a microsatellite instability phenotype similar to that described in colorectal 
carcinomas (Seitz et al., 2003). SF-1 was also found to be highly expressed in the liver 
cancer cell line HepG2 and was also highly expressed in the spleen, testes and ovary in 
the human tissue panel. Previously SF-1 was described as being highly expressed in 
steroidogenic and hypothalamo-pituitary-adrenal axis tissues (Val et al., 2003). No SF-1 
expression was noted in either breast or adipose tissue. Collectively these findings 
demonstrate that the LRH-1 homologue SF-1 is unlikely to be key in the 
function/growth of either normal breast or breast cancer cell lines. 
4.7.2 DAX-1 and LRH-1 activity in breast cancer 
DAX-1 controls cell differentiation in testes and adrenal glands and has been shown to 
interact with SF-1, thereby repressing transactivation (Lalli and Sassone-Corsi, 2003, 
Ikeda et al., 1996, Ikeda et al., 2001, Suzuki et al., 2003). DAX-1 also binds to the LBD 
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of LRH-1, where interaction also leads to inhibition of transcriptional activity (Sablin et 
al., 2008). We have seen that DAX-1 is highly expressed in the cell line MDA-MB-435 
and to a lesser degree in the MDA-MB-436 line, but was not expressed in those cell lines 
in which LRH-1 was expressed, therefore suggesting that DAX-1 is unlikely to be a 
repressor of LRH-1 in breast cancer. Indeed, the MDA-MB-435 breast cancer cell line 
has recently been shown to be melanocytic in origin, since it found to express a large 
number of melanoma associated genes and can be clustered with other melanoma cell 
lines (Ross et al., 2000, Ellison et al., 2002, Sellappan et al., 2004, Rae et al., 2007, Rae et 
al., 2004). In the tissue panel we have examined, DAX-1 was found to be highly 
expressed in gonadal tissues i.e. the ovary and the testes. DAX-1 is expressed with SF-1 
in the granulosa cells of the ovarian follicle, however it was also detected in stromal cells, 
primordial follicles, and primary follicles of the ovary in the absence of SF-1 (Sato et al., 
2003). DAX-1 expression has been described in the Sertoli and Leydig cells of murine 
testes and is thought to play a role in testicular maturation (Ikeda et al., 2001, Ikeda et al., 
1996, Schmahl et al., 2000, Yu et al., 1998). 
4.7.3 SHP and LRH-1 activity in breast cancer 
SHP is expressed in a number of tissues including the liver, intestine, adrenals, adipose, 
pancreas, skeletal muscle, and heart (Hartman et al., 2009, Seol et al., 1996, Johansson et 
al., 1999, Sanyal et al., 2002, Kovacic et al., 2004, Lee et al., 1998). SHP has been shown 
to bind to and inhibit many nuclear receptors, but increases the activity of PPARα and 
PPARγ (Seol et al., 1997). SHP lacks a classical DBD and binds to other NRs through 
two LXXLL motifs (Seol et al., 1996, Johansson et al., 2000, Borgius et al., 2002, 
Gobinet et al., 2001). An additional 12 amino-acids between helix 6 and helix 7 in SHP 
are key in the repression of NRs transactivation (Park et al., 2004). Our analysis has 
confirmed that SHP is widely expressed in many tissue types but is most highly 
expressed in the small intestine, spleen, liver and colon. No expression of SHP however 
was noted in either breast or adipose tissue. The liver cancer cell line HepG2, was the 
only cancer cell line, which expressed SHP. A recent study has suggested a role for SHP 
as a potential tumour suppressor in hepatocellular carcinoma (HCC), showing that 
hypermethylation is key to silencing SHP expression and vital to progression of liver 
cancer (He et al., 2008). Conversely overexpression of SHP was shown to inhibit the 
formation of HCC in vitro and attenuate the growth of HCC in vivo. 
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4.8 LRH-1 isoforms in MCF-7 breast cancer cells 
Previously, three isoforms of LRH-1 have been described, including LRH-1 variant 1, 
LRH-1 variant 2 and LRH-1v2, as described in section 1.18.1. LRH-1 variant 1 and 
variant 2 differ through alternative splicing that removes the A/B domain corresponding 
to exon 2 (Galarneau et al., 1998, Li et al., 1998, Nitta et al., 1999, Zhang et al., 2001). 
LRH-1v2 is the smallest form of LRH-1 described to date, and lacks sequences encoding 
the D and E regions (Zhang et al., 2001, Nitta et al., 1999). As previously described in 
section 3.7, immunoblotting for LRH-1 in MCF-7 cells using an antibody detecting the 
first 1-75 amino acids of LRH-1 (H-75; Santa Cruz) did not detect a protein consistent 
with that seen by transient transfection of LRH-1 in COS-1 cells. Two further antibodies 
(Abcam ab41900 and ab18293) also did not detect endogenous LRH-1 in MCF-7 cells. 
Taken together, these results raised the possibility that there may be additional forms of 
LRH-1, primarily differing in the N-terminal region of the protein.  Therefore, we used 
5’RLM-RACE to look for new variant LRH-1 transcripts. This analysis resulted in the 
identification of three new forms of LRH-1, which we have named LRH-1 152, LRH-1 
289 and LRH-1 326. Alignment of the LRH-1 289 and the 326 sequences showed that 
they each defined novel mRNAs with transcription initiated from alternative promoters. 
qRT-PCR analysis of LRH-1 variants1 and 2, LRH-1 289 and LRH-1 326 as well as total 
LRH-1 showed that the predominant form of LRH-1 expressed in MCF-7 cells 
corresponds to LRH-1 289. The expression profiles of LRH-1 289 and 326 were also 
shown to follow that of total LRH-1. The highest expression of both variants was seen in 
the estrogen positive cell lines MCF-7, T47D and ZR-75-1, which confirms previous 
data showing that LRH-1 is associated with ERα expression in breast cancer cell lines 
(Annicotte et al., 2005). LRH-1 variants 1/2 were predominantly expressed in the liver 
cell line HepG2. The two new forms of LRH-1 were more widely expressed in the 
human tissue panel than LRH-1 variant 1/2 that was more specifically expressed in tissue 
derived from the gut endoderm notably the liver, small intestine and the colon. 
Immunoblotting of MCF-7 lysates using an antibody able to detect all forms of LRH-1 
(H2325, Perseus Proteomics) detected a protein predicted with the expected size for the 
289 variant but no endogenous LRH-1 variant 1 or variant 2 protein was detected. 
Collectively these data suggest that LRH-1 289 may be a major form of LRH-1 expressed 
in breast cancer with the previously described forms variants 1 and 2 most likely to be 
the dominant forms in those tissues derived from the gut endoderm. Further work 
quantifying the relative comparison will need to be done in the future with separate 
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primers for both LRH-1 variant 1 and variant 2. 
These two new forms of LRH-1, LRH-1 289 and LRH-1 325 demonstrated significant 
estrogen-regulation to a greater degree than LRH-1 variant 1/2. Furthermore, the Ct 
values for LRH-1 289 were significantly lower than in the other forms of LRH-1 further 
highlighting that it is likely to be the dominant form expressed in MCF-7 cells. 
4.9 LRH-1 is required for estrogen-dependent growth in breast cancer cell lines 
Using siRNA-mediated knockdown of LRH-1 with a pool of four siRNAs and each of 
the four deconvoluted siRNAs, we have seen that LRH-1 is required for the estrogen-
dependent growth of MCF-7 cells. The degree of growth inhibition seen in MCF-7 cells 
when assayed in either complete media or stripped media correlated with the relative 
siRNA mediated reduction in expression of LRH-1. For example, siRNA LRH-1 No.1 
exhibited the weakest effect on reduction in LRH-1 expression and also demonstrated 
the weakest effect on growth. To further confirm these observations, these experiments 
were repeated using other LRH-1-positive (T47D, ZR-75-1) and LRH-1-negative 
(BT474, MDA-MB231) cell lines with LRH-1 pooled siRNA and the specific LRH-1 
siRNAs No.2 and No.4. Growth was inhibited in the other LRH-1-postive cell lines, 
when LRH-1 was knocked down, but not to the same degree as seen in the MCF-7 cell 
line. In T47D and ZR-75-1 cell lines, siRNA mediated knockdown of LRH-1 resulted in 
a lower degree of growth repression than in MCF-7 cells and this may reflect differences 
in the potency and stringency of estrogen-regulated growth between the three lines, as 
ZR-75-1 and T47D cells were seen to have some growth in the absence of estrogen. 
Silencing LRH-1 expression had no effect on the growth of the two cell lines which did 
not express LRH-1 i.e. BT474 (ERα-positive) and MDA-MB231 (ERα-negative). This 
suggests that inhibition of growth in MCF-7, T47D and ZR-75-1 is specifically due to the 
downregulation of LRH-1. These results are consistent with those demonstrated by 
Annicotte et. al. who showed that silencing LRH-1 abrogates the estrogen-stimulated 
growth of an MCF-7 cell line stably transfected with LRH-1 siRNA (Annicotte et al., 
2005).  
4.10 LRH-1 knockdown induces apoptosis in MCF-7 cells 
The role of estrogen in controlling the progression through and exit from G1 phase of 
the cell cycle is well documented. Early studies in rat uterine and mammary tissue 
demonstrated that estrogen increased the number cells in S-phase by recruiting non-
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cycling cells into the cycle and reducing the time spent in G1 phase (Leung and Potter, 
1987, Sutherland et al., 1983, Osborne et al., 1984, Foster and Wimalasena, 1996). By 
synchronizing cells, the site of action of anti-estrogens was demonstrated to be early G1 
(Osborne et al., 1983, Sutherland et al., 1983, Taylor et al., 1983, Leung and Potter, 1987, 
Musgrove et al., 1989). There appears to be a significant overlap between the effect of 
the pure antiestrogen ICI, 182 780 and tamoxifen resulting in a growth arrest in G1 phase 
(Doisneau-Sixou et al., 2003), which we have also seen in MCF-7 cells following 
treatment with the antiestrogens ICI 182, 780 and tamoxifen (Appendix 1.6). 
There is considerable evidence to support a role for LRH-1 in controlling proliferation, 
as overexpression of LRH-1 induces proliferation of hepatic and pancreatic cancer cell 
lines (Botrugno et al., 2004). Furthermore, LRH-1 reduces intestinal tumorigenesis in the 
ApcMin/- mice, a genetic model of intestinal cancer (Schoonjans et al., 2005). LRH-1+/- 
mice were also protected against the formation of aberrant crypt foci (ACF) in the colon 
of mice exposed to the carcinogen azoxymethane. 
Cell cycle analysis of MCF-7 cells in which LRH-1 was knocked down following targeted 
siRNA treatment demonstrated a significant sub-G1 peak. Further analysis using annexin 
V staining showed that this peak was a result of an increase in cells in apoptosis. LRH-1 
siRNA resulted in an increase of apoptosis in MCF-7 cells by more than 25%. This 
suggests that the reduction in cell number following silencing LRH-1, may in part be 
mediated by increased cell apoptosis. With this in mind, LRH-1 knockdown may result in 
an increased expression of pro-apoptotic genes and/or a reduction in the expression of 
those genes involved in cell survival (anti-apoptotic). Previous work by Wang et al. 
(2005) transiently transfected with pShLRH-1-1 and pShLRH-1-2 into the human HCC 
cell line, BEL-7402. This directed the synthesis of hLRH-1 specific hairpin-like siRNAs 
resulting in cell-cycle arrest (Wang et al., 2005a). This study demonstrated that 
knockdown of hLRH-1 in BEL-7402 resulted in a significantly reduced expression of 
cyclin E1, growth-arrest and DNA-damage-inducible proteins (Gadd45β) (Wang et al., 
2005a). Gadd45β inhibits apoptosis caused by tumour necrosis factor-α (TNF-α) by 
mediating inhibition of the c-Jun N-terminal kinase (JNK) pathway via the NFκB 
pathway (Papa et al., 2004). Levels of Gadd45β were significantly down-regulated by RT-
PCR in BEL-7402 in which hLRH-1 was knocked-down. Gene expression microarray 
analysis using the human HCC cell line stably expressing the RNAi vector (pSineohLRH-
1), targeting hLRH-1, identified approximately 400 genes whose expression was 
significantly altered when compared to control cells. These genes included c-MYC 
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binding protein (MYCBP), CCAAT/enhancer binding protein gamma (CEBPG), DNA-
damage-inducible transcript 3 (DDIT3), TP53 activated protein 1 (TP53AP1), Gadd45β 
and phosphate and tensin homolog (PTEN) (Wang et al., 2006). A low level expression 
of histones (HIST1H1B, HIST1H2BK, HIST2H2AC, HIST1H2BM, HIST1H2BC, 
HIST1H2BN, HIST3H2A, HIST2H2AA, HIST1H2BB) was also demonstrated in the 
microarray analysis, which is in keeping with the abrogation of proliferation, which was 
seen, in the hLRH-1 knockdown in these cells (Wang et al., 2006). 
Previous cell cycle analysis in MCF-7 cells in which LRH-1 expression was knocked 
down, has shown an accumulation of cells in the G1 phase with a decrease in both the S 
and G2/M phases (Annicotte et al., 2005). These studies also demonstrated that CCND1 
expression is regulated by LRH-1, and other work has confirmed CCND1 as a target of 
LRH-1 and ERα (Annicotte et al., 2005, Botrugno et al., 2004). Hence, it has been 
suggested this increased expression of CCND1 results from both LRH-1 and ERα, 
bringing about the recruitment of coactivators NCoA1 and P/CAF to the gene 
(McMahon et al., 1999, Neuman et al., 1997, Zwijsen et al., 1998, Annicotte et al., 2005). 
4.11 LRH-1 and ERα  expression  
Distinct gene expression patterns have been demonstrated between ERα-positive and 
negative breast cancers (van 't Veer et al., 2002, Perou et al., 2000, Gruvberger et al., 
2001). The expression of transcription factors such as FoxA1 and GATA3 has been 
shown to correlate highly with ERα expression (Lacroix and Leclercq, 2004). Recently it 
has been proposed that GATA3 and ERα may be involved in a positive cross-regulatory 
loop in breast cancer cells (Eeckhoute et al., 2007). GATA3 was shown to bind to cis-
regulatory elements within the ERα gene, recruiting RNA polymerase II to ERα 
promoters. Furthermore, in this study, GATA3 and ERα were shown to mediate their 
own expression in breast cancer cells (Eeckhoute et al., 2007). Knockout of GATA3 has 
also been shown to result in a loss in ERα expression in normal mammary tissue 
(Kouros-Mehr et al., 2006).  
I confirmed that LRH-1 siRNAs do indeed knockdown LRH-1 at a protein and RNA 
level. This was confirmed using a pool of siRNAs as well as the four deconvoluted, 
individual siRNAs. Using qRT-PCR, the knockdown of LRH-1 was shown to be 
between 80-90% for individual LRH-1 siRNAs nos. 2, 3 and the pool. This was 
confirmed at a protein level, where no detectable LRH-1 protein could be seen in MCF-7 
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cells following knockdown with either LRH-1 siRNAs nos. 2 and 4 and the siRNA pool. 
Interestingly, the less efficient knockdown of LRH-1 using siRNA no.1 (50%) at both an 
RNA and protein level may explain why this particular siRNA had a less marked effect 
on growth in MCF-7 cells. 
An unexpected finding of LRH-1 knockdown was the subsequent reduction in ERα 
expression at both the RNA and protein level in MCF-7 cells. The reduction in ERα was 
greatest when siRNAs nos. 2, 3 and the pool were used. Knockdown of LRH-1 was also 
seen to reduce the expression of the estrogen-regulated genes CTSD, pS2 and PR in 
these cells, further emphasising the resulting redution of ERα expression. The LRH-1 
mediated regulation of ERα expression was further confirmed by siRNA targeted LRH-
1 knockdown and qRT-PCR analysis in two other LRH-1+/ERα+ cell lines, T47D and 
ZR-75-1. In both of the these cell lines, even though the reduction in LRH-1 was 
significantly less than that seen in MCF-7 cells (30-40%) there was a significant reduction 
in ERα expression (20-25% in both cell lines). Further knockdown of LRH-1 expression 
in the BT474 cell line, which we have found to be LRH-1-/ ERα+ had no effect on 
ERα expression or estrogen-regulated gene expression. The BT474 cell line is an 
invasive ductal carcinoma derived from the malignant pleural effusion of a 60 year old 
woman, known to be ER+/PR+/HER2+ (Lasfargues et al., 1978, Neve et al., 2006). 
The effect of LRH-1 targeted siRNA in this cell line also help to confirm that the 
reduction in ERα expression seen in MCF-7, T47D and ZR-75-1 cells is not due to off-
target effects by LRH-1 siRNAs on ERα. 
Further confirmation that LRH-1 potentially regulates ERα expression was 
demonstrated by overexpressing LRH-1 289 and LRH-1 variant 1 in MCF-7 cells (LRH-
1-positive) and the cell line BT474 (LRH-1-negative). Overexpression of LRH-1 resulted 
in a significant increase in the expression of ERα in both of these cell lines. 
Furthermore, transfection of SHP, a known repressor of LRH-1 resulted in a 30% 
reduction in ERα expression. SHP is an orphan nuclear receptor, which like DAX-1 
lacks a classical DBD (Seol et al., 1996, Zanaria et al., 1994). SHP has been shown to 
interact with numerous members of the nuclear receptor superfamily including TR, RAR, 
RXR and ER (Seol et al., 1996, Seol et al., 1998). Using yeast and mammalian two-hybrid 
systems SHP has been shown to interact with ERα in a ligand dependent fashion (Seol et 
al., 1998). SHP is predominantly expressed in the liver, spleen, colon and small intestine 
(Seol et al., 1996, Masuda et al., 1997). ERα is also expressed in the liver and whilst its 
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expression is regulated by growth hormone (GH), (triiodothyronine) T3 and 
dexamethasone (Freyschuss et al., 1994, Ulisse and Tata, 1994), it may be that SHP may 
also be a key regulator of ERα. Whilst SHP has been shown to interact with ERα, the 
reduction in ERα may be due to its repressive effect on LRH-1. 
Previous studies in primary granulosa cells have shown that INHA is a directly regulated 
LRH-1 target gene (Weck and Mayo, 2006), and that overexpression of LRH-1 increases 
INHA promoter activity (Robert et al., 2006). I have found that INHA is expressed in 
MCF-7 cells and shows estrogen-regulation, which similar to LRH-1 peaks  around 8 
hours following estrogen treatment. The estrogen-regulation of INHA has been 
described in rat granulosa cells, (Turner et al., 1989), but has not previously been 
investigated in breast cancer cell lines.  Following knockdown of LRH-1, using qRT-
PCR, the expression of INHA was seen to be reduced by 50-60% by all four individual 
LRH-1 siRNAs and the pool siRNA. Taken together, these data suggest that INHA is 
also an LRH-1 target gene in breast cancer cells.  
4.12 Aromatase is weakly expressed in breast cancer cell lines 
Estrogens are synthesized from the conversion of C19 steroids in a number of tissues 
including the ovary, skin, adipose fibroblasts, hypothalamic neurons, bone and placenta 
(Bulun et al., 2005). Aromatase is encoded by the gene CYP19, and aromatase expression 
in adipose tissue is limited to undifferentiated fibroblasts and minimally expressed in 
adipose tissue (Bulun et al., 2005). Elevated aromatase expression has been reported in 
undifferentiated breast adipose fibroblasts adjacent to breast tumours (O'Neill et al., 
1988, Bulun et al., 1993). These fibroblasts are maintained in an undifferentiated state as 
a result of TNF and interleukin (IL)-11 secretion (Meng et al., 2001). In their studies 
Clyne et al. (2002) demonstrated the expression of aromatase using end-point RT-PCR in 
adipose tissue but only expressing a product at extremely high cycle numbers- 40 cycles 
(Clyne et al., 2002). Clyne stated that the expression of LRH-1 was significantly higher by 
qRT-PCR (11-fold) in primary adipose stromal cells than adipose tissue. The expression 
of aromatase was undetectable at a protein level in adipose cells and only just detectable 
in preadipocytes (Clyne et al., 2002). Whilst the expression of LRH-1 and aromatase in 
adipose stromal cells has not been investigated in this project, I have shown that 
expression of LRH-1 and aromatase is extremely low in normal breast and adipose tissue. 
Several studies have suggested the possibility that LRH-1 regulated cell proliferation in 
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breast cancer may be mediated through the regulation of aromatase. Local tumour 
production of estrogen through the aromatisation of androgens, is regulated by 
aromatase, which, in-turn, has been shown to be under the control of LRH-1 (Clyne et 
al., 2002, Clyne et al., 2004, Simpson et al., 2000). I have shown that the expression of 
aromatase in breast cancer cells is extremely low, even in LRH-1 positive breast cancer 
cell lines, suggesting that there is likely to be little conversion of androgens to estrogens 
by these cells. Hence, there are likely to be other mechanisms by which LRH-1 mediates 
the growth and proliferation of breast cancer cells, including the direct regulation of 
genes functioning in cell growth and cell survival. 
4.13 Development of synthetic small molecule agonists to LRH-1 
In order to confirm that LRH-1 regulates ERα activity in breast cancer cells, synthetic 
LRH-1 small molecule agonists named the ‘Whitby compounds’ (Whitby et al., 2006), 
were found to stimulate the growth of LRH-1-positive, but not LRH-1-negative breast 
cancer cell lines. These compounds were identified from a compound screen and have 
been shown to activate LRH-1 regulated gene reporter activity in HepG2 cells and 
significantly increase the expression of the LRH-1 regulated gene, SHP in HepG2 and 
primary hepatocytes cell lines (Whitby et al., 2006). The efficacy of these compounds to 
stimulate growth in breast cancer cell lines (LRH-1-negative and LRH-1 positive) was 
assessed using an SRB growth assay. Two of the compounds, 5b and 5L stimulated 
growth with greater efficacy at a lower concentration than compound 5a.  Confirmation 
of their effect on LRH-1 expression on MCF-7 cells was seen in a reporter assay. LRH-1 
reporter activity was stimulated to a greater effect by compounds 5L and 5b than 
compound 5a. Their effect on LRH-1 reporter gene activity mirrored their relative 
effects on growth in MCF-7 cells with compound 5L having the greatest effect on 
growth and 5a having the least. These three compounds also increased ER activity 
presumably through their effect on LRH-1 expression.  
Recently, the use of functional assays and high throughput screening of 64,908 
compounds made from the United States National Institutes of Health enabled 
investigators to discover two novel inhibitors of SF-1 (Madoux et al., 2008). Using 
computer aided design, it may be possible to examine the crystal structure of the ligand-
binding pocket of LRH-1 in order to develop further compounds based on the Whitby 
series with activities as improved LRH-1 agonists, or even antagonists. This approach has 
been utilized in our laboratory previously in the design of novel cdk7 inhibitors, based on 
 175 
the binding of roscovitine to cdk2 (Ali et al., 2009). 
4.14 LRH-1 regulation of the ERα  promoter activity in breast cancer cell lines 
Analysis of the 5’ region of human ERα demonstrated an area of significant homology 
to the first exon of the mouse ERα ~2kb upstream from the original transcriptional start 
site described by Green et. al. (Keaveney et al., 1991, White et al., 1987, Green et al., 
1986). The conserved acceptor splice site in human ERα exon at +163 was called exon 1 
(Keaveney et al., 1991). Subsequent to this Piva et. al. described an ERα promoter in 
exon 1, 1.1kb further upstream (Piva and Del Senno, 1993). These two promoters were 
called proximal (P0) or distal (P1). A third ERα promoter, named C was described by 
Grandien et al from a screen of several human cell lines and tissue types (Grandien, 
1996). The two previously described variants were, as a result renamed A and B. Two 
subsequent 5`exons were described in 1997 from an MCF-7 cDNA library designated E 
and H (Thompson et al., 1997). From a panel of endometrial and breast carcinomas, 
these two new transcripts were found to be expressed in all of the cell lines, which were 
ERα-positive. Furthermore, ten primary human breast cancers were assessed, six of 
which expressed the E transcript and five, the H transcript (Thompson et al., 1997). 
Further work showed that exon E was located in the intronic region between exon 1’ and 
1, and the H transcript was very similar to the 3’-section of exon C (Grandien, 1996). 
Using 5’RACE analysis, an exon D was identified from MCF-7 cells 3.7kb upstream of 
exon 1 (Flouriot et al., 1998). All 5’-upstream exons were then renamed from the original 
exon 1A going upstream to 1F.  
These studies have demonstrated that the ERα gene is expressed through more than one 
promoter (Grandien et al., 1995, Keaveney et al., 1991, Piva and Del Senno, 1993, 
Thompson et al., 1997, Flouriot et al., 1998). There are currently six ERα mRNA 
isoforms A-F, generated by differential promoter use, which differ in the 5’UTR as a 
result of alternative splicing. The function of several promoters in the ERα gene is likely 
to due be to tissue specific regulation of certain promoters and therefore regulation of 
expression of mRNA variants in these tissues. MCF-7 cells have been shown to use 
promoters A and C (Grandien et al., 1993), whereas only promoter C is used in ZR-75-1 
cells. Increased use of the A promoter and decreased use of the promoter B has been 
reported in cell lines derived from tumours as opposed normal breast tissue (Grandien et 
al., 1995). A specific liver promoter named “E2-E1” has also been described (Flouriot et 
al., 1998, Grandien, 1996).  
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Tissue specific expression of ERα mRNA variants has been described in human, mouse, 
rat and rainbow trout (Hirata et al., 1996a, Hirata et al., 1996b, Freyschuss and Grandien, 
1996, Griffin et al., 1998, Griffin et al., 1999, Pakdel et al., 1994). An explanation for the 
multiple promoters may be due to tissue-specific use and the production of different 
transcripts from these promoters encoding different protein isoforms (Kos et al., 2001). 
Using qRT-PCR, I have confirmed that transcript A is the major form of ERα expressed 
in the breast cancer cell lines MCF-7, ZR-75-1 and T47D, however F and A were seen to 
be the major forms found in the cell line BT474. Promoter F is predominantly expressed 
in the ovary, and osteoblasts (Flouriot et al., 1998). Knockdown of LRH-1 expression 
resulted in a global reduction in the expression of all isoforms of ERα. The greatest 
reduction in expression was seen in the distal ERα promoter E, however transcription 
from this occurs at a low level in all four of the breast cancer cell lines examined and 
therefore this effect is unlikely to be significant. 
Analysis of the region encoding the ERα gene promoters A through to F demonstrated 
the presence of 10 sequences conforming to the LRH-1 binding site 5'-
PyCAAGGPyCPu-3' (Ueda et al., 1992). The sequence preceding PyCA is not vital for 
LRH-1, however the core sequence AGGPyCPu is essential (Ueda et al., 1992, Ueda and 
Hirose, 1991). The closest of these sites is located within 6kb 5’ to promoters A and B, 
which I have shown are the major ERα promoters used in MCF-7 cells.  
To further confirm that ERα is regulated directly by LRH-1, the laboratory generated an 
ER promoter luciferase reporter gene (ERP-luc) encoding a 5.6kb region comprising 
promoters A through to D containing two putative LRH-1 binding sites (LRHRE2, 
LRHRE3). LRH-1 activated ERP-luc in MCF-7 cells. A number of structural studies 
have shown that the LRH-1 LBD is bound by a phospholipid (Ortlund et al., 2005, 
Krylova et al., 2005, Wang et al., 2005b). An LRH-1 mutant (LRH-1-F342W/I416W) has 
been shown to impair phospholipid binding, and in a reporter assay (Ortlund et al., 
2005), I have shown that its expression significantly reduces ER promoter activity.  
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5 MODEL FOR ACTION OF LRH-1 IN BREAST CANCER 
From my work I have proposed a model explaining the potential action of LRH-1 in 
breast cancer. LRH-1 and aromatase are highly expressed in breast cancer compared with 
normal breast tissue. LRH-1 controls aromatase enzyme expression, which synthesizes 
estrogen locally within the surrounding adipose tissue providing the mitogenic drive for 
tumour growth in postmenopausal women. This increase in local estrogen results in an 
increase in LRH-1 expression within the tumour through regulation by ERα. The rise in 
LRH-1 within the tumour results in an increase in LRH-1 regulated genes, which in part 
drive the growth of the tumour. LRH-1 may also act in a positive loop to increase ERα, 
thereby increasing ERα regulated genes which drive tumour growth also (Figure 5.1). 
This model is based on the potential activity of LRH-1 and ERα in breast cancer tissues, 
but I have not looked at the activity of LRH-1 and ERα in the normal mammary gland. 
Previous studies have demonstrated that approximately 5-10% of luminal mammary 
epithelial cells express ERα, and in contrast to ERα-positive breast cancer cells, these 
normal mammary ERα-positive cells do not proliferate in response to estrogen (Clarke 
et al., 1997, Petersen et al., 1987). The cells surrounding these normal mammary ERα-
positive cells are proliferating rapidly, indicating that paracrine factors may be involved in 
mediating the effects of estrogen in this normal mammary tissue (Clarke et al., 1997). A 
number of studies have shown a much higher concentration of estrogen and estrone in 
malignant and normal mammary breast tissue compared with plasma concentrations 
(Vermeulen et al., 1986, van Landeghem et al., 1985). Concentrations of estrogen are 
considerably higher in malignant than normal mammary tissue, which may be reflected in 
the increased expression of LRH-1 in these tissues. (Bonney et al., 1986). Interestingly 
the concentrations of estradiol in tumours are independent of menopausal status of the 
women (Thijssen et al., 1987). It would therefore be interesting to evaluate the 
expression of LRH-1 in normal mammary tissue in both pre and post-menopausal 
women, and evaluate the effects of estrogen on LRH-1 expression and ERα in these 
tissues. 
Furthermore other tissues where the expression of LRH-1 may be relevant requires 
evaluation. This includes those tissues that express not only LRH-1 but also ERα such as 
the ovary, brain and bone. 
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Figure 5.1 Proposed model for the action of LRH-1 in breast cancer. LRH-1 regulates 
aromatase expression in adipose tissue surrounding the breast cancer, resulting in increased 
local synthesis of estrogen. This estrogen provides the mitogenic drive for tumour growth by 
regulating estrogen responsive genes through ERα. LRH-1, regulates LRH-1 genes which may 
in part be involved in growth as well as acting in a positive feedback loop to regulate ERα 
expression.   
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6 CONCLUSIONS AND FUTURE WORK 
Recent data from a gene expression microarray performed in our laboratory (Buluwela et 
al, unpublished), using an engineered breast cancer cell line, in which ERα expression 
can be repressed, identified LRH-1 as an estrogen-responsive gene that may be 
important in the estrogen-regulated growth of breast cancer cells. Using the MCF-7 
breast cancer cell line, I have confirmed that LRH-1 is early estrogen-regulated with 
stimulation at 2 hours, reaching a maximal expression at 4-6 hours. Treatment of MCF-7 
cells with the anti-estrogens tamoxifen and ICI 182, 780 reduced the expression of LRH-
1 at the RNA and protein level. I have shown that known LRH-1 regulated genes INHA 
and CCND1 are estrogen-regulated, with their greatest expression seen, when LRH-1 
expression was maximal. Further confirmation that LRH-1 is estrogen-regulated was 
demonstrated by a reduction in LRH-1 expression following knockdown of ERα in 
MCF-7 cells using an siRNA to ERα. 
I have shown that LRH-1 is highly expressed in tissues derived from the gut endoderm 
such as the small intestine, colon, and liver as well as in the testes, ovary and breast. In a 
panel of cancer cell lines, LRH-1 was highly expressed in the liver cell line HepG2 and 
ERα-positive breast cancer cell lines but was minimally expressed in those breast cancer 
cell lines which do not express ERα. I have also shown that the homologue of LRH-1, 
SF-1 was minimally expressed in breast tissue, but highly expressed in the ovary and 
small intestine. SF-1 expression was also shown to be undetectable in nearly all breast 
cancer cell lines. The expression of LRH-1 repressors DAX-1 and SHP was very low in 
breast tissue and breast cancer cell lines. 
Using 5’RLM-RACE I have identified three novel LRH-1 variant transcripts, two of 
which, LRH-1 289 and LRH-1 326 were shown to be estrogen-regulated. Both LRH-1 
289 and 326 were expressed in LRH-1 containing tissues and LRH-1 positive breast 
cancer cell lines. LRH-1 289 was also shown to be a major form of LRH-1 expressed in 
the breast. 
Using siRNA mediated gene knockdown, I have shown that by inhibiting the expression 
of LRH-1, the growth of ERα/LRH-1-positive MCF-7, T47D and ZR-75-1 breast 
cancer cell lines was abrogated. No effect was seen in the ERα+/LRH-1-negative cell 
line BT474 nor the ERα/LRH-1-negative cell line MDA-MB-231. Confirmation of 
LRH-1 knockdown using qRT-PCR demonstrated ~50-90% reduction in LRH-1 
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expression in MCF-7 cells using several LRH-1 siRNAs. This was confirmed at a protein 
level using immunoblotting. Expression of the LRH-1 regulated gene INHA was seen 
following reduction in LRH-1 expression, and interestingly the expression of ERα was 
reduced following LRH-1 siRNA. The reduction in ERα expression mirrored the 
reduction in LRH-1 expression. This confirmed in two other ERα /LRH-1-positive 
breast cancer cell lines T47D and ZR-75-1 but not in the ER+/LRH-1-negative cell line 
BT474. Overexpression of LRH-1 resulted in an increase in ERα expression, and 
contrastingly transfection of the LRH-1 repressor SHP into MCF-7 cells reduced ERα 
expression, further confirming that LRH-1 regulates ERα expression. Further evidence 
that LRH-1 regulates breast cancer growth through ERα regulation was from the use of 
the ‘Whitby’ small molecule compounds5a, 5b and 5L. These small molecule activators 
of LRH-1 stimulate the growth of ERα/LRH-1 positive cell lines in a dose dependent 
manner, but have no effect in the ERα/LRH-1-negative line MDA-MB-231. These 
compounds also potently activate LRH-1 activity and ERα expression. Using FACS, I 
have shown that LRH-1 siRNA in MCF-7 cells results in a 25% increase in apoptotic 
cells, which may in part explain the reduction of cells seen in the growth assays. 
Using qRT-PCR, I have also assessed ERα gene promoter usage in MCF-7, T47D, ZR-
75-1 and BT474 breast cancer cell lines. Interestingly all isoforms of ERα were shown to 
be reduced following LRH-1 knockdown. My laboratory have mapped ten potential 
LRH-1 binding sites in the ERα promoter. Generation of a reporter gene encoding the 
region of the ERα gene 7kb upstream of promoter A and transfecting this into MCF-7 
cells with LRH-1 resulted in a significant increase in ERα activity. Transfection of a 
mutated form of LRH-1 (LRHRE1) resulted in a 40% reduction in ERα reporter activity 
compared to wild-type reporter, suggesting that this site is required for LRH-1 binding to 
the ERα gene promoter.  
Collectively these studies show that LRH-1 plays a significant role in regulating responses 
in ERα-positive breast cancer cells and this occurs, in part, through direct regulation of 
ERα expression. These findings identify LRH-1 as a potentially important new 
therapeutic target for treatment of breast cancer. Future work in LRH-1, which I have 
not been able to address, but which will be continued in our laboratory will include: 
 Gene expression microarray analysis in MCF-7 cells following siRNA mediated 
knockdown of LRH-1, to identify LRH-1 regulated genes which may be 
important in growth 
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 A comparison of the relative expressions of LRH-1 variants in tissues and cancer 
cell lines using Taqman based qRT-PCR assays. 
 Evaluation of the expression of LRH-1 289 by immunostaining in archival 
primary breast tissue and in breast cancers 
 Using Chromatin Immunoprecipitation (ChIP)-Sequencing (ChIP-Seq) 
approaches to identify LRH-1 binding sites in the genome of breast cancer cells. 
 Using computer aided design, to develop LRH-1 anatagonists, which may be 
potential therapeutic agents in inhibiting breast cancer growth 
 Evaluate the expression of LRH-1 in normal mammary breast tissue 
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Appendix 8-1 Real-time-qRT-PCR analysis of GATA-3 expression in 
cancer cell lines and RNA from a variety of tissues. (a) Real-time qRT-PCR 
was performed using one RNA preparation from ERα-positive breast cancer 
cell lines (MCF-7, ZR-75-1, T47D, BT20, BT474, BT483), ERα-negative 
breast cancer cell lines (SkBr3, MDA-MB-231, MDA-MB-436, MDA-
MB-231, Cal51), immortalised normal breast cell lines (HPRSV1.6.1, 
MCF10A), an endometrial cancer cell line (Ishikawa), prostate cancer cell 
lines (LNCaP, PC3), hepatocellular carcinoma cell line (HepG2) and an 
ovarian cancer cell line (PE04). The MDA-MB-435 cell line was believed to 
be derived from breast cancer cells, but microarray analysis has shown that it 
is a melanoma line. (b) A panel of RNAs from normal tissues (purchased from 
Ambion-ABI) was also used for real-time qRT-PCR analysis. The graphs 
show the means of each cDNA assayed in triplicate, as folds relative to 
expression in MCF-7 cells (a) or breast (b), following normalisation of 
expression relative to GAPDH expression. The errors bars represent the 
standard errors of the mean. 
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Appendix 8-2 Real-time-qRT-PCR analysis of CYP-19 expression in 
cancer cell lines and RNA from a variety of tissues. (a) Real-time qRT-PCR 
was performed using one RNA preparation from ERα-positive breast cancer 
cell lines (MCF-7, ZR-75-1, T47D, BT20, BT474, BT483), ERα-negative 
breast cancer cell lines (SkBr3, MDA-MB-231, MDA-MB-436, MDA-
MB-231, Cal51), immortalised normal breast cell lines (HPRSV1.6.1, 
MCF10A), an endometrial cancer cell line (Ishikawa), prostate cancer cell 
lines (LNCaP, PC3), hepatocellular carcinoma cell line (HepG2) and an 
ovarian cancer cell line (PE04). The MDA-MB-435 cell line was believed to 
be derived from breast cancer cells, but microarray analysis has shown that it 
is a melanoma line. (b) A panel of RNAs from normal tissues (purchased from 
Ambion-ABI) was also used for real-time qRT-PCR analysis. The graphs 
show the means of each cDNA assayed in triplicate, as folds relative to 
expression in MCF-7 cells (a) or breast (b), following normalisation of 
expression relative to GAPDH expression. The errors bars represent the 
standard errors of the mean. 
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Appendix 8-3 Identification of new LRH-1 variants in breast cancer cells.
(a) Shown is a schematic representation of the LRH-1 variants, including 
LRH-1-289, LRH-1-326 and LRH-1-152 identified here. (b) Amino acid 
sequences of LRH-1 variants. The underlined amino acids in LRH-1-289 are 
the residues arising from the newly described exon (exon 2b). 
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Appendix 8-4 Forward (FSC) and Side scatter plots (SSC) siRNA LRH-1.
(a) Shown are scatter plots for cell-cycle analysis in MCF7 cells treated with 
lipofectamine reagent, non-targeting siRNA and siRNA to LRH-1(b) Shown 
are scatter plots for apoptosis analysis in MCF7 cells treated with 
lipofectamine reagent, non-targeting siRNA and siRNA to LRH-1. 
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Appendix 8-5 Forward (FSC) and Side scatter plots (SSC) MCF7 cells 
treated with Tamoxifen or ICI.(a) Shown are scatter plots for cell-cycle 
analysis in MCF7 cells treated with Etoh, ICI 10-7M or Tamoxifen 10-7M (b) 
Shown are scatter plots for apoptosis analysis in MCF7 cells treated with 
Etoh, ICI 10-7M or Tamoxifen 10-7M. 
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Appendix 8-6 ICI and Tamoxifen result in G0/G1 growth arrest in MCF-7 cells. MCF-7 
cells were treated with Etoh, ICI-7M and Tamoxifen-7M. Cells were harvested after 72 hours 
and fixed for FACS analysis. (a) The cells were stained with the apoptotic marker Annexin V. 
Shown are the scatter plots, with cells in early and late early and late apoptosis. (b) Shown are 
the FACS profiles obtained. (c) This graph shows the percentage of cells in each phase of the 
cell cycle. The results of three replicates are shown, together with standard errors of the 
means. P-values were calculated using the Student’s t-test. Asterisks (*) represent a 
statistically significant (P<0.005) difference from the Etoh control. 
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Abstract Estrogen receptor-a (ER) is expressed in the
great majority of breast cancers, and the inhibition of ER
action is a key part of breast cancer treatment. The inhibition
of ER action is achieved using anti-estrogens, primarily
tamoxifen, and with aromatase inhibitors that inhibit estro-
gen biosynthesis, thereby preventing ER activation. How-
ever, resistance to these therapies is common. With the aim
of identifying new molecular targets for breast cancer
therapy, we have identified the liver receptor homolog-1
(LRH-1) as an estrogen-regulated gene. RNA interference
and over-expression studies were used to investigate the role
of the LRH-1 in regulating breast cancer growth and to
identify the targets of an LRH-1 action. Promoter recruit-
ment was determined using reporter gene and chromatin
immunoprecipitation (ChIP) assays. We show that LRH-1
regulates breast cancer cell growth by regulating the ER
expression. Reporter gene and in vitro DNA-binding assays
identified an LRH-1-binding site in the ER gene promoter,
and ChIP assays have demonstrated in vivo binding at this
site. We also provide evidence for new LRH-1 variants in
breast cancer cells arising from the use of alternative pro-
moters. Previous studies have shown that LRH-1 functions
in estrogen biosynthesis by regulating aromatase expres-
sion. Our findings extend this by highlighting LRH-1 as a
key regulator of the estrogen response in breast cancer cells
through the regulation of ER expression. Hence, inhibition
of LRH-1 could provide a powerful new approach for the
treatment of endocrine-resistant breast cancer.
Keywords Estrogen  Estrogen receptor 
Gene regulation  LRH-1
Introduction
Estrogen plays a critical role in the development and pro-
gression of breast cancer. Its actions are mediated by
estrogen receptors, with estrogen receptor-a (ER) being
expressed in the majority of breast cancers. ER is a member
of the nuclear receptor (NR) superfamily of transcription
factors, which acts by regulating specific gene expression
upon binding estrogen. Inhibition of ER activity is achieved
clinically through the use of selective estrogen receptor
modulators (SERMs), such as tamoxifen, that compete with
estrogen for binding to ER, to inhibit its activity [1, 2].
Electronic supplementary material The online version of this
article (doi:10.1007/s10549-010-0994-9) contains supplementary
material, which is available to authorized users.
P. T. R. Thiruchelvam  C.-F. Lai  H. Hua 
R. S. Thomas  F. J. Kyle  M. Periyasamy  A. Photiou 
R. C. Coombes  L. Buluwela (&)  S. Ali (&)
Department of Oncology, Imperial College London,
Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
e-mail: l.buluwela@imperial.ac.uk
S. Ali
e-mail: simak.ali@imperial.ac.uk
A. Hurtado  J. S. Carroll
Cancer Research UK, Cambridge Research Institute, Li Ka
Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
W. Hudson  E. A. Ortlund
Department of Biochemistry, Emory University School
of Medicine, Atlanta, GA 30322, USA
A. R. Bayly  A. C. Spivey
Department of Chemistry, Imperial College London, South
Kensington Campus, Exhibition Road, London SW7 2AZ, UK
R. J. Whitby
School of Chemistry, University of Southampton, Highfield,
Southampton SO17 1BJ, UK
123
Breast Cancer Res Treat
DOI 10.1007/s10549-010-0994-9
Aromatase inhibitors act by inhibiting the conversion of
androgens into estrogen, and provide an alternative and
effective approach for inhibiting ER activity, with newly
introduced aromatase inhibitors, such as Anastrozole and
Letrozole, already proving to be have greater efficacy than
tamoxifen [3, 4].
The regulation of ER gene expression has been sub-
jected to intense study due to its important role in the
regulation of breast cancer and in other important physio-
logical processes, such as cardiovascular protection, bone
homeostasis, and osteoporosis, and sexual development in
males and females [5]. The coding region of the ER gene is
located within eight exons spanning 140 kb on chromo-
some 6q25 [6, 7]. Regulation of an ER gene expression is
complex, with transcription being initiated within multiple
promoters spanning 150 kb [8]. Several of these promoters
show tissue specificity [9], which has further complicated
studies to define the transcriptional regulators of ER gene
expression.
The liver receptor homolog (LRH-1), like ER, is a
member of the NR superfamily. It belongs to the Ftz-f1 or
NR5A subfamily that includes steroidogenic factor-1 (SF-1),
members of which are characterised by the presence of
an extended DNA-binding domain (DBD), the so-called
Ftz-F1 box located at the C-terminus of the DBD [10].
Most NRs bind to DNA sequences conforming to the
consensus NR-binding sequence, AGGTCA, either as
homodimers (e.g., ER) to palindromes of the AGGTCA
motif or to direct repeats of the AGGTCA motif as het-
erodimers with retinoid X receptor-a (RXRa) [11]. By
contrast, members of the Ftz-F1 subfamily bind to
sequences having a 50 extension to the NR DNA-binding
motif as monomers, with the Ftz-F1 box targeting the
50-YCA extension to the NR DNA-binding motif [12],
where Y is C or T. Until recently classified as orphan
receptors, structural studies have shown that LRH-1 and
SF-1 bind phosphatidyl inositols, with their binding being
required for maximal activity [13–15]. LRH-1 plays
important roles in metabolism, being involved in the reg-
ulation of reverse cholesterol transport, lipid and choles-
terol absorption, bile acid homeostasis, and steroidogenesis
[10]. In particular, the LRH-1 has been implicated in the
regulation of aromatase (CYP19) expression in the ovary
[16]. Interestingly, in adipose tissue from normal women,
CYP19 expression is low and mainly originates from the use
of promoter I.4. By contrast, in breast cancer adipose tissue,
activation of additional CYP19 gene promoters is seen,
including importantly, the gonadal PII promoter. In the latter
context, LRH-1 regulates CYP19 expression through bind-
ing to a response element in the PII promoter [17–20].
In this study, we show that in breast cancer cells, LRH-1
is co-expressed with ER in breast cancer cell lines and that
RNAi-mediated LRH-1 knock-down inhibits breast cancer
cell growth. We demonstrate that this is due, at least in
part, to the regulation of ER expression by LRH-1 through
direct binding to the ER gene promoter. These studies
show, for the first time, that ER is an LRH-1 target gene, a
finding that is potentially relevant for the development of
new therapies for breast cancer.
Materials and methods
Cell lines
COS-1, MCF-7, T47D, ZR75-1, BT474, and MDA-MB-
231 cells were routinely cultured in DMEM containing
10% FCS. For estrogen-depletion experiments, the cells
were transferred to DMEM lacking phenol red and con-
taining 5% dextran-coated charcoal-stripped FCS for 72 h,
as described previously [21]. 17b-Estradiol (estrogen),
4-hydroxytamoxifen, and ICI 182, 780 were prepared in
ethanol and added to the medium at a final concentration of
10 nM (estrogen) or 100 nM (4-hydroxytamoxifen, ICI
182, 780). Compounds 5A, 5B, and 5L, which have pre-
viously been described [22], were prepared in DMSO and
added to a final concentration of 10 lM.
Plasmids
The renilla luciferase reporter gene was RLTK (Promega,
UK). LRH-1 and SHP expression plasmids were pCI-LRH-
1, pCDM8-hSHP, and the LRH-1; the firefly luciferase
reporter gene was SF-1-luc (gifts from Dr. Donald Mc-
Donnell and Dr. David Moore) [14]. The F342W/I416W
LRH-1 mutant was generated by site-directed mutagenesis
of pCI-LRH-1, using primers having the sequences 50-CA
AGCACGAAAAGCTGAGCACCTGGGGGCTTATGTG-
CAAAA-30 and 50-ACTGGGCAACAAGTGGACTATTC
CATATGGGCATCACAAGCCGG-30. The PII-516 aro-
matase reporter gene was kindly provided by Drs. Colin
Clyne and Evan Simpson. ERP-Luc was generated by
amplifying the genomic region covering the ER gene
promoter A to LRHRE3 (-5993/-117) using high fidelity
pfu DNA polymerase (Fermentas, UK) with DNA prepared
from the human ER gene Bacterial Artificial Chromosome
clone RP3-443C4 (Geneservice Ltd, UK). The PCR prod-
uct was cloned into pJET (Fermentas, UK) (pJET-ERP)
and re-cloned into the pGL3-Basic luciferase reporter
vector (Invitrogen), following digestion with BglII
restriction enzyme. The three putative LRH-1 response
elements in this region, LRHRE1-3, were mutated by site-
directed mutagenesis (Quickchange; Stratagene), changing
the LRH-1-binding site to a BamHI restriction site in each
case (details available on request).
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Transfections
MCF-7 and BT474 cells were transiently transfected with
100 ng of SHP or 50 ng of LRH-1, and the total RNA and
protein lysates were prepared 48 h later, as previously
described [21]. For reporter gene assays, COS-1 cells were
transiently transfected in 96-well plates, using FuGene HD
(Roche), according to manufacturer’s protocols. The cells
were transfected with 25 ng of the pGL3-Promoter-based
reporter plasmids or 100 ng of the pGL3-Basic, SF-1 Luc,
and RLTK, together with 50 ng of pCI-LRH-1. Cells were
lysed 24 h following transfection and firefly and renilla
luciferase activities were determined using the Dual Glo
system (Promega, UK). A similar method was used for
assaying ERP-luc and PII-516 aromatase reporter genes in
COS-1 or MCF-7 cells.
siRNA
Cells were transfected using Lipofectamine RNAiMAX,
according to manufacturer’s methods (Invitrogen). RNA
and protein were prepared 48 h following transfection. Cell
number was estimated using the sulphorhodamine B (SRB)
growth assay, as described previously [23]. siRNA LRH-1
On-TargetPlus Smartpool (Dharmacon) comprised siRNAs
having the sequences: 50-CAUAAUGGGCUAUUCAUA
U-30 (#1), 50-AGAGAAAUUUGGACAGCUA-30 (#2),
50-GGAGUGAGCUCUUAAUCCU-30 (#3) and 50-GAAGC
CAUGUCUCAGGUGA-30 (#4). siGenome non-targeting
siRNA (Dharmacon) had sequences 50-UAAGGCUAUG
AAGAGAUAC-30, 50-AUGUAUUGGCCUGUAUUAG-30,
50-AUGAACGUGAAUUGCUCAA-30, 50-UGGUUUACA
UGUCGACUAA-30.
RT-PCR
Total RNA was collected, and real-time RT-PCR was per-
formed as previously described [23]. Real-time RT-PCR was
carried out using Taqman Gene Expression Assays (Applied
Biosystems, UK) for ER (ESR1; Hs00174860_m1),
CTD (Hs00157201_m1), LRH-1 (Hs00187067_m1), pS2
(TFF1; Hs00170216_m1), SHP (Hs00222677_m1), Dax1
(Hs00230864_m1), SF-1 (Hs00610436_m1) and GAPDH
(Hs99999905_m1) on an ABI 7900HT machine.
Western blotting
Cells were cultured and protein lysates prepared as
described previously [21]. Antibodies used were anti-ERa
(Novacastra Laboratories), and anti-LRH-1 (Perseus Pro-
temics). SHP, cathepsin D, and b-actin antibodies were
purchased from Abcam.
ChIP
Chromatin immunoprecipitation (ChIP) was performed
as previously described [23]. Antibody used was LRH-1,
and primers for real-time PCR were: LRHRE1 Fwd
50-CTAGCCCAAGTGAACCGAGA-30, LRHRE1 Rev
50-ACCTCAGGTCACGAACCAAA-30. For normalization,
qPCR was performed for the previously described control
region for the c-myc gene [24], using oligonucleotides
having the sequences: c-myc Fwd 50-GCCAGTCCAAC
CGGCTTATG-30, c-myc Rev 50-GGTTCTCCCAAGCAG
GAGCA-30.
In vitro DNA-binding assay
Binding affinities for LRH-1 to LRHRE1 sequences were
obtained using a fluorescence polarization assay, following
expression and purification of the LRH-1 amino acid res-
idues 79–184 as a MBP fusion protein in E. coli, as
described previously [12]. Carboxyfluorescin (FAM)-
labeled duplex oligonucleotides based on the LRHRE1
sequence 50-AATTGCCAAAGCTTTGGT-30 and the
CYP7A1 LRH-1-binding site described previously [12],
(Integrated DNA Technologies, USA), were used. 10 nM
of FAM-labeled oligonucleotide was mixed with MBP–
LRH-1 DBD at varying concentrations, and polarization
was measured in milli-polarization units (mP). The
experiments were performed on a Panvera Beacon 2000,
with an excitation wavelength of 495 nm, and an emission
wavelength of 520 nm. The results were analyzed by Sig-
maPlot to generate binding data and dissociation constants.
Results
LRH-1 regulates the growth of breast cancer cells
As a strategy to identify key estrogen-regulated genes in
breast cancer cells, we modified the estrogen-responsive
and ER-positive MCF-7 breast cancer cell line, to condi-
tionally express a transcriptionally repressive ER, PLZF-
ER, composed of the PLZF transcriptional repressor fused
to the ER DNA and ligand-binding domains [21]. The
resulting line grows in an estrogen-dependent manner in
the absence of PLZF-ER expression, but induction of
PLZF-ER expression blocks its growth. Gene-expression
microarray analysis carried out using this line, identified
1,627 genes which showed [1.5-fold regulation by estro-
gen within 16 h. Of these genes, 149 were repressed by
PLZF-ER, suggesting that these genes are important for
estrogen-regulated growth of MCF-7 cells (Buluwela et al.,
in preparation). One of the 149 genes whose expression
was repressed by PLZF-ER in MCF-7 cells was LRH-1.
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Estrogen treatment of MCF-7 cells showed a four-fold
increase in the LRH-1 expression (Fig. 1a), confirming the
microarray findings; no stimulation of LRH-1 expression
was observed when the cells were treated with the anti-
estrogens 4-hydroxytamoxifen or ICI182, 780. Further,
LRH-1 expression was considerably higher in ER-positive,
compared to ER-negative lines (Fig. 1b), suggestive of an
association between the ER expression and the LRH-1
expression in breast cancer cells.
Analysis of the ER-binding and PolII occupancy data,
generated from ChIP-chip and ChIP-seq profiling of global
ER and PolII binding following treatment of estrogen-
depleted MCF-7 cells with estrogen for 1 h [24, 25],
showed ER binding to a region 10.5 kb upstream from the
LRH-1 exon 1. Real-time PCR of ChIP following estrogen
treatment of MCF-7 cells confirmed that estrogen
stimulates ER binding to this region of the LRH-1 pro-
moter (Fig. 1d).
Several LRH-1 splice variants have been described [10,
26], including hLRH-1 and LRH-1v2 both of which lack
exon 2 encoded amino acids 22–67 (Fig. 2b). In perform-
ing immunoblotting for the LRH-1, we noted that many of
the commercially available antibodies, whilst detecting the
transfected LRH-1 did not detect the LRH-1 in breast
cancer lines. As these antibodies were directed to the LRH-
1 N-terminus, we wondered whether this was due to the
predominance of exon 2-deleted LRH-1 variants in these
lines. 50-Rapid amplification of complementary DNA ends
(50-RACE) for defining 50 ends of the LRH-1 transcripts in
MCF-7 cells identified three main forms (Fig. 2a), the
well-described LRH-1 variant 1 (v1) encoding a polypep-
tide of 541 amino acids, and two new variants, which we
named variant 4 (v4) and variant 5 (v5) to distinguish them
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Fig. 1 LRH-1 is an estrogen-regulated gene that functions in breast
cancer cell growth. a Hormone-depleted MCF-7 cells were stimulated
with vehicle, estrogen, tamoxifen or ICI182780 and LRH-1 mRNA
levels were assessed by real-time RT-PCR (lower panel). Protein
lysates prepared following stimulation of hormone-depleted MCF-7
cells were immunoblotted (upper panel). b The LRH-1 and ER
mRNA levels were determined by real-time RT-PCR analysis of total
RNA. c Shown is the LRH-1 locus with the positions of ER-binding
regions (black box) and RNA PolII occupancy for MCF-7 cells treated
with estrogen for 1 h. Also shown is the region of ER binding for
ZR75-1. Shown are the ER and PolII occupancy representations,
generated by uploading the ChIP-Seq datasets to the UCSC genome
browser gateway (http://genome.ucsc.edu). d ChIP was performed
using mouse immunoglobulins (IgG) or an ER antibody, and quan-
titative PCR was carried out for the ER-binding site identified in (c).
PCR for a region in intron 3 served as a negative control for ER
binding. The results of three independent replicates are shown
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from the previously described LRH-1 variants. v4 and v5
would be expected to encode polypeptides of 501 and 482
amino acids, respectively. Interestingly, LRH-1-v4 tran-
scription is initiated in intron 1 of the LRH-1 gene,
extending the previously identified exon 2 further 50 into
intron 1 (named exon 2a) (Fig. 2c; Supplementary Fig. 1).
The mapped 50 end of LRH-1-v5 defined an exon in intron
2 (here, named exon 2b). Hence, v4 and v5 define tran-
scripts from the previously undescribed, alternative LRH-1
gene promoters. Blast searches of the NCBI database
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) identified one EST
clone, TRACH3028697 (GenBank number: DC418114.1;
the 50 end of which precisely matched the 50 end deter-
mined by 50-RACE. Also identified was an EST clone that
contained the sequences present in v4 and extended the 50
untranslated region by a further 87 bp (Fig. 2b). No cor-
roborating evidence for v5 was found in EST databases.
Expression analysis using isoform-specific real-time
RT-PCR showed that v4 and v5 are highly estrogen-regu-
lated, whereas variants hLRH-1, v1, and v2 expression
were weakly stimulated by estrogen in MCF-7 cells
(Fig. 3a). Note that using these primer sets, we did not
distinguish between hLRH-1, v1, and v2. Furthermore, RT-
PCR and immunoblotting showed that v4 is the predomi-
nant form of LRH-1 expressed in breast cancer cell lines
(Fig. 3b, c). However, extensive reporter gene analysis did
not reveal a significant difference between LRH-1 v1, and
v4 (data not shown; Fig. 3d), despite the fact that v4 lacks
the N-terminal 40 amino acids present in v1.
RNA interference (RNAi) used to determine whether
LRH-1 is an important mediator of estrogen-stimulated
growth of MCF-7 cells, showed that LRH-1 down-regula-
tion using a pool of four small interfering RNAs (siRNA)
potently inhibited MCF-7 growth (Fig. 4a). The individual
siRNAs all inhibited MCF-7 growth, with the least growth
inhibition being observed for siRNA #1, the siRNA that
gave the smallest reduction in LRH-1 expression (Sup-
plementary Figs. 2, 4b, f). Transfection with the LRH-1
siRNAs also inhibited the growth of the LRH-1 positive
ZR-75-1 and T47D cells, but growth of the LRH-1-nega-
tive cell lines, BT474 and MDA-MB-231, was unaffected
by the LRH-1 siRNA (Supplementary Fig. 3a).
LRH-1 regulates ER expression in breast cancer cells
Determination of the expression of estrogen-regulated
genes showed that LRH-1 knockdown reduced expression
of the pS2 and cathepsin D (CTD) genes (Fig. 4c, d),
prompting us to determine whether the growth inhibitory
effects of the LRH-1 knockdown could be due to the LRH-
1 regulation of ER expression. Indeed, ER mRNA and
protein were reduced following siRNA for LRH-1 (Fig. 4e,
f). Inhibition of ER expression following LRH-1
knockdown was also observed in T47D and ZR75-1 cells
(Supplementary Fig. 3b, c).
In order to confirm these findings, we investigated
whether synthetic LRH-1 activating compounds could
stimulate MCF-7 cell growth. A number of substituted cis-
bicyclo[3.3.0]-oct-2-enes have been identified as small
molecule agonists of LRH-1 and SF-1 [22]. As there was
no detectable expression of SF-1 in MCF-7 and BT-474
Fig. 2 Identification of new LRH-1 variants in breast cancer cells.
a Products of 50-RACE are shown for RNA prepared from MCF-7 cells
treated with estrogen (E2) or vehicle (NL) for 8 h. The products were
cloned and sequenced to assign their identities, as marked. b Shown is a
schematic representation of the LRH-1 variants, including variants v4
and v5 identified here. c Sequences of LRH-1 variants v4 and v5. The
DNA sequences in italics represent the 50 untranslated regions present
in the 50-RACE cloning products. The sequences in lower case shown
for v4 are also present in an EST (UTERU3011183) (http://www.
ncbi.nlm.nih.gov/). The underlined amino acids in v5 are the residues
arising from the newly described exon (exon 2b)
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cells (Supplementary Fig. 4), we determined the effect of
three of these compounds (5A, 5B, and 5L) on cell growth.
MCF-7 cell growth was stimulated, whereas growth of the
ER-positive, but LRH-1-negative BT-474 cells, was unaf-
fected (Fig. 5a). As seen with a reporter gene assay, these
compounds stimulated the activity of an LRH-1 responsive
luciferase reporter gene (Fig. 5b), and treatment with the
compounds increased the ER levels in MCF-7 cells
(Fig. 5c). Moreover, LRH-1 transfection stimulated ER
expression in MCF-7 and BT474 cells (Fig. 5d, e), whereas
transfection of the small heterodimer partner (SHP), a NR
that acts as a co-repressor for LRH-1 [27], reduced ER
expression in MCF-7 cells (Fig. 5f, g). Further, LRH-1
transfection stimulated the growth of MCF-7 cells, while
SHP inhibited MCF-7 growth (Fig. 5h).
LRH-1 regulates ER expression by direct recruitment
to the ER gene promoter
Expression of the human ER gene is initiated at multiple
promoters spanning 150 kb [8]. RT-PCR showed that in
the lines examined, the majority of ER expression is ini-
tiated at promoters A, B, and C, with some expression from
promoter F (Fig. 5a; Supplemental Fig. 5). Analysis of the
region encoding ER gene promoters A through F revealed
the presence of 11 sequences conforming to the LRH-1
consensus binding site (YCAAGGYCR [28]), with the
closest of these sites being located less than 6 kb 50 to
promoters A/B (Fig. 6a). In addition, our analysis high-
lighted an extended palindrome centered around a HinDIII
restriction enzyme site (50-CCAAAGCTTTGG-30) which
Fig. 3 LRH-1 variant 4 is the major form of the LRH-1 in breast
cancer cells. a LRH-1 variant mRNA levels in MCF-7 cells were
determined by real-time RT-PCR using primers that specifically
amplify v4 or v5 sequences. Primers for v1/v2 amplify the LRH-1
variants 1 and 2, as well as hLRH-1. The results for three independent
RNA samples are shown, with in each case expression level in the
absence of ligand (NL) being taken as 1 and expression level in the
presence of E2 shown relative to that. b Expression of the LRH-1
variants in breast cancer cell lines is shown. Expression of v1/v2 in
MCF-7 was taken as 1 and all other values are shown relative to this.
c Protein lysates prepared from breast cancer lines and COS-1 cells
transfected with LRH-1 v1 or v4 were immunoblotted for LRH-1 and
b-actin. d COS-1 cells were co-transfected with an LRH-1-responsive
luciferase reporter gene (SF-1-luc) and increasing amounts of LRH-1
v1 or v4. Reporter gene activities are shown relative to the vehicle
control. Protein lysates prepared from these lysates were immuno-
blotted for LRH-1 to determine relative expression of the variants
(lower panel)
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encoded a sequence (underlined) similar to that identified
in the mouse SEBP gene as an LRH-1-binding site [29],
912 bp 50 to the promoter A start site (named LRHRE1).
As promoters A and B constitute the major promoters
utilized in MCF-7 cells, we generated an ER promoter
luciferase reporter gene (ERP-luc) encoding a 6.0 kb
region comprising promoters A through D and containing
two putative LRH-1-binding sites (LRHRE2, and
LHRRE3) that conform to the LRH-1 consensus binding
site sequence, as well as LRHRE1. The ERP-luc reporter
was activated by LRH-1 in MCF-7 cells (Fig. 6b). Struc-
tural studies have shown that the LRH-1 ligand-binding
domain (LBD) has phospholipids bound [13–15]. An LRH-
1 mutant (LRH-1-F342W/I416W), which is impaired for
phospholipid binding and shows reduced transcriptional
activity [14] also showed reduced activation of ERP-luc.
Mutation of LRHRE2 and LRHRE3 had modest effects on
LRH-1 regulation of the reporter gene, with a considerably
larger reduction in reporter gene activity being observed if
LRHRE1 was mutated (Fig. 6c), suggesting that LRH-1
binds to the LRHRE1 sequence.
As the LRHRE1 sequence does not conform to the
LRH-1 consensus binding site, LRH-1 binding to this
sequence was determined using a fluorescence polarization
assay using E. coli-expressed LRH-1 DBD and FAM-
labeled oligonucleotides. The Kd of LRH-1 binding to
LRHRE1 (126 nM) was similar to that obtained for the
LRH-1 site in the Cyp7A1 gene promoter (200 nM)
(Fig. 6d; Supplemental Fig. 5).
ChIP analysis of MCF-7 cell lysates with an LRH-1
antibody demonstrated LRH-1 recruitment to the region of
the ER promoter containing the LRHRE1 sequence
(Fig. 6e). Taken together, these findings indicate that
LRH-1 is recruited to the LRHRE1 sequence in the ER
gene promoter, and that this sequence is important for
LRH-1 regulation of ER expression.
Discussion
LRH-1 is an estrogen-regulated gene in breast cancer
cells
Estrogens play critical roles in the initiation and progres-
sion of human breast cancer, as well as other gynaeco-
logical cancers. Estrogen actions are mediated by ER
which acts primarily as a transcription factor that, upon
binding estrogen, regulates the expression of a large
number of estrogen-responsive genes [30], causing, in the
case of breast cancer cells, inhibition of apoptosis and
promotion of proliferation. Defining the key estrogen-reg-
ulated genes in cancer cells would provide important
insights into the mechanisms by which estrogen/ER pro-
motes breast cancer growth. Using an engineered MCF-7
cell line that conditionally expresses a dominant-negative
form of ER in which the PLZF transcriptional repressor
was fused to ER [21], we identified LRH-1 as a gene whose
expression was repressed upon PLZF-ER expression. RT-
PCR analysis and immunoblotting confirmed estrogen-
regulation of LRH-1, as has previously been described
[31]. As also described previously, siRNA-mediated
LRH-1 silencing potently inhibited the estrogen-stimulated
growth of MCF-7 cells. Moreover, we observed inhibition
of the growth of other ER/LRH-1-positive breast cancer
cell lines (ZR75-1 and T47D).
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Fig. 4 Targeted knockdown of LRH-1 inhibits Estrogen Receptor
(ER) expression. a MCF-7 cells grown in estrogen-depleted medium
were transfected with the LRH-1 siRNA, treated with vehicle or
estrogen and cell number estimated after 4 days using the sulpho-
rhodamine B (SRB) assay. Growth is shown relative to the reagent
alone control for three experiments. b–e siRNA pool for LRH-1 or
individual siRNAs were transfected into MCF-7 cells, RNA and
protein was prepared after 48 h. LRH-1 (b), pS2 (c) cathepsin D
(CTD) (d) and ER (e) mRNA levels were determined by real-time
RT-PCR analysis. Shown are the means and s.e.m. for three
experiments. Asterisks show statistically significant difference
(unpaired t-test, P \ 0.05) from the reagent or non-targeting controls.
f Immunoblotting was performed following preparation of protein
lysates from MCF-7 cells transfected with siRNAs for LRH-1
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The study by Annicotte et al. [31] previously identified an
estrogen response element 2.3 kb upstream of the LRH-1
exon 1. ChIP based global analysis of ER-binding sites did
not, however, detect significant binding to this region in
MCF-7 and ZR75-1 cells. Instead, binding to a region
10.5 kb upstream of exon 1 was seen in both cell lines. This
region contains the sequence 50-AGGaCAcacTG ACCT-30
(starting at chromosome 1 bp 198,252,853 in the NCBI hg18
human genome release, in which exon 1 of the LRH-1 gene is
at bp 198,263,393 (http://genome.ucsc.edu)), which con-
forms well to the consensus ERE sequence (AGGTC
AnnnTGACCT) [32]. ChIP analysis confirmed estrogen-
stimulated ER recruitment to this site, indicating that this site
is involved in ER regulation of LRH-1 expression.
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Fig. 5 LRH-1 stimulates Estrogen Receptor (ER) expression in
breast cancer cells. a Hormone-depleted MCF-7 and BT-474 cells
were stimulated with a vehicle, estrogen or LRH-1 activator, over a
12-day period. Shown is growth at day 12, relative to the vehicle
control, as measured using the SRB assay. b COS-1 cells transfected
with an LRH-1 responsive luciferase reporter gene (SF-1-luc) were
stimulated with vehicle (DMSO) or the LRH-1 activators 5A, 5B and
5L. Reporter gene activities are shown relative to the vehicle control.
c RNA was prepared from MCF-7 cells treated with compounds 5A,
5B and 5L for 8 h. ER mRNA levels were determined by real-time
RT-PCR. d, g Protein lysates prepared from MCF-7 cells following
transfection with LRH-1 (d) or SHP (g) were immunoblotted. e, f
Real-time RT-PCR was performed using RNA prepared from MCF-7
cells transfected with LRH-1 (e) or SHP (f). h MCF-7 cells were
transiently transfected with LRH-1 or SHP and cell numbers
estimated after 4 days using the SRB assay. Growth is shown relative
to the vector control. All graphical results are shown as the means and
s.e.m. relative to the vehicle or vector controls, of at least three
replicates. Asterisks denote statistically significant difference
(P \ 0.05) relative to the appropriate vehicle or vector control,
determined using the unpaired t-test
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A new LRH-1 variant is the predominant form
of LRH-1 in breast cancer cells
LRH-1 transcript mapping identified two new LRH-1
variants, both of which are expressed from distinct new
promoters, one initiating within intron 1 and extending
exon 2 127 bp 50 (v4), and the second initiating in intron 2
and lacking exon 1 and 2 sequences (v5). Both of these
variants are estrogen regulated, but v5 expression is low in
breast cancer cells. LRH-1-v1 was the only other variant
whose expression was observed by 50-RACE, but it was
also expressed at low levels, with v4 being the major form
of LRH-1 in breast cancer cells, which was confirmed by
immunoblotting. Forms of LRH-1 corresponding to v4, as
well as v1 are seen in the mouse, chicken (Supplementary
Fig. 1b, c), and rat, while v4 corresponds to LRH-1
Fig. 6 LRH-1 binds to a specific site within the ER gene promoter.
a Shown is a schematic representation of the ER gene, with the
positions of ER promoters A through F highlighted. Transcription
start site positions shown are as previously described [9]. Sequences
that are similar to the consensus LRH-1-binding site are shown, either
above or below the rectangle with the sequences shown below the
rectangle denote sites on the lower DNA strand, whilst those above
the rectangle represent sites on the upper DNA strand. The region of
the ER gene used to generate the ER promoter luciferase reporter
gene (ERP-luc) is shaded. b MCF-7 cells were transfected with ERP-
luc, together with the LRH-1 or the LRH-1-F342W/I416W mutant.
c Reporter gene activities were determined for MCF-7 cells
transfected with ERP-luc, or mutants in which LRHRE1-3 were
mutated. All reporter gene activities are shown as the means and
s.e.m., for three replicates, relative to the vector control. d DNA
binding to LRHRE1 and the Cyp7A1 LRH-1 response element was
measured by changes in fluorescence polarization for the LRH-1
DBD. The results of at least three replicates are shown. e ChIP was
performed using lysates prepared from MCF-7 cells, and real-time
PCR for three replicates using primers for a control region mapping to
the c-myc locus and the ER promoter encompassing LRHRE1, are
shown. In all cases asterisks show statistically significant differences
(P \ 0.05), determined using the unpaired t-test, between sample 1
and the other samples, or relative to the control samples
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transcripts predicted to come from the xenopus and zeb-
rafish LRH-1 genes. Furthermore, analysis of the ChIP-
chip for RNA polymerase II (PolII) [25] showed that at the
LRH-1 locus, the strongest binding of PolII is centered on
exon 2 sequences (see Fig. 2c), which indicates that in
MCF-7 cells the major transcription initiation sites for the
LRH-1 gene are centered around exon 2. Finally, real-time
RT-PCR using RNA from a panel of human tissues showed
that v4 is expressed more widely than the other variants.
Indeed, we did not detect expression of the other variants in
the absence of v4 expression. Taken together, these find-
ings provide strong evidence for the in vivo importance of
LRH-1-v4. A previous study examining LRH-1 expression
immunohistochemically in invasive ductal carcinoma
showed that 43% of breast tumours are LRH-1 positive
[33], expression being negatively associated with clinical
stage and histological status and positively associated with
steroid receptor status. As this study was carried out using
an antibody directed to amino acids 2–33 of LRH-1-v1
(absent in v4), it is possible that the LRH-1 positivity was
underestimated, highlighting the need for re-evaluation of
LRH-1 in breast cancer, the lack of currently ascribed
differences in the activities of LRH-1 variants 1 and 4
notwithstanding. As the antibodies available to us have
proved to be unsuitable for immunohistochemistry, we are
currently developing new antibodies to address this issue.
LRH-1 regulates estrogen receptor expression
in breast cancer cells
LRH-1 knockdown inhibits breast cancer cell growth, as
previously described [31] and confirmed here. Importantly,
LRH-1 knockdown reduced ER expression, LRH-1 over-
expression or stimulation of its activity by synthetic ago-
nists increased ER levels, whilst the LRH-1 repressor SHP
reduced ER expression. Reporter gene studies and muta-
tional analysis showed that three sites contribute to the
LRH-1 regulation of the ER reporter gene, with an LRH-1-
binding site, named LRHRE1 (50-AATTGCCAAAGCT
TTGGT-30) having a sequence similar to LRH-1-binding
site in the mouse SEBP gene (50-CCCAAAGGCTT-30)
[29], being the most important site for the LRH-1 regula-
tion of ER expression. Finally, ChIP confirmed binding of
LRH-1 to the ER gene in a region encompassing this site.
Taken together, these results show that LRH-1 regulates
ER-positive breast cancer cell growth through a mecha-
nism involving regulation of ER gene expression through
direct recruitment to the ER promoter.
Previous study has highlighted a positive regulatory
loop in which ER and GATA-3 reciprocally regulate each
other in breast cancer cells [34], and provides a possible
explanation for the co-expression of ER and GATA-3 in
breast cancers (see [34, 35]). Other estrogen-regulated
genes have been shown to be important for ER action in
breast cancer cells, with FoxA1 being required for the
recruitment of ER to the promoters of many estrogen-
responsive genes [36, 37]. Our findings show that ER and
LRH-1 form a positive cross-regulatory loop in which each
transcription factor is required for the expression of the
other gene.
The aromatase (CYP19) gene is transcribed from a
number of different promoters, with expression from the
different promoters being highly tissue selective. The
aromatase promoter II (PII) is used in gonadal tissues, and
its regulation by SF-1 has been demonstrated [38–40].
Whilst in normal breast tissue, aromatase is expressed at
low levels, with promoter 1.4 being utilized, in tumor-
bearing breast tissue, aromatase expression is elevated,
with transcription being driven largely through PII pro-
moter [19]. These studies have also indicated that SF-1 is
not expressed in breast tumours, whilst LRH-1 is expressed
in adipose tissue, with LRH-1 and aromatase co-expression
being evident particularly in pre-adipocytes [17]. In this
context, LRH-1 regulates aromatase expression thorough
recruitment to the PII Promoter [17, 18]. Furthermore,
regulation of the PII promoter by LRH-1 occurs synergis-
tically with GATA3 [18]. Interestingly, regulation of ER
expression by GATA3 has also previously been described
[34]. Our preliminary analysis shows that LRH-1 and
GATA3 also act synergistically at the ER promoter (Sup-
plementary Fig. 7). Aromatase expression is additionally
dependent on tumor-derived growth factors, particularly
prostaglandin E2, acting through protein kinase A (PKA) to
stimulate aromatase PII activity [17, 18]. In agreement with
these findings, activity of the aromatase PII reporter gene
was strongly increased by PKA, whereas PKA did not
similarly potentiate the synergism between LRH-1 and
GATA3 at the ER gene promoter (Supplementary Fig. 7).
Together, these results indicate that aromatase and ER
expression are similarly regulated, albeit in different cell
types, indicating that the cell-type specificity may be due to
differences in cell signaling pathways, such as those
involving PKA (for potential model of aromatase and ER
regulation by LRH-1 see Supplementary Fig. 7c).
Of course, differential expression of the LRH-1 vari-
ants may also be important in specifying cell-type selec-
tivity for the differential regulation of aromatase and ER
genes in different cell types. Furthermore, we did not
observe expression of the LRH-1 regulated SHP gene in
the breast cancer cell lines; nor was Dax1 expression
evident in LRH-1 positive breast cancer lines. As SHP
and Dax1 are important regulators of LRH-1 activity [27],
their presence or absence may also be important in
defining promoter and cell-dependent activities of the
LRH-1, as well as responses to other signaling pathways,
such as PKA.
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In conclusion, our studies show that LRH-1 is a key reg-
ulator of estrogen responses in breast cancer, which acts by
regulating estrogen synthesis in breast tumour tissue and by
regulating ER expression in breast cancer cells. As such,
LRH-1 presents as an important target for the development
of new therapeutic agents for use in breast cancer treatment.
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Abstract Estrogen receptor-a (ERa) positive breast can-
cer frequently responds to inhibitors of ERa activity, such
as tamoxifen, and/or to aromatase inhibitors that block
estrogen biosynthesis. However, many patients become
resistant to these agents through mechanisms that remain
unclear. Previous studies have shown that expression of
ERa in ERa-negative breast cancer cell lines frequently
inhibits their growth. In order to determine the consequence
of ERa over-expression in ERa-positive breast cancer cells,
we over-expressed ERa in the MCF-7 breast cancer cell line
using adenovirus gene transduction. ERa over-expression
led to ligand-independent expression of the estrogen-regu-
lated genes pS2 and PR and growth in the absence of
estrogen. Interestingly, prolonged culturing of these cells in
estrogen-free conditions led to the outgrowth of cells
capable of growth in cultures from ERa transduced, but not
in control cultures. From these cultures a line, MLET5, was
established which remained ERa-positive, but grew in an
estrogen-independent manner. Moreover, MLET5 cells
were inhibited by anti-estrogens showing that ERa remains
important for their growth. Gene expression microarray
analysis comparing MCF-7 cells with MLET5 highlighted
apoptosis as a major functional grouping that is altered in
MLET5 cells, such that cell survival would be favoured.
This conclusion was further substantiated by the demon-
stration that MLET5 show resistance to etoposide-induced
apoptosis. As the gene expression microarray analysis also
shows that the apoptosis gene set differentially expressed in
MLET5 is enriched for estrogen-regulated genes, our find-
ings suggest that transient over-expression of ERa could
lead to increased cell survival and the development of
estrogen-independent growth, thereby contributing to
resistance to endocrine therapies in breast cancer patients.
Keywords Estrogen  Estrogen withdrawal 
Anti-estrogens  Estrogen receptor  Endocrine
resistance  Gene profiling  Apoptosis
Introduction
Two-thirds of breast cancers express estrogen receptor-a
(ERa), and estrogen plays a critical role in the development
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and progression of these tumours. This understanding has led
to the development of anti-estrogens, primarily tamoxifen,
which compete with estrogen for binding to the ERa.
Treatment with tamoxifen for 5 years following surgery
leads to 50% lower annual recurrence rate and a 28%
decrease in annual rates of mortality in patients with early
stage ER-positive breast cancer [1, 2]. However, many
patients who respond to tamoxifen, eventually relapse.
Aromatase inhibitors act by preventing the conversion of
androgens into estrogens by the aromatase enzyme, with new
aromatase inhibitors displaying greater efficacy than
tamoxifen. However, resistance to aromatase inhibitors also
develops in many cases [3, 4].
In a proportion of cases, patients who initially present with
ERa-positive breast cancer, become ERa-negative [5]. The
mechanisms by which ERa expression is lost are unclear,
although epigenetic silencing of the ERa gene may be
involved [6]. In most cases, however, resistant tumours
remain ERa-positive and show a response to a change of
endocrine agent [2], indicating that ERa continues to be
important in regulating tumour growth in these cases. For the
latter, recent studies suggest that endocrine resistance could
result from modulation of ERa activity by altered co-activator
and co-repressor balance and/or crosstalk with growth factor
signalling cascades, including phosphorylation of ERa at
specific residues. In this context, elevated HER2 and EGFR
expression have been observed in cell line models of tamox-
ifen resistance, whilst elevated ERK1/2 MAPK [7] and high
levels of phosphorylated AKT have been associated with poor
response to tamoxifen and a worse patient prognosis [8].
Further, phosphorylation of ERa at serine 118 (S118) is ele-
vated in recurrence following tamoxifen treatment [9].
Finally, high-level expression of the coactivator AIB1 is
associated with poor response to tamoxifen in ERa-positive
breast cancer, with AIB1- and HER2-positive patients having
the worst outcome following tamoxifen treatment [10].
Ectopic expression of ERa in ERa-negative breast cancer
cell lines and in immortalised non-tumourigenic breast cells
inhibits their growth, despite showing estrogen-dependent
stimulation of expression of estrogen-responsive genes
[11–13]. In contrast, over-expression of ERa did not inhibit
the growth of ERa-positive breast cancer cell lines [12],
although conditional over-expression of ERa did lead to
increased growth of MCF-7 cells in the absence of ligand
[14], suggesting that ERa over-expression in ERa-positive
breast cancer cells may facilitate adaptation to estrogen
deprivation.
To further investigate the consequences of ERa over-
expression on the estrogen responses in ERa-positive
breast cancer cells, we have transduced MCF-7 cells with
an adenovirus encoding ERa. Prolonged culturing of the
ERa-transduced cells in estrogen-free medium allowed
the establishment of an estrogen-independent line,
MLET5, in which ERa expression was maintained.
MLET5 cells did not retain adenoviral sequences and
microsatellite genotyping confirmed their lineage as
MCF-7-derived. In further characterising MLET5 cells by
gene expression microarray analysis, we found changes
in apoptosis associated gene expression when compared
to MCF-7 cells, so as to favour cell survival. As a result
of these differences, we have gone on to show that the
MLET5 line has altered cell survival characteristics, as
indicated by a greatly reduced sensitivity to etoposide-
induced apoptosis. Together, these findings indicate that
transient ERa over-expression in breast cancer cells
could be sufficient to promote the development of
endocrine resistance in breast cancer through altered
expression of estrogen-regulated genes involved in cell
survival.
Materials and methods
Cell culture and cell lines
MCF-7 cells were obtained from the ATCC (LGC Pro-
chem, USA) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Sigma–Aldrich Ltd., UK)
supplemented with 10% fetal calf serum (FCS) (First Link
Ltd., UK). For culturing in estrogen-free conditions, MCF-
7 cells were cultured in DMEM lacking phenol red
(DMEM-PR) (Gibco-BRL, UK), supplemented with 10%
dextran-coated charcoal-stripped FCS (DSS) (First Link
Ltd., UK). MLET5 cells were routinely cultured in
DMEM-PR, containing 10% DSS.
Recombinant adenovirus construction and infection
of MCF-7 cells
The human ERa open reading frame was cloned into the
adenoviral shuttle vector pAdTrack-CMV [15], which
encodes GFP, to generate pAdTrack-CMV-ERa. Recom-
binant adenoviral genome AdERa and control virus
(AdGFP) were generated following recombination by
co-transformation of E. coli BJ5183 cells with pAdEasy-1,
as described and packaged in HEK293 cells, also as
described [15]. The viruses were purified by caesium
chloride banding and viral particle concentration was
determined by spectrophotometric analysis. MCF-7 cells
(6 9 106) were seeded in 10-cm plates in DMEM-PR,
containing 10% DSS and allowed to settle for 24 h prior to
infection. FACS analysis of single cell suspensions pre-
pared 2 days following adenoviral transduction, was used
to determine the percentage of cells transduced. Cell counts
were performed using a haemocytometer with trypan blue
exclusion for counting of viable cells.
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Sulphorhodamine B (SRB) Growth assay
Sixteen hours following seeding of 3 9 103 cells in 96-
well plates in DMEM-PR containing 10% DSS, the med-
ium was replaced with fresh medium supplemented with
17ß-estradiol (E2), anti-estrogens, or an equivalent volume
of the vehicle (ethanol). Medium was changed every
3 days. Cells were fixed using 40% (w/v) TCA, for 1 h at
4C, washed five times with distilled, deionised H2O, fol-
lowed by incubation with 0.4% SRB in 1% acetic acid for
1 h at room temperature. Excess dye was removed with
five washes with 1% acetic acid and drying at room tem-
perature. Absorbance at 480 nm was determined following
solubilisation of the dye by the addition of 100 ll of
10 mM Tris base to each well.
For measuring growth following addition of Etoposide
(Sigma–Aldrich), 2 9 103 cells were seeded in each well.
Medium supplemented with the inhibitors in a titration of
2-fold dilutions, starting from 100 lM, was added after
48 h. Cell growth was measured 48 and 72 h after treat-
ment, using the SRB assay, with the GI50 being defined as
the concentration of drug required to obtain 50% of the
growth exhibited by untreated, control cells.
Cell cycle analysis
Cells were seeded in six-well plates (105/well) in DMEM
containing 10% FCS and allowed to adhere for 48 h, fol-
lowed by the addition of 1 nM–100 lM etoposide (Sigma–
Aldrich) or DMSO and incubation for 48 h. Cells were
harvested, cell cycle Annexin V/propidium iodide staining
and analysis was carried out as previously described [16].
RT-PCR analysis
RNA was prepared and RT-PCR performed as described pre-
viously [17]. For quantitative RT-PCR (Q-RT-PCR) mea-
surements, Taqman Gene Expression Assays were used with a
7900HT Fast Real-time PCR machine (Applied Biosystems).
Primer details are given in supplementary information.
Immunoblotting
MCF-7 and MLET5 cells (1 9 106) were seeded in 10-cm
plates in DMEM containing 10% FCS and lysed after 48 h,
as described [17]. For experiments where ligands were to
be added, the cells were incubated in DMEM-PR con-
taining 10% DSS for 3 days prior to seeding. Ligands were
added, as appropriate, with an equal volume of ethanol
being added to the controls. Cell lysates were prepared
24 h later. Immunoblotting was carried out as described
previously [17], using antibodies detailed in Supplemen-
tary material.
Gene expression microarray analysis
For gene expression microarray analysis, MCF-7 and
MLET5 cultures were seeded in estrogen-depleted medium
as described above for 3 days, with three bioreplicate cul-
tures used for each cell line and treatment. Following 16 h
treatment with 10 nM E2, RNA was purified from the cul-
tures (RNeasy, Quiagen) and used to probe bead arrays
(Illumina, Human WG-6) through Cambridge Genomic
Services (http://www.path.cam.ac.uk/cgs/). Hybridisation
data were obtained using BeadStudio software (Illumina)
and raw gene expression data analysed using GeneSpring
GX 10 software (Agilent, Santa Clara USA). All samples
were normalised by quantile normalisation to minimise
variation between microarray chips. Data were filtered to
include only those probes expressed in at least one sample
(present and marginal flags). The three replicates for the no
ligand and E2 treatments were compared by unpaired t tests,
and differentially expressed genes were considered signifi-
cant at a multiple testing corrected P value (Benjamini
Hochberg FDR) of\0.05.
Results
Adenoviral transduction of ERa stimulates MCF-7 cell
growth and expression of estrogen-regulated genes
MCF-7 cells were infected with an adenovirus encoding GFP
for monitoring infection (AdGFP), into which the human ERa
coding region was inserted (AdERa) (Supplementary Fig. 1).
FACS analysis showed that 47, 76 and 90% of the cells were
GFP-positive using multiplicity of infection (MOI) of 400,
2,000 and 10,000 particles per cell, respectively. However,
infection with AdGFP at MOI = 10,000 resulted in cell
death, so all subsequent infections were performed using
MOI = 2,000. Under these conditions, stimulation of growth
was observed in the absence as well as in the presence of
estrogen. ERa levels were 5–6-fold higher in the AdERa-
infected cells, compared to the AdGFP-infected cells at the
protein and RNA levels (Fig. 1a, b). However, in the presence
of estrogen, expression of the estrogen-responsive PR and pS2
genes was similar in both cases (Fig. 1b–e), with inhibition of
expression with the anti-estrogen ICI182,780 (ICI), but their
expression was markedly elevated in the absence of ligand,
suggesting that adenoviral over-expression of ERa leads to
ligand-independent activation of E2-regulated genes, as well
as growth in the absence of estrogen.
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Survival of MCF-7 cells transduced with ERa
is enhanced during long-term culturing
in estrogen-depleted medium
Since transduction of ERa in MCF-7 cells conferred a
growth advantage in estrogen-free culture conditions, we
determined the effect of long-term culturing of AdERa-
infected MCF-7 cells in E2-depleted growth medium
(Fig. 1f). Under these conditions, cell numbers fell in
all cultures over a period of 2–3 months, resulting in a
complete loss in the mock and AdGFP-infected cultures by
month 5. In contrast, cell numbers started to recover in the
AdERa cultures. The loss of control AdGFP-infected and
mock-infected MCF-7 cells, with the emergence of a small
number of surviving cells following infection with AdERa
over the course of 5–6 months, was observed in four
additional, independent transduction experiments. In order
to confirm these findings, the infections were repeated.
From 3 out of the 5 separate infections and selection over
8 months, the recovered cells were cultured, one of these
giving rise to the MLET5 cell line. Monitoring of the cul-
tures by fluorescence microscopy showed no evidence of
GFP expression 2–3 months following infection; nor was
GFP expression evident in the MLET5 line (Supplementary
Fig. 1E). Furthermore, there was no detectable expression
of GFP by RT-PCR, nor was there any evidence for the
presence of adenoviral sequences by PCR (data not shown).
These observations are consistent with adenoviruses being
Fig. 1 Transduction of MCF-7 cells with an adenovirus encoding
human ERa. a Immunoblots of total cell lysates prepared 48 h
following infection of MCF-7 cells with AdGFP or AdERa at MOI
400. b For preparing RNA, estrogen (E2; 10 nM) and/or ICI182, 780
(ICI; 100 nM) were added 24 h prior to harvesting. RT-PCR was
performed to analyse expression of the PR, pS2, ERa, and GAPDH
genes. The expression of each gene was normalised to GAPDH
following densitometric analysis and relative expression calculated
for each gene, relative to the no ligand control for AdGFP-infected
cells. The means for the relative expression levels of ERa (c), PR
(d) and pS2 (e), as determined from densitometric analysis of
RT-PCR carried out on three replicate RNA preparations are shown,
the error bars represent the SEM. Significance for gene expression
differences was calculated using the t test. Statistically significant
differences (P \ 0.05) are shown for comparisons for any given
treatment between the lines (*). f MCF-7 cells mock infected or
infected with AdGFP or AdERa (MOI = 2,000), were grown over a
period of 8 months, in estrogen-depleted medium. The cell number
was determined at monthly intervals. The graphs show the average
cell numbers from five independent experiments, the error bars
representing the SEM
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non-integrative and, as a result of cell division, having
transduced genomes that become diluted, resulting in loss
of transgene expression. Finally, microsatellite genotyping
analysis showed that MLET5 cells are indeed identical to
MCF-7 cells for 10 markers examined (Supplementary
Table 1). All of the markers used are highly polymorphic
with multiple alleles. Assuming a conservative figure of 0.5
for the frequency of each allele at the 10 loci examined, the
probability that the cell lines are not derived from MCF-7 is
0.516 (P \ 0.0001) (Supplementary Table 1).
MLET5 cells grow in an estrogen-independent manner,
but show differential sensitivity to anti-estrogens
Estrogen is required for MCF-7 cell growth (Fig. 2a). In
contrast, growth of the MLET5 cells was independent of
E2, and was indistinguishable from growth in the absence
of ligand (Fig. 2b). Moreover, in contrast to MCF-7 cells,
the growth of MLET5 cells was only partially inhibited by
anti-estrogens (Fig. 2c, d). At the RNA level ERa remained
unchanged in MLET5 cells, although there was an apparent
decrease in ERa expression in the absence of E2 (Fig. 3a).
Overall however, ERa protein levels were elevated in
MLET5 cells compared with MCF-7 cells (Fig. 3h), which
may be indicative of a post-transcriptional mechanism of
ERa protein stabilisation in MLET5 cells. Despite the
elevated level of ERa protein, expression of several
well-characterised estrogen-regulated genes was reduced
(PR, CTD, TFF1/pS2), at the mRNA and protein level
(Fig. 3b–d and Fig. 3h), suggesting that the responsiveness
of some, but not all E2-regulated genes (GREB1, MYC,
CCND1; Fig. 3f–h) is attenuated in MLET5 cells.
This reduced stimulation in expression of some estro-
gen-regulated genes could be due to a reduction in ERa
phosphorylation in MLET5 cells. However, levels of
Ser118 and Ser167 phosphorylation (Supplementary
Fig. 2), previously associated with increased ER activity
were found to be higher in MLET5 cells than in MCF-7
cells, with the higher levels of phosphorylation reflecting
the elevated ERa expression in MLET5 cells. Alterna-
tively, altered ERa transcriptional co-regulator levels
could lead to attenuation of expression of regulated genes
[18–20]. Although expression of the p160 co-activators of
ER SRC1 and AIB1 were not altered in MLET5 cells
(Supplementary Fig. 3), there was a marked up-regulation
of the co-repressor SMRT in MLET5 cells, suggesting the
possibility of its involvement in reduced expression of
E2-responsive genes in MLET5 cells.
Gene expression microarray analysis of MLET5
In order to determine if reduced estrogen regulation was a
general feature of ERa activity in MLET5 cells, and to
determine the gene expression changes that may have led to
the development of the estrogen-independent outgrowth of
MLET5 cells, gene expression microarray analysis was
carried out. For this, RNA prepared from MCF-7 and
MLET5 cells cultured in estrogen-depleted medium,
C
14
16
18
20
MCF-7
NL
10-14 M 
14
16
18
20
MCF-7
NL
E2
0
2
4
6
8
10
12
10
A
(F
old
)
R
el
at
iv
e 
G
ro
w
th
 10-12 M
10-10 M
10-8 M
0
2
4
6
8
10
12
0 2 4 6 8 0 2 4 6 8 10
(F
old
)
R
el
at
iv
e 
G
ro
w
th
 
OHT
ICI
RAL
B D
Time (Days)
25
MLET5
NL
Time (Days)
18
20
MLET5
0
5
10
15
20 10-14 M 
10-12 M 
10-10 M
0
2
4
6
8
10
12
14
16
d)
R
el
at
iv
e 
G
ro
w
th
 (F
ol NL
E2
OHT
ICI
RAL
10
d)
R
el
at
iv
e 
G
ro
w
th
 (F
ol
R
Time (Days)
0 2 4 6 8 0 5 10
Time (Days)
Fig. 2 MLET5 cells grow in an
estrogen-independent manner
MCF-7 (a, c) and MLET5
(b, d) cells were grown in the
absence of ligand (NL) or in the
presence of increasing
concentrations of 17ß-estradiol
(E2) (a, b). Growth in the
presence of anti-estrogens was
carried out following the
addition of E2 (10 nM),
4-hydroxytamoxifen
(OHT; 100 nM), ICI 182, 780
(ICI; 100 nM) or Raloxifene
(RAL; 100 nM) (c, d). Growth
was determined using the SRB
assay for three experiments.
Error bars depict the standard
errors of the mean
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followed by addition of E2 for 16 h, was used to probe
Illumina Human WG-6 bead chips. Of the 42,620 genes on
the array, 4,353 genes showed significant differential
expression in MCF-7 in the presence of E2, compared with
the vehicle control, with similar numbers of genes showing
up-and down-regulation. About half as many (2,134) genes
showed significant differential expression in MLET5 cells,
consistent with the reduced expression of estrogen-regu-
lated genes observed using Q-RT-PCR (Fig. 3). Applying a
fold change (FC) of 1.5 showed that 414 and 971 genes
were up-, or down-regulated with estrogen in MLET5 and
MCF-7 cells, respectively (Fig. 4a, b). Of the genes show-
ing 1.5-fold up-regulation in expression in E2-treated MCF-
7 cells, 34% (171 of 501) genes were also up-regulated
C1.5-fold in MLET5 cells (representing 79% of the genes
up-regulated by estrogen) and included known estrogen-
regulated targets such as GREB1, PDZK1, PGR, MYB,
RET and IGFBP4 (Supplementary Table 2). It should also
be noted that a further 140 genes with C1.5-fold induction
by estrogen in MCF-7 cells showed a significant estrogen
regulation in MLET5 cells per se.
Similarly, 115 (24%) of the estrogen down-regulated
genes in MCF-7 cells were also down-regulated [1.5-fold
in MLET5 and a further 140 genes showed significant
down-regulation in MLET5 cells. These data are shown in
a scatterplot analysis (Fig. 4c) and highlights the fact that
most of the genes that show estrogen regulation in MCF-7
cells are also estrogen-regulated in MLET5 cells, indicat-
ing that despite their adaptation to growth in the absence of
estrogen, MLET5 cells still feature a marked, but attenu-
ated estrogen-regulated gene response.
In examining the MCF-7 and MLET5 gene expression
profiles we also noted that a number of previously descri-
bed estrogen up-regulated genes which showed moderate,
but significant estrogen regulation in MCF-7 cells, were
up-regulated in MLET5 cells in the absence of ligand. For
example, the expression of CXCL12 was 4.4-fold higher in
MLET5 than in MCF-7. The same was also true for some
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Fig. 3 The expression of
estrogen-regulated genes in
MLET5 cells. a–g Total RNA
prepared from MCF-7 and
MLET5 cells cultured in
estrogen-depleted medium, to
which 10 nM E2 was added
16 h prior to harvesting, was
subjected to Q-RT-PCR.
Expression level for MCF-7
cells in the absence of ligand
was taken as 1, and expression
for the other samples are
depicted relative to this for three
RNA preparations. The grey
bars show expression in the
absence of estrogen, with the
black bars representing
expression in the presence of
E2. Error bars show the
standard errors of the mean.
Significance for gene expression
differences was calculated using
the t test. Statistically significant
differences (P \ 0.05) are
shown for comparisons between
the no ligand and estrogen-
treated samples within each line
(*), for the no ligand samples
between lines (#) and for the
estrogen-treated samples (§).
h Whole cell lysates were
immunoblotted, as shown
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estrogen down-regulated genes, such as INHBB, whose
expression was 0.25-fold in vehicle treated MLET5 cells
compared to MCF-7 cells. This suggests the possibility that
in MLET5 cells ER regulates the expression of estrogen-
responsive genes in the absence of estrogen and that
estrogen is able to further modulate the expression of these
genes.
Estrogen regulation and apoptosis in MCF-7
and MLET5 cells
A total of 717 genes were differentially expressed
(P \ 0.05, FC C 2.0) in MLET5 compared with MCF-7,
whilst 886 genes showed differential expression in the
presence of estrogen, with 563 of these genes being differ-
entially regulated in both the vehicle and estrogen-treated
samples (Fig. 4d). Pathway analysis of the genes showing
differential expression in MLET5 cells compared with
MCF-7 cells (P \ 0.05, FC C 2.0) using gene set enrich-
ment analysis (GSEA) identified cellular and molecular
functional groupings (Supplementary Table 3), the most
significant of which were functional groups encompassing
apoptosis and included molecules involved in cell survival
and the regulation of cell death. David (http://
david.abcc.ncifcrf.gov/) also showed significant enrich-
ment of cell death groups in MLET5 cells (Supplementary
table 3).
With GSEA 5 of the top 6 annotated groups are associ-
ated with apoptosis and accounted for 22 genes showing
differential expression in MLET5 vs. MCF-7 cells,
including the key apoptotic regulators BCL2, BAD and BIK
(Table 1; Supplementary Fig. 4). Q-RT-PCR showed that
BCL2 expression was estrogen regulated in MCF-7 and
MLET5 cells, but was dramatically elevated in MLET5
cells (Fig. 5a). Conversely, the BH3-only pro-apoptotic
BIK (BCL2-interacting killer) gene was down-regulated by
estrogen in MCF-7 and MLET5 cells and its expression was
greatly reduced in MLET5 cells (Fig. 5b). The related gene
BID, which showed estrogen regulation, was also down-
regulated in MLET5 cells (Fig. 5c), whereas expression of
BAD, reduced upon estrogen treatment in MCF-7 cells, was
increased in MLET5 cells (Fig. 5d). Western blotting
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Fig. 4 Gene expression microarray profiling of MCF-7 and MLET5
cells in the absence and presence of estrogen. a, b Venn Diagrams to
show the number of genes whose expression was up- or down-
regulated (FC C 1.5, P \ 0.05) following the addition of estrogen for
16 h in MCF-7 and MLET5 cells. c A scatterplot is shown for genes
whose expression is altered [1.5-fold with estrogen treatment in
MCF-7 to show the fold change in expression with estrogen in
MLET5 cells, where the estrogen regulation was deemed to be
significant (P \ 0.05). Genes showing a 1.5-fold change in MLET5
treated with estrogen are similarly plotted to show genes in MCF-7
cells whose expression was significantly altered in MCF-7 cells
following estrogen treatment. d The Venn diagram shows the number
of differentially regulated genes in MCF-7 and MLET5 cells
(P \ 0.05, FC C 2.0)
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confirmed Q-RT-PCR data, with reduced BID and BIK and
elevated BCL2 and BAD (Fig. 5e).
These findings suggest that altered cell survival is a
key feature in the progression of the estrogen-independent
MLET5 cells. To test this, the response of MCF-7 and
MLET5 cells to the pro-apoptotic drug, etoposide was
compared. MLET5 cells were considerably less sensitive
to etoposide, with a GI50 = 19.3 lM, compared with a
GI50 = 4.6 lM for MCF-7 (t test: P \ 0.0001) (Fig. 6a,
b). Cell cycle analysis performed with etoposide at con-
centrations ranging from 1 nM to 100 lM showed an
accumulation of MCF-7 and MLET5 in G2/M (Fig. 6c).
There was also an accumulation of MCF-7 cells in the
sub-G1 phase, indicative of cells undergoing apoptosis,
which was confirmed with direct determination of cells in
apoptosis following staining for Annexin V, with 60% of
the MCF-7 cells undergoing apoptosis in the presence of
100 lM etoposide (Fig. 6d). However, even at a con-
centration of 100 lM, the proportion of MLET5 cells in
apoptosis is similar to that seen for vehicle (DMSO)
treated cells.
Discussion
Estrogen receptor-a over-expression by adenoviral
transduction results in ligand-independence in MCF-7
cells
In the normal breast, ERa expression is restricted to a small
proportion of epithelial cells, with ERa expression being
associated with a lack of estrogen-regulated proliferation.
In the majority of primary breast cancer patients, however,
the cancer cells are distinguished by expression of ERa in
proliferating cells, with levels of expression often being
elevated. Although the presence of ERa in breast cancer is
associated with the likelihood of response to endocrine
therapies, the impact of ERa levels in breast cancer cells on
Table 1 Genes associated with cell death showing differential expression in MLET5 vs. MCF-7 cells
Gene MLET5 vs. MCF-7
Vehicle
MLET5 E2 vs.
MCF-7 E2
MCF-7 E2 vs.
Vehicle
MLET5 E2 vs.
Vehicle
Symbol Description FC P value FC P value FC P value FC P value
MX1 Myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
8.9 0.000 10.8 0.000 0.6 0.014 0.8 0.060
BCL2 B-cell CLL/lymphoma 2 5.7 0.000 5.8 0.000 1.7 0.001 1.7 0.032
IFI6 Interferon, alpha-inducible protein 6 4.8 0.000 5.1 0.000 0.7 0.042 0.8 0.042
RTKN Rhotekin 3.6 0.001 3.3 0.001 1.3 0.104 1.2 0.105
TSPO Translocator protein (18 kDa) 3.1 0.000 3.4 0.001 0.8 0.111 0.9 0.308
BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) 2.9 0.000 2.7 0.000 0.9 0.003 0.8 0.033
INHA Inhibin, alpha 2.7 0.000 2.2 0.001 1.1 0.169 0.9 0.103
BAD BCL2-antagonist of cell death 2.6 0.000 2.5 0.000 0.9 0.013 0.8 0.047
CSE1L CSE1 chromosome segregation 1-like (yeast) 2.1 0.001 2.1 0.000 1.2 0.026 1.2 0.038
DFFA DNA fragmentation factor, 45 kDa,
alpha polypeptide
1.9 0.001 2.1 0.001 1.1 0.241 1.2 0.058
PIM1 pim-1 oncogene 0.8 0.010 0.4 0.001 2.3 0.001 1.2 0.088
NFKBIA Nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha
0.5 0.001 0.5 0.000 1.0 0.904 0.9 0.396
BIRC3 Baculoviral IAP repeat-containing 3 0.5 0.004 0.4 0.001 1.8 0.002 1.7 0.038
TNF Tumour necrosis factor (TNF superfamily,
member 2)
0.4 0.000 0.4 0.000 1.3 0.008 1.2 0.032
BIK BCL2-interacting killer (apoptosis-inducing) 0.4 0.001 0.4 0.001 0.6 0.006 0.6 0.030
ZAK Sterile alpha motif and leucine zipper
containing kinase AZK
0.4 0.001 0.5 0.002 0.8 0.071 1.0 0.888
PEA15 Phosphoprotein enriched in astrocytes 15 0.4 0.000 0.4 0.001 1.0 0.700 1.1 0.112
SOCS2 Suppressor of cytokine signaling 2 0.2 0.000 0.4 0.000 0.6 0.002 0.9 0.051
BNIPL BCL2/adenovirus E1B 19 kD
interacting protein like
0.2 0.000 0.2 0.000 0.6 0.001 0.7 0.031
SCIN Scinderin 0.2 0.000 0.2 0.000 0.8 0.069 0.9 0.236
IGF1R Insulin-like growth factor 1 receptor 0.1 0.000 0.2 0.000 1.0 0.302 1.7 0.034
ANXA1 Annexin A1 0.1 0.000 0.2 0.000 0.6 0.003 0.9 0.150
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prognosis and response to endocrine treatments remain
unclear. Determination of ERa levels using a ligand
binding assay showed that patients with high ERa levels
had a shorter relapse-free period than patients with low
ERa [21]. Further, fluorescence in situ hybridization of
ERa-positive breast tumours has shown that the ERa gene
(ESR1) is amplified in about 20% of cases, the amplifica-
tion being strongly associated with poor disease-free sur-
vival [22], whilst multiplex ligation-dependent probe
amplification-based copy number analysis shows a similar
percentage of ESR1 amplification in breast cancer, an
association with higher mitotic index and a trend towards
higher grade [23]. Other studies have shown similar levels
of ERa gene amplification, but in contrast, ESR1 amplifi-
cation was associated with better response to endocrine
therapies [24, 25]. Further adding to the controversy are
findings from other laboratories showing that the frequency
of ESR1 amplification is considerably lower than 20%
[26]. Additionally, there is no apparent relationship
between ERa levels and response in patients with advanced
disease and response in the IMPACT trial which assessed
tamoxifen, anastrozole or the combination in the neo-
adjuvant setting, had significantly more responders in the
patient group with higher ERa levels, but only in the
combination arm [27]. Therefore, it remains unclear as to
whether ERa levels are related to clinical response.
In order to better understand the consequences of high
ERa expression in breast cancer cells, we over-expressed
ERa in the MCF-7 ERa-positive breast cancer cell line.
Interestingly, the transient over-expression of ERa led to
the eventual outgrowth of cells that were estrogen inde-
pendent for growth. These cells were negative for GFP
expression and PCR indicated that adenoviral sequences
are absent from these lines. Further, in the generation of
LTED cells, Chan et al. [28] noted a transient over-
expression of ERa levels in MCF-7 cells within 3 weeks of
culturing in an estrogen deprived environment. This tran-
sient over-expression preceded subsequent changes leading
to estrogen-independent growth, in which ERa over-
expression was again seen. Taken together, these findings
suggest that transient over-expression of ERa could play a
role in the acquisition of an estrogen-independent pheno-
type by breast cancer cells. The mechanisms by which ERa
over-expression may promote the development of resistant
cells are unclear, but one possibility is that transient ERa
over-expression provides a survival advantage that allows
estrogen-independent cells to emerge. The minimum per-
iod of ERa over-expression that would be sufficient for
establishment of the resistant lines is also unclear. How-
ever, at an MOI of 2,000 particles/cell, 90% of the cells
were GFP-positive on day 3 following infection, falling to
48% on day 9 and no GFP expression was detectable after
12 weeks in culture (data not shown; and see Fig. 1f).
Hence continued over-expression of transduced ERa was
not required for the emergence of the MLET cell.
The MLET5 line was not responsive to estrogen for
growth but was partially sensitive to anti-estrogens, indi-
cating the continued importance of ERa in MLET5.
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Fig. 5 Expression of genes
associated with apoptosis is
altered in MLET5 cells. a–d
Q-RT-PCR for RNA prepared
from estrogen-treated MCF-7
and the MLET5 cells. Gene
expression is shown relative to
the expression in MCF-7 cells in
the absence of ligand. Error bars
show the standard errors of the
mean. Significance for gene
expression differences was
calculated using the t test.
Statistically significant differ-
ences (P \ 0.05) are shown for
comparisons between the no
ligand and estrogen-treated
samples within each line (*), for
the no ligand samples between
lines (#) and for the estrogen-
treated samples (§). e MCF-7 and
MLET5 cells were cultured in
estrogen-depleted medium and
whole cell lysates were prepared
24 h following the addition of
10 nM E2 (e) or an equal volume
of ethanol (V)
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Although ERa protein levels were significantly higher in
MLET5 compared to MCF-7 cells, E2 induction of pS2 and
CTD was markedly reduced. Phosphorylation of ERa at
S118 and S167 stimulates its activity [29] and phosphory-
lation at these sites was seen to be increased in MLET5,
suggesting that the reduced apparent ERa activity is not due
to a reduction in ERa phosphorylation. However, levels of
NCoR and particularly SMRT were elevated in MLET5
cells, compared to MCF-7 cells. This is in contrast to a
previously described MCF-7 derived line, LCC1, generated
through in vivo selection under conditions of low estrogen
availability, and LCC9, derived from LCC1 following
selection for growth in the presence of ICI [30]. LCC1 and
LCC9 remain ERa-positive, but show reduced expression
of the p160 co-activators (SRC1, TIF2 and AIB1) and the
co-repressors NCoR and SMRT [31]. The elevated levels of
NCoR and SMRT may explain the reduced expression of
pS2, CTD and PR in MLET5 cells. The reason for increased
NCoR and SMRT proteins in the absence of increases in
their mRNA is unclear. However, the ubiquitin ligase
mSiah2 has been implicated in regulating proteasomal
degradation of NCoR [32]. Siah2 expression has been
shown to be estrogen-regulated and to mediate the estrogen-
stimulated down-regulation of NCoR, but not SMRT pro-
tein [33], although examination of the microarray data did
not show a significant difference in Siah2 levels between
MCF-7 and MLET5 cells, with 2.3 and 2.1-fold stimulation
of Siah2 expression by estrogen, respectively.
High-level of AIB1 expression has been associated with
a poor prognosis and non-responsiveness to tamoxifen in
ERa-positive breast cancers, with AIB1-positive patients
also over-expressing HER1, 2 or 3, being most likely to
Fig. 6 MLET5 cells are
resistant to apoptosis. MCF-7
and MLET5 cells were treated
with etoposide at concentrations
ranging from 1 nM to 100 lM.
a, b Cell growth was determined
using the SRB assay. Shown are
the results of three independent
experiments. GI50 values were
determined as the concentration
of etoposide that inhibited
growth by 50%. SD standard
deviation. c MCF-7 cells were
treated with etoposide at the
concentrations shown, or with
vehicle (DMSO) for 48 h, prior
to fixation, staining with
propidium iodide (PI) and flow
cytometric analysis. Shown are
representative FACS profiles,
with the black line representing
the profile obtained for DMSO
treated cells and the grey areas
represent profiles for etoposide
treated cells. d Cells treated for
48 h with DMSO or etoposide
were stained with an antibody
for Annexin V and with PI. The
percentage of cells that stained
positive for Annexin V is shown
for three independent
experiments. Error bars
represent the standard errors of
the mean (SEM). Statistically
significant differences between
MCF-7 and MLET5 cells were
reached at concentrations of
etoposide of 50, 75 and 100 lM
(t test; P \ 0.05)
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relapse on tamoxifen [10, 34, 35]. These findings indicate
that crosstalk between ERa, AIB1 and growth factor
receptor pathways are important in determining response
and resistance to tamoxifen. HER2 expression and
P-MAPK levels are elevated in the LTED cells [36], sim-
ilar results being obtained in other LTED cells [37].
However, there was no evidence for increased expression
or activity of either EGFR or HER2 in MLET5 cells.
Moreover, MAPK phosphorylation levels were comparable
in MCF-7 and MLET5 cells, although there was an ele-
vation in P-AKT levels and MLET5 cells were about 5-fold
more sensitive to the PI3K inhibitor LY294002 than were
MCF-7 cells (Supplementary Fig. 2).
MLET5 cells are resistant to apoptosis
The gene expression microarray analysis showed that genes
involved in cell survival and apoptosis are highly differ-
entially regulated in MLET5 cells compared with MCF-7
cells. Examination of the proposed functions of these genes
showed that the majority of the anti-apoptotic genes were
up-regulated, whilst pro-apoptotic genes were down-regu-
lated in MLET5 cells compared with MCF-7 cells. Of
particular note were members of the Bcl2 gene family,
particularly those genes whose expression is estrogen-
regulated in MCF-7 cells. Hence, expression of the estro-
gen-regulated, anti-apoptotic Bcl2 gene was dramatically
elevated in MLET5 cells at the mRNA and protein levels,
whereas expression of the pro-apoptotic Bcl2 antagonists
Bik, Bid, but also BMF and BNIPL was repressed by
estrogen and reduced in MLET5 cells. Although expression
of the pro-apoptotic BAD gene did not follow this trend, its
expression being elevated in MLET5 cells, levels of Bcl2
expression were increased to a considerably greater extent
than those of Bad. It is interesting to note that analysis of
the real-time RT-PCR data of Bcl2 and Bad expression
shows that expression levels were similar in MCF-7 cells in
the absence of estrogen, with Bcl2 levels in the presence of
estrogen being 2–3-fold greater than levels of Bad. In
contrast, in MLET5 cells, Bcl2 levels were 16 and 20-fold
higher in MLET cells compared with MCF-7 cells in the
absence and presence of estrogen, respectively. This, taken
together with down-regulation of Bid, Bik, as well as
BNIPL and BMF, is indicative of anti-apoptotic program-
ming of MLET5 cells, a fact confirmed by the demon-
stration that MLET5 cells are significantly less sensitive to
etoposide-induced apoptosis. Although Bcl2 over-expres-
sion has been noted in MCF-7 LTED cells [38], it is not
clear if this occurs in the context of other changes in gene
expression indicative of overall cell survival, as we have
seen in MLET5 cells. Given that Bcl2 positivity and high
level Bad expression have been associated with better
outcome in breast cancer patients [39, 40], it is likely that
the reduced expression of other pro-apoptotic proteins such
as Bid and Bik are important for the resistance to apoptotic
agents observed in MLET5 cells. Indeed, low Bik expres-
sion, as found in MLET5, has previously been associated
with resistance to anti-estrogens in MCF-7 cells [41].
Further confirmation of Bcl2 up-regulation was determined
by analysing its expression in LTED cells (Supplementary
Fig. 5). In these cells there was an increase in Bcl2
expression as the cells progressed from the quiescent stage
(weeks 2–12) to the estrogen hypersensitive stage (weeks
21–40) [28]. As observed for MLET5 cells, Bik and Bid
expression fell over this time course, levels of expression in
the absence of estrogen being reduced to levels similar to,
or lower than those seen in the presence of estrogen in
MCF-7 cells. Interestingly, Bad expression was unaltered.
These findings further confirm the association between the
development of estrogen independence and altered
expression of Bcl2, Bik and Bid in breast cancer cells.
Taken together, our findings indicate that increased
levels of ERa and/or transient over-expression of ERa in
breast cancer cells may provide a mechanism for promoting
estrogen-independence in breast cancer cells by facilitating
cell survival under conditions of low estrogen availability,
for example in patients treated with adjuvant aromatase
inhibitor therapy. Our data, together with those of other
groups who have over-expressed ERa in breast cancer cell
lines, would indicate that breast cancer patients with high-
level ERa expression would respond less well to endocrine
treatment. Indeed, other studies have shown that ERa levels
are elevated in LTED cells that emerge following long-term
growth in estrogen-depleted media. In any case, our data
indicate that even a transient over-expression of ERa would
be sufficient for the development of resistance to aromatase
inhibitors. In summary, the MLET5 line described here
provides a useful new model for studying the mechanisms
of endocrine response and resistance in breast cancer, and
address the paucity of such lines that are currently available.
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